|
G |
Comt |
catechol-O-methyltransferase |
increases methylation decreases activity |
ISO |
COMT protein results in increased methylation of Methyldopa Methyldopa results in decreased activity of COMT protein |
CTD |
PMID:7053299 PMID:11160877 |
|
NCBI chr11:82,568,052...82,587,642
Ensembl chr11:82,568,025...82,587,642
|
|
G |
Gsta1 |
glutathione S-transferase alpha 1 |
decreases activity |
ISO |
Methyldopa analog results in decreased activity of GSTA1 protein |
CTD |
PMID:8131222 |
|
NCBI chr 9:23,703,476...23,720,121
Ensembl chr 9:23,703,477...23,720,121
|
|
G |
Gstm1 |
glutathione S-transferase mu 1 |
decreases activity |
ISO |
Methyldopa analog results in decreased activity of GSTM1 protein |
CTD |
PMID:8131222 |
|
NCBI chr 2:195,649,845...195,655,402
Ensembl chr 2:195,649,845...195,655,411
|
|
G |
Gstp1 |
glutathione S-transferase pi 1 |
decreases activity |
ISO |
Methyldopa analog results in decreased activity of GSTP1 protein |
CTD |
PMID:8131222 |
|
NCBI chr 1:201,337,762...201,340,230
Ensembl chr 1:201,321,672...201,340,226
|
|
G |
Prl |
prolactin |
increases expression increases secretion |
ISO |
Methyldopa results in increased expression of PRL protein Methyldopa results in increased secretion of PRL protein |
CTD |
PMID:1867878 PMID:7265421 |
|
NCBI chr17:37,859,999...37,870,062
Ensembl chr17:37,860,007...37,870,062
|
|
G |
Ren |
renin |
decreases activity |
EXP |
Methyldopa results in decreased activity of REN protein |
CTD |
PMID:145319 |
|
NCBI chr13:44,796,260...44,807,491
Ensembl chr13:44,796,091...44,807,489
|
|
|
G |
Dpp3 |
dipeptidylpeptidase 3 |
increases cleavage multiple interactions |
ISO |
DPP3 protein results in increased cleavage of Enkephalin, Leucine spinorphin inhibits the reaction [DPP3 protein results in increased cleavage of Enkephalin, Leucine]; tynorphin inhibits the reaction [DPP3 protein results in increased cleavage of Enkephalin, Leucine] |
CTD |
PMID:10873616 |
|
NCBI chr 1:202,204,683...202,228,501
Ensembl chr 1:202,204,693...202,228,541
|
|
G |
Oprd1 |
opioid receptor, delta 1 |
increases activity |
ISO |
Enkephalin, Leucine results in increased activity of OPRD1 protein |
CTD |
PMID:26476280 |
|
NCBI chr 5:144,306,188...144,340,960
Ensembl chr 5:144,306,188...144,340,960
|
|
G |
Oprm1 |
opioid receptor, mu 1 |
increases activity |
ISO |
Enkephalin, Leucine results in increased activity of OPRM1 protein |
CTD |
PMID:26476280 |
|
NCBI chr 1:43,160,057...43,413,409
Ensembl chr 1:43,160,057...43,413,409
|
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions |
ISO |
maculosin inhibits the reaction [Diethylnitrosamine results in decreased expression of BAX protein] |
CTD |
PMID:34726822 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions |
ISO |
maculosin inhibits the reaction [Diethylnitrosamine results in increased expression of BCL2 protein] |
CTD |
PMID:34726822 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
ISO |
maculosin inhibits the reaction [Diethylnitrosamine results in decreased expression of CASP3 mRNA]; maculosin inhibits the reaction [Diethylnitrosamine results in decreased expression of CASP3 protein] |
CTD |
PMID:34726822 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Cat |
catalase |
multiple interactions |
ISO |
maculosin inhibits the reaction [Diethylnitrosamine results in decreased activity of CAT protein] |
CTD |
PMID:34726822 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Gsr |
glutathione-disulfide reductase |
multiple interactions |
ISO |
maculosin inhibits the reaction [Diethylnitrosamine results in decreased activity of GSR protein] |
CTD |
PMID:34726822 |
|
NCBI chr16:58,482,209...58,525,256
Ensembl chr16:58,482,505...58,525,661
|
|
G |
Pik3r1 |
phosphoinositide-3-kinase regulatory subunit 1 |
multiple interactions |
ISO |
maculosin inhibits the reaction [Diethylnitrosamine results in increased expression of PIK3R1 protein modified form] |
CTD |
PMID:34726822 |
|
NCBI chr 2:32,878,942...32,963,668
Ensembl chr 2:32,882,032...32,963,631
|
|
G |
Pten |
phosphatase and tensin homolog |
multiple interactions |
ISO |
maculosin inhibits the reaction [Diethylnitrosamine results in decreased expression of PTEN protein] |
CTD |
PMID:34726822 |
|
NCBI chr 1:230,630,443...230,697,070
Ensembl chr 1:230,630,338...230,696,838
|
|
G |
Tp53 |
tumor protein p53 |
multiple interactions |
ISO |
maculosin inhibits the reaction [Diethylnitrosamine results in decreased expression of TRP53 mRNA]; maculosin inhibits the reaction [Diethylnitrosamine results in decreased expression of TRP53 protein] |
CTD |
PMID:34726822 |
|
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
|
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
multiple interactions |
EXP ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [isoborneol results in decreased expression of ABCB1A protein] benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [CERS6 protein affects the expression of ABCB1 protein] |
CTD |
PMID:26593909 PMID:34915026 |
|
NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709
|
|
G |
Abcg2 |
ATP binding cassette subfamily G member 2 |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [indolo(3,2-b)carbazole results in increased expression of ABCG2 mRNA] |
CTD |
PMID:17077187 |
|
NCBI chr 4:87,676,241...87,802,757
Ensembl chr 4:87,745,319...87,802,409
|
|
G |
Acaa2 |
acetyl-CoA acyltransferase 2 |
decreases expression multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of ACAA2 mRNA MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of ACAA2 mRNA] |
CTD |
PMID:25566086 |
|
NCBI chr18:68,345,136...68,373,246
Ensembl chr18:68,345,012...68,373,249
|
|
G |
Ace |
angiotensin I converting enzyme |
multiple interactions |
ISO |
[Butyrates co-treated with benzyloxycarbonylleucyl-leucyl-leucine aldehyde] affects the localization of ACE protein mutant form; [Butyrates co-treated with benzyloxycarbonylleucyl-leucyl-leucine aldehyde] results in increased activity of ACE protein mutant form |
CTD |
PMID:20454656 |
|
NCBI chr10:90,910,316...90,930,437
Ensembl chr10:90,910,316...90,931,131
|
|
G |
Ace2 |
angiotensin converting enzyme 2 |
multiple interactions decreases expression |
ISO |
ATF6 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of ACE2 protein]; ERN1 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of ACE2 protein] |
CTD |
PMID:27638906 |
|
NCBI chr X:30,293,597...30,340,961
Ensembl chr X:30,293,589...30,340,977
|
|
G |
Ache |
acetylcholinesterase |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Lithium Chloride results in decreased stability of ACHE protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Lithium Chloride results in increased degradation of ACHE protein] |
CTD |
PMID:22944069 |
|
NCBI chr12:19,406,133...19,413,713
Ensembl chr12:19,407,360...19,413,651
|
|
G |
Acta2 |
actin alpha 2, smooth muscle |
decreases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of ACTA2 mRNA |
CTD |
PMID:25566086 |
|
NCBI chr 1:231,746,527...231,759,307
Ensembl chr 1:231,746,548...231,759,554
|
|
G |
Actb |
actin, beta |
decreases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of ACTB mRNA |
CTD |
PMID:15857753 |
|
NCBI chr12:11,663,112...11,666,697
Ensembl chr12:11,663,109...11,672,877
|
|
G |
Actc1 |
actin, alpha, cardiac muscle 1 |
decreases expression multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of ACTC1 mRNA MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of ACTC1 mRNA] |
CTD |
PMID:25566086 |
|
NCBI chr 3:100,811,987...100,817,523
Ensembl chr 3:100,811,987...100,817,523
|
|
G |
Adam17 |
ADAM metallopeptidase domain 17 |
increases expression multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of ADAM17 protein 4-methylumbelliferone 8-carbaldehyde inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of ADAM17 protein]; 4-phenylbutyric acid inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of ADAM17 protein] |
CTD |
PMID:27638906 |
|
NCBI chr 6:40,872,936...40,920,700
Ensembl chr 6:40,872,856...40,920,639
|
|
G |
Adss1 |
adenylosuccinate synthase 1 |
multiple interactions decreases expression |
ISO |
MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of ADSS1 mRNA] |
CTD |
PMID:25566086 |
|
NCBI chr 6:131,679,795...131,702,012
Ensembl chr 6:131,679,701...131,701,998
|
|
G |
Agrp |
agouti related neuropeptide |
increases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of AGRP mRNA |
CTD |
PMID:20061341 |
|
NCBI chr19:33,447,992...33,481,602
Ensembl chr19:33,447,992...33,449,584
|
|
G |
Agt |
angiotensinogen |
multiple interactions |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [[Curcumin binds to carboxymethyl-chitosan analog] inhibits the reaction [AGT protein modified form results in decreased degradation of TP53 protein]]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [AGT protein results in increased degradation of SYP protein] |
CTD |
PMID:18487452 PMID:26612707 |
|
NCBI chr19:52,529,139...52,549,618
Ensembl chr19:52,529,185...52,540,977
|
|
G |
Ahr |
aryl hydrocarbon receptor |
multiple interactions increases expression increases localization affects localization decreases expression |
ISO EXP |
AHR protein affects the reaction [[TNF protein co-treated with alpinetin co-treated with benzyloxycarbonylleucyl-leucyl-leucine aldehyde] results in increased ubiquitination of SUV39H1 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde affects the reaction [beta-hexachlorocyclohexane affects the expression of AHR protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [6-formylindolo(3,2-b)carbazole results in decreased expression of AHR protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [AHR protein results in decreased expression of VIM protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Cycloheximide results in decreased expression of AHR protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Diethylhexyl Phthalate inhibits the reaction [AHR protein results in increased expression of ESR1 protein]]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [geldanamycin results in decreased expression of AHR protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [herbimycin results in decreased expression of AHR protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [monorden results in decreased expression of AHR protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [tanespimycin results in decreased expression of AHR protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of AHR protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Tetrachlorodibenzodioxin results in increased degradation of AHR protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Tetrachlorodibenzodioxin results in increased degradation of and affects the localization of AHR protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Tetrachlorodibenzodioxin results in increased degradation of and results in decreased expression of AHR protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [AHR protein binds to VIM protein] MG132 pretreatment increases expression of protein in liver of intestinal ischemia/reperfusion rats benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased localization of AHR protein benzyloxycarbonylleucyl-leucyl-leucine aldehyde affects the localization of AHR protein benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [geldanamycin results in increased degradation of AHR protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Tetrachlorodibenzodioxin results in increased degradation of AHR protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Tetrachlorodibenzodioxin results in increased degradation of and affects the localization of AHR protein] benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of AHR protein |
CTD RGD |
PMID:10497241 PMID:10722677 PMID:10922479 PMID:12002481 PMID:12237327 PMID:12606767 PMID:15385644 PMID:15899923 PMID:16891617 PMID:17445780 PMID:20057149 PMID:27752740 PMID:31676321 PMID:33207735 PMID:34801851 PMID:37217010 PMID:22079846 More...
|
RGD:401794136 |
NCBI chr 6:52,234,089...52,271,568
Ensembl chr 6:52,234,089...52,271,568
|
|
G |
Akr1b1 |
aldo-keto reductase family 1 member B1 |
increases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of AKR1B1 mRNA |
CTD |
PMID:21215737 |
|
NCBI chr 4:62,932,033...62,946,126
Ensembl chr 4:62,932,031...62,946,157
|
|
G |
Akr1b10 |
aldo-keto reductase family 1 member B10 |
increases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of AKR1B10 mRNA |
CTD |
PMID:21215737 |
|
NCBI chr 4:63,038,459...63,060,336
Ensembl chr 4:63,040,169...63,053,852
|
|
G |
Akr1c1 |
aldo-keto reductase family 1, member C1 |
increases expression multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of AKR1C1 mRNA benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [Salicylic Acid inhibits the reaction [AKR1C1 protein results in decreased susceptibility to Cisplatin]] |
CTD |
PMID:21215737 PMID:23165153 |
|
NCBI chr17:65,810,474...65,837,385
Ensembl chr17:65,810,475...65,837,326
|
|
G |
Akr1c3 |
aldo-keto reductase family 1, member C3 |
multiple interactions increases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [tolfenamic acid inhibits the reaction [AKR1C3 protein results in decreased susceptibility to Cisplatin]] benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of AKR1C3 mRNA |
CTD |
PMID:21215737 PMID:23165153 |
|
NCBI chr17:66,110,970...66,127,867
Ensembl chr17:66,110,963...66,127,873
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions increases phosphorylation increases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [cadmium acetate results in decreased expression of AKT1 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Cadmium Chloride results in increased phosphorylation of AKT1 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Cadmium results in increased phosphorylation of AKT1 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [triptolide results in decreased phosphorylation of AKT1 protein] AKT1 protein modified form inhibits the reaction [[benzyloxycarbonylleucyl-leucyl-leucine aldehyde co-treated with dihydromyricetin] results in increased ubiquitination of BIRC5 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde affects the reaction [sodium arsenite affects the expression of AKT1 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [tubocapsenolide A results in increased degradation of AKT1 protein] benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased phosphorylation of AKT1 protein benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of AKT1 protein |
CTD |
PMID:18442981 PMID:24085292 PMID:24449419 PMID:24933620 PMID:32061799 PMID:33256086 PMID:36807944 More...
|
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Anln |
anillin, actin binding protein |
decreases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of ANLN mRNA |
CTD |
PMID:25566086 PMID:31806706 |
|
NCBI chr 8:20,858,227...20,921,602
Ensembl chr 8:20,858,228...20,921,538
|
|
G |
Anxa2 |
annexin A2 |
decreases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of ANXA2 mRNA |
CTD |
PMID:31806706 |
|
NCBI chr 8:70,105,268...70,141,663
Ensembl chr 8:70,105,253...70,141,658
|
|
G |
Aoc3 |
amine oxidase, copper containing 3 |
decreases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of AOC3 mRNA |
CTD |
PMID:25566086 |
|
NCBI chr10:86,272,757...86,280,702
|
|
G |
Aph1a |
aph-1 homolog A, gamma secretase subunit |
decreases expression multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of APH1A mRNA MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of APH1A mRNA] |
CTD |
PMID:25566086 |
|
NCBI chr 2:183,437,676...183,443,113
Ensembl chr 2:183,438,434...183,441,955
|
|
G |
App |
amyloid beta precursor protein |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [APP protein modified form results in decreased expression of and results in decreased activity of TERT protein] |
CTD |
PMID:21520056 |
|
NCBI chr11:24,019,774...24,236,584
Ensembl chr11:24,019,778...24,236,561
|
|
G |
Appl1 |
adaptor protein, phosphotyrosine interacting with PH domain and leucine zipper 1 |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Lipopolysaccharides results in increased degradation of APPL1 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Poly I-C results in increased degradation of APPL1 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [resiquimod results in increased degradation of APPL1 protein] |
CTD |
PMID:25780039 |
|
NCBI chr16:2,118,503...2,166,741
Ensembl chr16:2,121,255...2,166,692
|
|
G |
Aqp2 |
aquaporin 2 |
decreases degradation |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased degradation of AQP2 protein |
CTD |
PMID:21734099 |
|
NCBI chr 7:130,711,433...130,716,468
Ensembl chr 7:130,711,413...130,716,468
|
|
G |
Aqp3 |
aquaporin 3 (Gill blood group) |
multiple interactions |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Oxygen inhibits the reaction [AQP3 protein results in increased stability of EPAS1 protein]] |
CTD |
PMID:23545307 |
|
NCBI chr 5:56,239,200...56,244,718
Ensembl chr 5:56,239,201...56,244,720
|
|
G |
Aqp5 |
aquaporin 5 |
multiple interactions |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Oxygen inhibits the reaction [AQP5 protein results in increased stability of EPAS1 protein]] |
CTD |
PMID:23545307 |
|
NCBI chr 7:130,722,675...130,726,207
Ensembl chr 7:130,721,748...130,726,209
|
|
G |
Ar |
androgen receptor |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [decursin results in increased degradation of AR protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [isobavachin results in decreased expression of and results in increased degradation of AR protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Niclosamide results in decreased expression of and results in increased degradation of AR protein alternative form]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [sulforaphane results in decreased expression of AR protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Testosterone results in increased expression of AR mRNA]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [trichostatin A results in decreased expression of AR protein] |
CTD |
PMID:12376534 PMID:17723170 PMID:19805354 PMID:24740322 PMID:37019376 |
|
NCBI chr X:63,104,771...63,273,934
Ensembl chr X:63,104,771...63,273,925
|
|
G |
Arg1 |
arginase 1 |
decreases expression multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of ARG1 mRNA MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of ARG1 mRNA] |
CTD |
PMID:25566086 |
|
NCBI chr 1:20,475,878...20,488,422
Ensembl chr 1:20,475,968...20,488,422
|
|
G |
Arih1 |
ariadne RBR E3 ubiquitin protein ligase 1 |
increases expression multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of ARIH1 protein 2-morpholin-4-yl-6-thianthren-1-yl-pyran-4-one inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of ARIH1 protein] |
CTD |
PMID:25624349 |
|
NCBI chr 8:59,777,378...59,879,762
Ensembl chr 8:59,777,379...59,880,245
|
|
G |
Arl6ip5 |
ARF like GTPase 6 interacting protein 5 |
multiple interactions |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [ARL6IP5 mutant form inhibits the reaction [Morphine results in increased expression of OPRD1 protein]] |
CTD |
PMID:21600884 |
|
NCBI chr 4:129,810,650...129,838,628
Ensembl chr 4:129,810,645...129,838,608
|
|
G |
Arnt |
aryl hydrocarbon receptor nuclear translocator |
increases expression multiple interactions decreases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of ARNT mRNA benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Curcumin results in increased degradation of ARNT protein] benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of ARNT protein benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [SP1 protein binds to ARNT promoter]; bisindolylmaleimide I inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of ARNT mRNA] |
CTD |
PMID:14529614 PMID:15899923 PMID:16880289 |
|
NCBI chr 2:182,997,731...183,056,584
Ensembl chr 2:182,997,736...183,056,580
|
|
G |
Art3 |
ADP-ribosyltransferase 3 |
decreases expression multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of ART3 mRNA MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of ART3 mRNA] |
CTD |
PMID:25566086 |
|
NCBI chr14:15,637,230...15,719,442
Ensembl chr14:15,637,237...15,665,407
|
|
G |
Asb2 |
ankyrin repeat and SOCS box-containing 2 |
decreases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of ASB2 mRNA |
CTD |
PMID:25566086 |
|
NCBI chr 6:122,474,754...122,511,014
Ensembl chr 6:122,474,756...122,510,854
|
|
G |
Atf3 |
activating transcription factor 3 |
increases expression multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of ATF3 protein Cycloheximide inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of ATF3 protein] |
CTD |
PMID:23593480 |
|
NCBI chr13:102,751,278...102,800,520
Ensembl chr13:102,751,321...102,764,631
|
|
G |
Atf4 |
activating transcription factor 4 |
increases expression multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of ATF4 mRNA; benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of ATF4 protein Cycloheximide inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of ATF4 protein] |
CTD |
PMID:14604972 PMID:17912641 PMID:23593480 PMID:31806706 |
|
NCBI chr 7:111,804,135...111,806,457
Ensembl chr 7:111,804,183...111,806,446
|
|
G |
Atf6 |
activating transcription factor 6 |
multiple interactions increases expression |
ISO |
4-phenylbutyric acid inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of ATF6 protein]; ATF6 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of ACE2 protein]; ATF6 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased cleavage of CTSD protein] |
CTD |
PMID:27638906 |
|
NCBI chr13:82,927,579...83,106,381
Ensembl chr13:82,930,034...83,107,177
|
|
G |
Atg12 |
autophagy related 12 |
multiple interactions |
ISO |
[MYBPC3 protein affects the susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde] which results in increased expression of ATG12 mRNA |
CTD |
PMID:25566086 |
|
NCBI chr18:39,452,247...39,462,424
Ensembl chr18:39,452,191...39,462,418
|
|
G |
Atg13 |
autophagy related 13 |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [ATG13 protein results in decreased expression of SQSTM1 protein] |
CTD |
PMID:27629431 |
|
NCBI chr 3:77,647,069...77,681,028
Ensembl chr 3:77,645,790...77,681,043
|
|
G |
Atg7 |
autophagy related 7 |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [ATG7 protein results in decreased expression of SQSTM1 protein] |
CTD |
PMID:27629431 |
|
NCBI chr 4:147,718,663...147,925,656
Ensembl chr 4:147,718,752...147,925,593
|
|
G |
Atp13a2 |
ATPase cation transporting 13A2 |
decreases response to substance |
ISO |
ATP13A2 protein results in decreased susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde analog |
CTD |
PMID:22847264 |
|
NCBI chr 5:153,292,722...153,312,143
Ensembl chr 5:153,292,751...153,312,139
|
|
G |
Atp1a1 |
ATPase Na+/K+ transporting subunit alpha 1 |
multiple interactions |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Cadmium Chloride results in decreased expression of ATP1A1 protein] |
CTD |
PMID:10506578 |
|
NCBI chr 2:189,020,722...189,048,826
Ensembl chr 2:189,020,722...189,048,837
|
|
G |
Atp5f1b |
ATP synthase F1 subunit beta |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [troglitazone results in decreased expression of ATP5F1B mRNA] |
CTD |
PMID:20860658 |
|
NCBI chr 7:515,454...521,858
Ensembl chr 7:515,460...567,273
|
|
G |
Atp7b |
ATPase copper transporting beta |
decreases degradation |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased degradation of ATP7B protein |
CTD |
PMID:21189263 |
|
NCBI chr16:69,952,286...70,024,404
Ensembl chr16:69,951,778...70,023,636
|
|
G |
Aurka |
aurora kinase A |
multiple interactions |
ISO |
[benzyloxycarbonylleucyl-leucyl-leucine aldehyde co-treated with Nocodazole] results in increased expression of and results in increased phosphorylation of AURKA protein; MLN8054 inhibits the reaction [[benzyloxycarbonylleucyl-leucyl-leucine aldehyde co-treated with Nocodazole] results in increased phosphorylation of AURKA protein] |
CTD |
PMID:24976383 |
|
NCBI chr 3:161,128,309...161,144,524
Ensembl chr 3:161,128,313...161,144,390
|
|
G |
Aurkb |
aurora kinase B |
multiple interactions |
ISO |
4-(4-(N-benzoylamino)anilino)-6-methoxy-7-(3-(1-morpholino)propoxy)quinazoline inhibits the reaction [[benzyloxycarbonylleucyl-leucyl-leucine aldehyde co-treated with Nocodazole] results in increased phosphorylation of AURKB protein]; [benzyloxycarbonylleucyl-leucyl-leucine aldehyde co-treated with Nocodazole] results in increased phosphorylation of AURKB protein |
CTD |
PMID:24976383 |
|
NCBI chr10:53,744,290...53,750,831
Ensembl chr10:53,745,142...53,750,837
|
|
G |
Bach1 |
BTB domain and CNC homolog 1 |
multiple interactions increases expression increases ubiquitination |
ISO |
2-tert-butylhydroquinone promotes the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased ubiquitination of BACH1 protein]; [benzyloxycarbonylleucyl-leucyl-leucine aldehyde co-treated with Hemin] affects the localization of BACH1 protein; [benzyloxycarbonylleucyl-leucyl-leucine aldehyde co-treated with Hemin] results in increased expression of BACH1 protein; [Hemin co-treated with benzyloxycarbonylleucyl-leucyl-leucine aldehyde] results in increased expression of BACH1 mRNA; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [tetrachlorobenzoquinone results in increased degradation of BACH1 protein]; hydroquinone promotes the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased ubiquitination of BACH1 protein]; quinone promotes the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased ubiquitination of BACH1 protein] benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of BACH1 mRNA; benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of BACH1 protein |
CTD |
PMID:27393035 PMID:28645578 PMID:33434570 |
|
NCBI chr11:26,939,429...26,974,876
Ensembl chr11:26,939,480...26,972,447
|
|
G |
Bag3 |
BAG cochaperone 3 |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Staurosporine results in increased degradation of BAG3 protein] |
CTD |
PMID:19352495 |
|
NCBI chr 1:183,103,038...183,126,862
Ensembl chr 1:183,102,871...183,126,858
|
|
G |
Bak1 |
BCL2-antagonist/killer 1 |
increases ubiquitination |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased ubiquitination of BAK1 protein |
CTD |
PMID:36346691 |
|
NCBI chr20:5,100,480...5,109,669
Ensembl chr20:5,100,480...5,109,264
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions increases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Arachidonic Acid affects the localization of BAX protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased degradation of and results in increased expression of BAX protein MitoTEMPO inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of BAX protein] |
CTD |
PMID:15782132 PMID:19540902 PMID:34418242 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bbc3 |
Bcl-2 binding component 3 |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [[Ascorbic Acid co-treated with Zinc Acetate co-treated with motexafin gadolinium] results in decreased expression of BBC3 protein] |
CTD |
PMID:20530418 |
|
NCBI chr 1:77,013,281...77,022,509
Ensembl chr 1:77,014,543...77,022,509
|
|
G |
Bcas2 |
BCAS2, pre-mRNA processing factor |
decreases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of BCAS2 mRNA |
CTD |
PMID:31806706 |
|
NCBI chr 2:190,692,503...190,700,386
Ensembl chr 2:190,692,461...190,700,389
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions decreases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Arachidonic Acid results in decreased expression of BCL2 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [evodiamine results in increased cleavage of BCL2 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [trimethyltin chloride results in decreased expression of BCL2 protein] benzyloxycarbonyl-valyl-alanyl-aspartic acid promotes the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of BCL2 protein]; MitoTEMPO inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of BCL2 protein] benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of BCL2; benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of BCL2 protein |
CTD |
PMID:19540902 PMID:20005289 PMID:20100472 PMID:20449726 PMID:23423712 PMID:34418242 More...
|
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Bcl2l1 |
Bcl2-like 1 |
multiple interactions decreases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Arachidonic Acid results in decreased expression of BCL2L1 protein] benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of BCL2L1 protein benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Topotecan results in increased degradation of BCL2L1 protein] |
CTD |
PMID:16960866 PMID:19540902 PMID:19812371 |
|
NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479 Ensembl chr 1:141,253,523...141,303,479
|
|
G |
Bcl2l11 |
Bcl2-like 11 |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Arsenic Trioxide results in increased degradation of BCL2L11 protein] |
CTD |
PMID:36509116 |
|
NCBI chr 3:115,366,783...115,404,068
Ensembl chr 3:115,366,646...115,404,068
|
|
G |
Birc2 |
baculoviral IAP repeat-containing 2 |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [BIRC2 protein results in increased degradation of SOD1 protein mutant form] |
CTD |
PMID:27773815 |
|
NCBI chr 8:4,968,856...4,989,325
Ensembl chr 8:4,968,842...4,988,732
|
|
G |
Birc3 |
baculoviral IAP repeat-containing 3 |
multiple interactions increases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [BIRC3 protein results in increased degradation of SOD1 protein mutant form]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of BIRC3 mRNA] benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of BIRC3 mRNA; benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of BIRC3 protein |
CTD |
PMID:14527959 PMID:24085292 PMID:27773815 |
|
NCBI chr 8:5,000,844...5,028,470
Ensembl chr 8:5,000,845...5,015,802
|
|
G |
Birc5 |
baculoviral IAP repeat-containing 5 |
increases expression multiple interactions decreases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of BIRC5 protein [benzyloxycarbonylleucyl-leucyl-leucine aldehyde co-treated with dihydromyricetin] results in increased ubiquitination of BIRC5 protein; [benzyloxycarbonylleucyl-leucyl-leucine aldehyde co-treated with MK 2206] results in increased ubiquitination of BIRC5 protein; AKT1 protein modified form inhibits the reaction [[benzyloxycarbonylleucyl-leucyl-leucine aldehyde co-treated with dihydromyricetin] results in increased ubiquitination of BIRC5 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [(+)-JQ1 compound results in decreased expression of BIRC5 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [[pifithrin co-treated with Topotecan] results in increased degradation of BIRC5 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Capsaicin results in decreased expression of BIRC5 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [dihydromyricetin results in decreased expression of BIRC5 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Quercetin results in decreased expression of BIRC5 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased susceptibility to [Oxaliplatin results in decreased expression of BIRC5 protein] benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of BIRC5 mRNA benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Topotecan results in increased degradation of BIRC5 protein] |
CTD |
PMID:16328441 PMID:17510429 PMID:17548900 PMID:19812371 PMID:19939880 PMID:20708607 PMID:23872705 PMID:25566086 PMID:36807944 More...
|
|
NCBI chr10:103,072,530...103,081,382
Ensembl chr10:103,073,408...103,081,380
|
|
G |
Blvrb |
biliverdin reductase B |
increases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of BLVRB mRNA |
CTD |
PMID:25566086 |
|
NCBI chr 1:82,738,646...82,756,312
Ensembl chr 1:82,738,695...82,770,375
|
|
G |
Bmi1 |
BMI1 proto-oncogene, polycomb ring finger |
increases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of BMI1 protein |
CTD |
PMID:33157086 |
|
NCBI chr17:81,332,175...81,341,625
Ensembl chr17:81,332,214...81,388,690
|
|
G |
Bnip3 |
BCL2 interacting protein 3 |
multiple interactions increases expression |
ISO |
[arsenic trioxide co-treated with benzyloxycarbonylleucyl-leucyl-leucine aldehyde] results in decreased expression of BNIP3 mRNA; arsenic trioxide inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of BNIP3 mRNA]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [Valproic Acid results in increased expression of BNIP3 mRNA] |
CTD |
PMID:25446377 |
|
NCBI chr 1:193,708,164...193,725,348
Ensembl chr 1:193,708,167...193,725,359
|
|
G |
Bok |
BCL2 family apoptosis regulator BOK |
multiple interactions |
ISO |
[MYBPC3 protein affects the susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde] which results in decreased expression of BOK mRNA |
CTD |
PMID:25566086 |
|
NCBI chr 9:94,223,493...94,234,476
Ensembl chr 9:94,223,389...94,234,476
|
|
G |
Brd4 |
bromodomain containing 4 |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [ARV-825 results in increased degradation of BRD4 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [BRD4 mutant form affects the localization of RELA protein] benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [STA 9090 inhibits the reaction [PKD1 gene mutant form results in increased expression of BRD4 protein]] |
CTD |
PMID:23686307 PMID:25877301 PMID:26051217 |
|
NCBI chr 7:11,216,446...11,296,029
Ensembl chr 7:11,216,446...11,295,539
|
|
G |
C1qb |
complement C1q B chain |
multiple interactions decreases expression |
ISO |
MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of C1QB mRNA] |
CTD |
PMID:25566086 |
|
NCBI chr 5:149,118,843...149,124,394
Ensembl chr 5:149,118,846...149,124,407
|
|
G |
Cacna1h |
calcium voltage-gated channel subunit alpha1 H |
decreases expression decreases degradation |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of CACNA1H mRNA benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased degradation of CACNA1H protein |
CTD |
PMID:25566086 PMID:30552955 |
|
NCBI chr10:14,390,104...14,448,204
Ensembl chr10:14,390,113...14,448,376
|
|
G |
Canx |
calnexin |
affects localization |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde affects the localization of CANX protein |
CTD |
PMID:17912641 |
|
NCBI chr10:34,623,865...34,656,866
Ensembl chr10:34,625,191...34,656,821
|
|
G |
Capn1 |
calpain 1 |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Acrylamide results in increased expression of CAPN1 protein] |
CTD |
PMID:37353096 |
|
NCBI chr 1:203,275,912...203,300,848
Ensembl chr 1:203,277,344...203,300,177
|
|
G |
Car14 |
carbonic anhydrase 14 |
decreases expression multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of CAR14 mRNA MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of CAR14 mRNA] |
CTD |
PMID:25566086 |
|
NCBI chr 2:183,442,263...183,449,231
Ensembl chr 2:183,441,667...183,449,693
|
|
G |
Casp1 |
caspase 1 |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [IFNG protein results in increased activity of CASP1 protein]; Quercetin inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [IFNG protein results in increased activity of CASP1 protein]] |
CTD |
PMID:15914627 |
|
NCBI chr 8:2,587,812...2,597,403
Ensembl chr 8:2,587,831...2,597,383
|
|
G |
Casp3 |
caspase 3 |
multiple interactions increases cleavage increases expression increases activity |
ISO EXP |
4-phenylbutyric acid inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased cleavage of CASP3 protein]; [Arsenic Trioxide co-treated with benzyloxycarbonylleucyl-leucyl-leucine aldehyde] results in increased cleavage of CASP3 protein; [XBP1 mutant form co-treated with benzyloxycarbonylleucyl-leucyl-leucine aldehyde] promotes the reaction [Tobacco Smoke Pollution analog results in increased cleavage of CASP3 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [evodiamine results in increased activity of and results in increased cleavage of CASP3 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased cleavage of and results in increased activity of CASP3 protein benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of CASP3 protein modified form benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased activity of CASP3 protein Acetylcysteine inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased activity of CASP3 protein] |
CTD |
PMID:15498850 PMID:15725397 PMID:16880202 PMID:18463101 PMID:18790767 PMID:20005289 PMID:20100472 PMID:20449726 PMID:20649845 PMID:23684743 PMID:25449439 PMID:25568320 PMID:27638906 PMID:29944914 PMID:34418242 More...
|
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp6 |
caspase 6 |
multiple interactions decreases activity |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [IFNG protein results in increased activity of CASP6 protein]; Quercetin inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [IFNG protein results in increased activity of CASP6 protein]] benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased activity of CASP6 protein |
CTD |
PMID:15914627 |
|
NCBI chr 2:218,466,063...218,478,503
Ensembl chr 2:218,466,076...218,478,502
|
|
G |
Casp7 |
caspase 7 |
increases activity |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased activity of CASP7 protein |
CTD |
PMID:19139269 |
|
NCBI chr 1:255,437,438...255,476,737
Ensembl chr 1:255,437,172...255,476,729
|
|
G |
Casp8 |
caspase 8 |
multiple interactions increases activity |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased cleavage of and results in increased activity of CASP8 protein benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased activity of CASP8 protein benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [[benzyloxycarbonyl-isoleucyl-glutamyl-threonyl-aspartic acid fluoromethyl ketone results in decreased activity of CASP8 protein] inhibits the reaction [Dexamethasone results in increased expression of TSC22D3 protein]]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [IFNG protein results in increased activity of CASP8 protein]; Quercetin inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [IFNG protein results in increased activity of CASP8 protein]] |
CTD |
PMID:15498850 PMID:15914627 PMID:20100472 PMID:20449726 PMID:20671745 |
|
NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542
|
|
G |
Casp9 |
caspase 9 |
multiple interactions increases activity |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased cleavage of and results in increased activity of CASP9 protein benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased activity of CASP9 protein |
CTD |
PMID:15498850 PMID:16880202 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Cast |
calpastatin |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Acrylamide results in increased cleavage of CAST protein] |
CTD |
PMID:37353096 |
|
NCBI chr 2:3,973,112...4,082,658
Ensembl chr 2:3,973,112...4,082,659
|
|
G |
Cat |
catalase |
increases expression multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of CAT mRNA CAT protein inhibits the reaction [[SOD2 protein co-treated with benzyloxycarbonylleucyl-leucyl-leucine aldehyde] results in decreased expression of HDAC2 protein] |
CTD |
PMID:20061341 PMID:24973648 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Cav1 |
caveolin 1 |
decreases expression multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of CAV1 protein [MYBPC3 protein affects the susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde] which results in decreased expression of CAV1 mRNA |
CTD |
PMID:19706615 PMID:25566086 |
|
NCBI chr 4:45,640,624...45,673,708
Ensembl chr 4:45,634,918...45,673,705
|
|
G |
Cavin1 |
caveolae associated protein 1 |
multiple interactions decreases expression |
ISO |
MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of CAVIN1 mRNA] |
CTD |
PMID:25566086 |
|
NCBI chr10:85,884,100...85,896,136
Ensembl chr10:85,889,036...85,896,120
|
|
G |
Cavin2 |
caveolae associated protein 2 |
decreases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of CAVIN2 mRNA |
CTD |
PMID:25566086 |
|
NCBI chr 9:50,302,079...50,314,096
Ensembl chr 9:50,301,206...50,314,147
|
|
G |
Cbr3 |
carbonyl reductase 3 |
increases expression |
ISO |
[benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of NFE2L2 protein] which results in increased expression of CBR3 mRNA |
CTD |
PMID:20806931 |
|
NCBI chr11:33,008,615...33,016,877
Ensembl chr11:33,008,615...33,016,875
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
multiple interactions |
ISO EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Chloroquine results in increased expression of CCL2 mRNA]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [IL1A protein results in increased secretion of CCL2 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [TNF protein results in increased expression of CCL2 mRNA]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [TNF protein results in increased expression of CCL2 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [TNF protein results in increased secretion of CCL2 protein] benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of CCL2 mRNA] benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [IL1B protein results in increased expression of CCL2 mRNA] |
CTD |
PMID:10541287 PMID:11230753 PMID:11698246 PMID:15139008 PMID:19945525 |
|
NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Ccna2 |
cyclin A2 |
decreases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of CCNA2 mRNA |
CTD |
PMID:20061341 |
|
NCBI chr 2:119,427,239...119,433,645
Ensembl chr 2:119,426,089...119,433,577
|
|
G |
Ccnb1 |
cyclin B1 |
multiple interactions decreases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [arsenite results in increased ubiquitination of CCNB1 protein] [MYBPC3 protein affects the susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde] which results in decreased expression of CCNB1 mRNA benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of CCNB1 mRNA |
CTD |
PMID:17373649 PMID:20061341 PMID:25566086 |
|
NCBI chr 2:31,912,190...31,921,163
Ensembl chr 2:31,912,193...31,921,172
|
|
G |
Ccnb2 |
cyclin B2 |
decreases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of CCNB2 mRNA |
CTD |
PMID:20061341 |
|
NCBI chr 8:71,087,594...71,100,794
Ensembl chr 8:71,087,595...71,100,874
|
|
G |
Ccnd1 |
cyclin D1 |
multiple interactions increases expression increases phosphorylation |
ISO EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased expression of CCND1 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [2,4,5,2',4',5'-hexachlorobiphenyl results in decreased expression of CCND1 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [3,3'-diindolylmethane analog results in decreased expression of CCND1 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [alopestatin metabolite results in decreased expression of CCND1 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Carbamazepine results in decreased expression of CCND1 mRNA]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Carbamazepine results in decreased expression of CCND1 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [deguelin results in decreased expression of CCND1 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Drugs, Chinese Herbal results in decreased expression of CCND1 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [kahweol results in decreased expression of CCND1 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [lysocellin results in decreased expression of CCND1 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [nickel chloride results in decreased expression of and results in increased degradation of CCND1 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [nickel chloride results in decreased phosphorylation of CCND1 protein] benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of CCND1 protein benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased phosphorylation of CCND1 protein benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Dexamethasone results in increased degradation of CCND1 protein]; Tetrachlorodibenzodioxin inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased phosphorylation of CCND1 protein] |
CTD |
PMID:15247282 PMID:16051428 PMID:16525630 PMID:16707792 PMID:16965676 PMID:18792914 PMID:20394812 PMID:21472727 PMID:24231000 PMID:27424123 PMID:28548306 PMID:30703377 More...
|
|
NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602
|
|
G |
Ccnd3 |
cyclin D3 |
decreases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of CCND3 mRNA |
CTD |
PMID:20061341 |
|
NCBI chr 9:13,394,161...13,400,341
Ensembl chr 9:13,394,169...13,489,371
|
|
G |
Ccs |
copper chaperone for superoxide dismutase |
multiple interactions |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [[Copper Sulfate co-treated with 2,3,2-tetramine] results in increased degradation of CCS protein] |
CTD |
PMID:12832419 |
|
NCBI chr 1:202,113,792...202,134,931
Ensembl chr 1:202,113,804...202,134,915
|
|
G |
Cd14 |
CD14 molecule |
increases expression multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of CD14 mRNA MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of CD14 mRNA] |
CTD |
PMID:25566086 |
|
NCBI chr18:28,335,522...28,337,383
Ensembl chr18:28,335,340...28,337,261
|
|
G |
Cd1d1 |
CD1d1 molecule |
increases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of CD1D1 mRNA |
CTD |
PMID:25566086 |
|
NCBI chr 2:172,423,582...172,427,089
Ensembl chr 2:172,423,582...172,427,089
|
|
G |
Cd248 |
CD248 molecule |
decreases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of CD248 mRNA |
CTD |
PMID:25566086 |
|
NCBI chr 1:202,373,676...202,376,240
Ensembl chr 1:202,373,676...202,376,240
|
|
G |
Cd36 |
CD36 molecule |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CD36 protein] |
CTD |
PMID:36534932 |
|
NCBI chr 4:17,317,343...17,410,084
Ensembl chr 4:17,354,466...17,513,903
|
|
G |
Cdc20 |
cell division cycle 20 |
multiple interactions decreases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Cadmium Chloride results in increased degradation of CDC20 protein] benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of CDC20 mRNA |
CTD |
PMID:20054826 PMID:20061341 PMID:25566086 |
|
NCBI chr 5:131,966,203...131,970,406
Ensembl chr 5:131,966,215...131,970,512
|
|
G |
Cdc25b |
cell division cycle 25B |
decreases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of CDC25B mRNA |
CTD |
PMID:20061341 |
|
NCBI chr 3:118,407,127...118,417,272
Ensembl chr 3:118,407,128...118,417,272
|
|
G |
Cdc25c |
cell division cycle 25C |
decreases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of CDC25C mRNA |
CTD |
PMID:20061341 |
|
NCBI chr18:26,335,156...26,356,199
Ensembl chr18:26,335,834...26,356,185
|
|
G |
Cdca3 |
cell division cycle associated 3 |
decreases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of CDCA3 mRNA |
CTD |
PMID:20061341 |
|
NCBI chr 4:157,634,775...157,638,799
Ensembl chr 4:157,634,928...157,638,799
|
|
G |
Cdh3 |
cadherin 3 |
multiple interactions |
ISO |
[MYBPC3 protein affects the susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde] which results in decreased expression of CDH3 mRNA |
CTD |
PMID:25566086 |
|
NCBI chr19:34,393,596...34,444,084
Ensembl chr19:34,393,727...34,444,084
|
|
G |
Cdk1 |
cyclin-dependent kinase 1 |
decreases expression multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of CDK1 mRNA [MYBPC3 protein affects the susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde] which results in decreased expression of CDK1 mRNA |
CTD |
PMID:20061341 PMID:25566086 |
|
NCBI chr20:19,266,226...19,281,417
Ensembl chr20:19,266,248...19,281,408
|
|
G |
Cdk2 |
cyclin dependent kinase 2 |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [troglitazone results in decreased expression of CDK2 protein] benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [bruceantinol results in decreased expression of CDK2 protein] |
CTD |
PMID:15610522 PMID:38608999 |
|
NCBI chr 7:1,129,878...1,137,431
Ensembl chr 7:1,129,811...1,137,403
|
|
G |
Cdk4 |
cyclin-dependent kinase 4 |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [bruceantinol results in decreased expression of CDK4 protein] |
CTD |
PMID:38608999 |
|
NCBI chr 7:62,886,124...62,889,562
Ensembl chr 7:62,883,105...62,942,403
|
|
G |
Cdk6 |
cyclin-dependent kinase 6 |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [bruceantinol results in decreased expression of CDK6 protein] |
CTD |
PMID:38608999 |
|
NCBI chr 4:30,637,650...30,829,688
Ensembl chr 4:30,646,460...30,829,634
|
|
G |
Cdkn1b |
cyclin-dependent kinase inhibitor 1B |
decreases degradation |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased degradation of CDKN1B protein |
CTD |
PMID:17283133 |
|
NCBI chr 4:167,760,067...167,765,177
Ensembl chr 4:167,760,181...167,764,982
|
|
G |
Cdkn2a |
cyclin-dependent kinase inhibitor 2A |
decreases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of CDKN2A mRNA |
CTD |
PMID:20061341 |
|
NCBI chr 5:103,984,949...103,992,143
Ensembl chr 5:103,984,949...104,003,149
|
|
G |
Cdkn2c |
cyclin-dependent kinase inhibitor 2C |
decreases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of CDKN2C mRNA |
CTD |
PMID:20061341 |
|
NCBI chr 5:124,411,123...124,416,278
Ensembl chr 5:124,411,124...124,416,278
|
|
G |
Cdkn3 |
cyclin-dependent kinase inhibitor 3 |
decreases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of CDKN3 mRNA |
CTD |
PMID:20061341 |
|
NCBI chr15:20,022,522...20,033,948
Ensembl chr15:20,022,664...20,033,945
|
|
G |
Cebpa |
CCAAT/enhancer binding protein alpha |
increases ubiquitination multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased ubiquitination of CEBPA protein benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [NSC606985 results in decreased expression of CEBPA protein] |
CTD |
PMID:19662097 |
|
NCBI chr 1:87,759,631...87,762,303
Ensembl chr 1:87,759,433...87,762,412
|
|
G |
Cebpb |
CCAAT/enhancer binding protein beta |
multiple interactions |
ISO EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of and results in increased localization of CEBPB protein; Quercetin inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of and results in increased localization of CEBPB protein] benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [N-acetylsphingosine results in decreased localization of CEBPB protein] |
CTD |
PMID:11779194 PMID:15319326 |
|
NCBI chr 3:156,398,035...156,399,466
Ensembl chr 3:156,397,052...156,399,473
|
|
G |
Cebpd |
CCAAT/enhancer binding protein delta |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of and results in increased localization of CEBPD protein; Quercetin inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of and results in increased localization of CEBPD protein] |
CTD |
PMID:11779194 |
|
NCBI chr11:84,764,670...84,765,808
Ensembl chr11:84,764,565...84,765,829
|
|
G |
Cebpe |
CCAAT/enhancer binding protein epsilon |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [Tretinoin results in increased expression of CEBPE protein] |
CTD |
PMID:20945414 |
|
NCBI chr15:28,169,711...28,171,471
Ensembl chr15:28,169,704...28,171,814
|
|
G |
Cenpa |
centromere protein A |
decreases expression multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of CENPA mRNA MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of CENPA mRNA] |
CTD |
PMID:25566086 |
|
NCBI chr 6:25,700,142...25,711,767
Ensembl chr 6:25,700,142...25,711,675
|
|
G |
Cers6 |
ceramide synthase 6 |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [CERS6 protein affects the expression of ABCB1 protein] |
CTD |
PMID:34915026 |
|
NCBI chr 3:53,630,637...53,879,692
Ensembl chr 3:53,630,959...53,876,848
|
|
G |
Cflar |
CASP8 and FADD-like apoptosis regulator |
affects expression multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde affects the expression of CFLAR protein alternative form benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [(+)-JQ1 compound results in decreased expression of CFLAR protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [alvocidib results in decreased expression of CFLAR protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Quercetin results in decreased expression of CFLAR protein alternative form]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [shogaol results in decreased expression of CFLAR protein modified form] |
CTD |
PMID:16951203 PMID:17510429 PMID:18980244 PMID:25619640 PMID:26415225 |
|
NCBI chr 9:60,185,338...60,236,173
Ensembl chr 9:60,185,452...60,237,034
|
|
G |
Cftr |
CF transmembrane conductance regulator |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [5-butyl-7-chloro-6-hydroxybenzo(c)quinolizinium inhibits the reaction [CFTR protein mutant form inhibits the reaction [[Colforsin co-treated with Genistein] results in increased transport of Iodides]]]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [miglustat inhibits the reaction [CFTR protein mutant form inhibits the reaction [[Colforsin co-treated with Genistein] results in increased transport of Iodides]]]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [miglustat results in increased activity of CFTR protein mutant form] |
CTD |
PMID:18230692 |
|
NCBI chr 4:46,561,269...46,728,759
Ensembl chr 4:46,560,885...46,728,756
|
|
G |
Chek1 |
checkpoint kinase 1 |
decreases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of CHEK1 mRNA |
CTD |
PMID:20061341 |
|
NCBI chr 8:36,420,565...36,443,477
Ensembl chr 8:36,420,569...36,441,009
|
|
G |
Chrm2 |
cholinergic receptor, muscarinic 2 |
multiple interactions decreases expression |
ISO |
MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of CHRM2 mRNA] |
CTD |
PMID:25566086 |
|
NCBI chr 4:65,015,408...65,149,104
Ensembl chr 4:65,014,144...65,149,103
|
|
G |
Chuk |
component of inhibitor of nuclear factor kappa B kinase complex |
increases activity |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased activity of CHUK protein |
CTD |
PMID:24085292 |
|
NCBI chr 1:242,959,539...242,995,066
Ensembl chr 1:242,959,760...242,995,065
|
|
G |
Cidea |
cell death-inducing DFFA-like effector a |
decreases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of CIDEA mRNA |
CTD |
PMID:25566086 |
|
NCBI chr18:60,894,917...60,920,485
Ensembl chr18:60,894,874...60,920,481
|
|
G |
Cited4 |
Cbp/p300-interacting transactivator, with Glu/Asp-rich carboxy-terminal domain, 4 |
decreases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of CITED4 mRNA |
CTD |
PMID:25566086 |
|
NCBI chr 5:134,246,936...134,247,827
Ensembl chr 5:134,246,682...134,248,135
|
|
G |
Ckb |
creatine kinase B |
multiple interactions |
ISO |
[MYBPC3 protein affects the susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde] which results in decreased expression of CKB mRNA |
CTD |
PMID:25566086 |
|
NCBI chr 6:130,729,420...130,732,301
Ensembl chr 6:130,729,423...130,732,315
|
|
G |
Ckmt2 |
creatine kinase, mitochondrial 2 |
decreases expression multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of CKMT2 mRNA MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of CKMT2 mRNA] |
CTD |
PMID:25566086 |
|
NCBI chr 2:23,079,918...23,110,518
Ensembl chr 2:23,079,918...23,110,430
|
|
G |
Cldn4 |
claudin 4 |
increases expression multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of CLDN4 mRNA MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of CLDN4 mRNA] |
CTD |
PMID:25566086 |
|
NCBI chr12:21,751,638...21,753,436
Ensembl chr12:21,751,331...21,753,436
|
|
G |
Cldn5 |
claudin 5 |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [9,10-phenanthrenequinone results in decreased expression of and affects the localization of CLDN5 protein] |
CTD |
PMID:34391839 |
|
NCBI chr11:82,212,822...82,214,248
Ensembl chr11:82,211,475...82,214,992
|
|
G |
Clip4 |
CAP-GLY domain containing linker protein family, member 4 |
multiple interactions decreases expression |
ISO |
MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of CLIP4 mRNA] |
CTD |
PMID:25566086 |
|
NCBI chr 6:23,616,280...23,697,625 NCBI chr 6:23,718,580...23,729,231 NCBI chr 6:23,597,729...23,601,000
Ensembl chr 6:23,616,281...23,677,874
|
|
G |
Cmya5 |
cardiomyopathy associated 5 |
multiple interactions decreases expression |
ISO |
MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of CMYA5 mRNA] |
CTD |
PMID:25566086 |
|
NCBI chr 2:24,279,520...24,378,253
Ensembl chr 2:24,279,528...24,378,364
|
|
G |
Cnr1 |
cannabinoid receptor 1 |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Gemcitabine results in increased expression of CNR1 mRNA] |
CTD |
PMID:21525939 |
|
NCBI chr 5:48,408,543...48,436,099
Ensembl chr 5:48,408,574...48,435,099
|
|
G |
Cnr2 |
cannabinoid receptor 2 |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Gemcitabine results in increased expression of CNR2 mRNA] |
CTD |
PMID:21525939 |
|
NCBI chr 5:148,125,222...148,151,548
Ensembl chr 5:148,125,604...148,151,548
|
|
G |
Col1a1 |
collagen type I alpha 1 chain |
multiple interactions |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Asbestos, Amosite results in increased expression of COL1A1 mRNA] |
CTD |
PMID:11306436 |
|
NCBI chr10:79,883,622...79,900,625
Ensembl chr10:79,883,622...79,900,624
|
|
G |
Commd1 |
copper metabolism domain containing 1 |
increases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of COMMD1 protein |
CTD |
PMID:23401744 |
|
NCBI chr14:96,880,463...96,984,494
Ensembl chr14:96,880,463...96,984,501
|
|
G |
Corin |
corin, serine peptidase |
decreases expression multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of CORIN mRNA MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of CORIN mRNA] |
CTD |
PMID:25566086 |
|
NCBI chr14:35,680,601...35,910,703
Ensembl chr14:35,681,304...35,909,503
|
|
G |
Cox4i2 |
cytochrome c oxidase subunit 4i2 |
decreases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of COX4I2 mRNA |
CTD |
PMID:25566086 |
|
NCBI chr 3:141,228,443...141,239,337
Ensembl chr 3:141,228,443...141,239,331
|
|
G |
Cpxm1 |
carboxypeptidase X (M14 family), member 1 |
increases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of CPXM1 mRNA |
CTD |
PMID:20061341 PMID:25566086 |
|
NCBI chr 3:117,588,532...117,595,330
Ensembl chr 3:117,588,532...117,595,330
|
|
G |
Crct1 |
cysteine-rich C-terminal 1 |
increases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of CRCT1 mRNA |
CTD |
PMID:25566086 |
|
NCBI chr 2:178,633,789...178,635,274
Ensembl chr 2:178,634,092...178,634,394
|
|
G |
Crebbp |
CREB binding protein |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Valproic Acid results in decreased expression of CREBBP protein] |
CTD |
PMID:27381264 |
|
NCBI chr10:11,335,551...11,461,888
Ensembl chr10:11,335,953...11,461,888
|
|
G |
Crip2 |
cysteine-rich protein 2 |
decreases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of CRIP2 mRNA |
CTD |
PMID:25566086 |
|
NCBI chr 6:132,221,120...132,226,066
Ensembl chr 6:132,221,082...132,226,065
|
|
G |
Cryaa |
crystallin, alpha A |
decreases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of CRYAA mRNA; benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of CRYAA protein |
CTD |
PMID:15914627 |
|
NCBI chr20:9,783,605...9,787,351
Ensembl chr20:9,783,605...9,787,349
|
|
G |
Cryab |
crystallin, alpha B |
increases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of CRYAB mRNA |
CTD |
PMID:15914627 |
|
NCBI chr 8:51,093,441...51,099,161
Ensembl chr 8:51,093,441...51,099,157
|
|
G |
Csnk2b |
casein kinase 2 beta |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Diethylhexyl Phthalate results in increased degradation of CSNK2B protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [TNFAIP1 protein results in increased degradation of CSNK2B protein] |
CTD |
PMID:37302538 |
|
NCBI chr20:3,700,363...3,705,331
Ensembl chr20:3,698,733...3,707,133
|
|
G |
Cst5 |
cystatin D |
decreases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of CST5 mRNA |
CTD |
PMID:31806706 |
|
NCBI chr 3:137,573,194...137,577,754
Ensembl chr 3:137,573,194...137,577,754
|
|
G |
Ctnnb1 |
catenin beta 1 |
multiple interactions decreases degradation |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde affects the reaction [bruceine D affects the reaction [Oxygen deficiency affects the expression of CTNNB1 protein]]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [arctigenin results in decreased expression of CTNNB1 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Aspirin results in increased ubiquitination of CTNNB1 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [deguelin results in decreased expression of CTNNB1 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [deguelin results in increased degradation of CTNNB1 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Drugs, Chinese Herbal results in decreased expression of CTNNB1 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [GW 4064 results in decreased expression of CTNNB1 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [quinocetone results in decreased expression of CTNNB1 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [RASSF5 protein results in decreased expression of CTNNB1 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [sulindac sulfide results in decreased expression of CTNNB1 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [sulindac sulfone results in decreased expression of CTNNB1 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Vitamin A results in decreased expression of CTNNB1 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [Nitroglycerin results in increased degradation of CTNNB1 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of and affects the localization of CTNNB1 protein; thymoquinone inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased degradation of CTNNB1 protein] benzyloxycarbonylleucyl-leucyl-leucine aldehyde affects the phosphorylation of and affects the localization of CTNNB1 protein; benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased degradation of and results in increased expression of CTNNB1 protein; Phenobarbital inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of CTNNB1 protein] |
CTD |
PMID:14555707 PMID:16878161 PMID:17030184 PMID:17219422 PMID:20510325 PMID:21472727 PMID:25217643 PMID:26990689 PMID:27693619 PMID:28343033 PMID:28548306 PMID:31115591 PMID:32112862 PMID:34900531 PMID:38216027 More...
|
|
NCBI chr 8:120,640,008...120,667,110
Ensembl chr 8:120,639,995...120,667,111
|
|
G |
Ctsd |
cathepsin D |
increases cleavage multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased cleavage of CTSD protein 4-phenylbutyric acid inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased cleavage of CTSD protein]; ATF6 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased cleavage of CTSD protein]; ERN1 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased cleavage of CTSD protein] |
CTD |
PMID:27638906 |
|
NCBI chr 1:197,527,467...197,539,343
Ensembl chr 1:197,527,467...197,539,488
|
|
G |
Cul2 |
cullin 2 |
multiple interactions |
ISO |
CUL2 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased ubiquitination of MAF1 protein] |
CTD |
PMID:31645432 |
|
NCBI chr17:54,169,093...54,210,197
Ensembl chr17:54,169,086...54,209,968
|
|
G |
Cx3cl1 |
C-X3-C motif chemokine ligand 1 |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [TNF protein results in increased expression of CX3CL1 mRNA] |
CTD |
PMID:11698246 |
|
NCBI chr19:10,227,337...10,237,826
Ensembl chr19:10,227,340...10,236,833
|
|
G |
Cxcl1 |
C-X-C motif chemokine ligand 1 |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [TNF protein results in increased expression of CXCL1 mRNA]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [TNF protein results in increased expression of CXCL1 protein] |
CTD |
PMID:11698246 |
|
NCBI chr14:17,193,364...17,195,143
Ensembl chr14:17,193,365...17,195,215
|
|
G |
Cxcl12 |
C-X-C motif chemokine ligand 12 |
decreases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of CXCL12 mRNA |
CTD |
PMID:25566086 |
|
NCBI chr 4:150,388,326...150,401,173
Ensembl chr 4:150,388,325...150,401,168
|
|
G |
Cxcl3 |
C-X-C motif chemokine ligand 3 |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [TNF protein results in increased expression of CXCL1 mRNA]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [TNF protein results in increased expression of CXCL1 protein] |
CTD |
PMID:11698246 |
|
NCBI chr14:17,287,727...17,289,451
Ensembl chr14:17,270,146...17,289,511
|
|
G |
Cxcr4 |
C-X-C motif chemokine receptor 4 |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [TPD7 compound results in decreased expression of CXCR4 protein] |
CTD |
PMID:25753200 |
|
NCBI chr13:40,077,976...40,081,883
Ensembl chr13:40,077,976...40,081,883
|
|
G |
Cycs |
cytochrome c, somatic |
affects localization |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde affects the localization of CYCS protein |
CTD |
PMID:15725397 |
|
NCBI chr 4:79,651,894...79,653,994
Ensembl chr 4:79,651,378...79,654,054 Ensembl chr18:79,651,378...79,654,054
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
multiple interactions increases expression increases activity |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [[Cycloheximide co-treated with Harmaline] results in decreased expression of CYP1A1 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [[Cycloheximide co-treated with harmalol] results in decreased expression of CYP1A1 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Harmine results in decreased stability of CYP1A1 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [harmol results in decreased stability of CYP1A1 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA] benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of CYP1A1 mRNA; benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of CYP1A1 protein benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased activity of CYP1A1 protein benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of CYP1A1 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [Cadmium Chloride results in increased expression of CYP1A1 mRNA]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [Copper results in increased expression of CYP1A1 mRNA]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [Cycloheximide results in increased expression of CYP1A1 mRNA]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [Lead results in increased expression of CYP1A1 mRNA]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [Mercury results in increased expression of CYP1A1 mRNA]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [sodium arsenite results in increased expression of CYP1A1 mRNA]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA] |
CTD |
PMID:10722677 PMID:10777561 PMID:16093525 PMID:16891617 PMID:17606337 PMID:18835339 PMID:22001777 PMID:22037238 More...
|
|
NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
increases expression |
EXP |
MG132 pretreatment increases expression of protein in liver of intestinal ischemia/reperfusion rats |
RGD |
PMID:22079846 |
RGD:401794136 |
NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312
|
|
G |
Cyp1b1 |
cytochrome P450, family 1, subfamily b, polypeptide 1 |
increases stability |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased stability of CYP1B1 protein |
CTD |
PMID:15486049 |
|
NCBI chr 6:15,342,312...15,350,886
Ensembl chr 6:15,342,344...15,350,917
|
|
G |
Cyp26a1 |
cytochrome P450, family 26, subfamily a, polypeptide 1 |
decreases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of CYP26A1 mRNA |
CTD |
PMID:31806706 |
|
NCBI chr 1:235,471,368...235,475,204
Ensembl chr 1:235,471,298...235,475,204
|
|
G |
Cyp2b3 |
cytochrome P450, family 2, subfamily b, polypeptide 3 |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime results in increased expression of CYP2B6 mRNA]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Phenobarbital results in increased expression of CYP2B6 mRNA] |
CTD |
PMID:24224465 |
|
NCBI chr 1:81,652,762...81,732,153
Ensembl chr 1:81,652,787...81,732,143
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime results in increased expression of CYP3A4 mRNA]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Phenobarbital results in increased expression of CYP3A4 mRNA] |
CTD |
PMID:24224465 |
|
NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Cyp3a23-3a1 |
cytochrome P450, family 3, subfamily a, polypeptide 23-polypeptide 1 |
multiple interactions |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Dexamethasone results in increased expression of CYP3A23-3A1 mRNA]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Dexamethasone results in increased expression of CYP3A23-3A1 protein] |
CTD |
PMID:17083955 |
|
NCBI chr12:9,256,159...9,285,020
Ensembl chr12:9,254,475...9,285,030 Ensembl chr12:9,254,475...9,285,030
|
|
G |
Ddc |
dopa decarboxylase |
decreases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of DDC mRNA |
CTD |
PMID:25566086 |
|
NCBI chr14:86,378,685...86,469,189
Ensembl chr14:86,378,685...86,469,208
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
multiple interactions increases expression increases activity |
ISO EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [1,2-dithiol-3-thione inhibits the reaction [Tunicamycin results in increased expression of DDIT3 mRNA]] benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of DDIT3 mRNA benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of DDIT3 protein benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased activity of DDIT3 protein benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of DDIT3 mRNA; benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of DDIT3 protein |
CTD |
PMID:17912641 PMID:19135031 PMID:19139269 PMID:22959925 PMID:23684743 PMID:25566086 PMID:27638906 More...
|
|
NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201
|
|
G |
Dffa |
DNA fragmentation factor subunit alpha |
multiple interactions |
ISO |
DFFA protein inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased ubiquitination of DFFB protein] |
CTD |
PMID:18178165 |
|
NCBI chr 5:159,540,715...159,553,639
Ensembl chr 5:159,540,715...159,553,633
|
|
G |
Dffb |
DNA fragmentation factor subunit beta |
multiple interactions decreases degradation increases ubiquitination |
ISO |
DFFA protein inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased ubiquitination of DFFB protein] benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased degradation of DFFB protein |
CTD |
PMID:18178165 |
|
NCBI chr 5:164,522,446...164,534,733
Ensembl chr 5:164,522,463...164,534,628
|
|
G |
Diablo |
diablo, IAP-binding mitochondrial protein |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Cannabidiol promotes the reaction [DIABLO protein binds to XIAP protein]] |
CTD |
PMID:31699976 |
|
NCBI chr12:33,055,784...33,070,401
Ensembl chr12:33,055,263...33,070,387
|
|
G |
Dio2 |
iodothyronine deiodinase 2 |
multiple interactions increases expression increases activity |
ISO EXP |
[Cycloheximide co-treated with benzyloxycarbonylleucyl-leucyl-leucine aldehyde] inhibits the reaction [2,2',4,4',5-brominated diphenyl ether metabolite results in decreased activity of DIO2 protein]; [Cycloheximide co-treated with benzyloxycarbonylleucyl-leucyl-leucine aldehyde] results in decreased activity of DIO2 protein; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [2,2',4,4',5-brominated diphenyl ether results in decreased activity of DIO2 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Cycloheximide results in decreased activity of DIO2 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [decabromobiphenyl ether results in increased degradation of DIO2 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Thyroxine results in decreased activity of DIO2 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Triiodothyronine, Reverse results in decreased activity of DIO2 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of and results in increased activity of DIO2 protein; Cycloheximide promotes the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [2,2',4,4',5-brominated diphenyl ether results in decreased activity of DIO2 protein]]; Cycloheximide promotes the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Triiodothyronine, Reverse results in decreased activity of DIO2 protein]] benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of DIO2 protein benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased activity of DIO2 protein |
CTD |
PMID:11425850 PMID:17615150 PMID:26004626 PMID:37330034 |
|
NCBI chr 6:109,665,523...109,679,809
Ensembl chr 6:109,665,523...109,679,809
|
|
G |
Dnajb1 |
DnaJ heat shock protein family (Hsp40) member B1 |
increases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of DNAJB1 mRNA; benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of DNAJB1 protein |
CTD |
PMID:15525353 PMID:25566086 |
|
NCBI chr19:24,522,731...24,526,419
Ensembl chr19:24,522,717...24,526,458
|
|
G |
Dnajc2 |
DnaJ heat shock protein family (Hsp40) member C2 |
increases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of DNAJC2 mRNA |
CTD |
PMID:25566086 |
|
NCBI chr 4:13,270,239...13,297,438
Ensembl chr 4:13,270,191...13,297,431
|
|
G |
Dnajc7 |
DnaJ heat shock protein family (Hsp40) member C7 |
multiple interactions increases ubiquitination |
ISO |
1,4-bis(2-(3,5-dichloropyridyloxy))benzene promotes the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased ubiquitination of DNAJC7 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [DNAJC7 protein results in increased expression of NR1I3 protein]; NR1I3 protein affects the reaction [1,4-bis(2-(3,5-dichloropyridyloxy))benzene promotes the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased ubiquitination of DNAJC7 protein]] |
CTD |
PMID:24789201 |
|
NCBI chr10:85,518,637...85,555,079
Ensembl chr10:85,518,621...85,555,575
|
|
G |
Dnmt1 |
DNA methyltransferase 1 |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Benzo(a)pyrene results in increased degradation of DNMT1 protein] benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Ethanol results in increased degradation of DNMT1 protein] |
CTD |
PMID:21150308 PMID:23395981 |
|
NCBI chr 8:19,440,611...19,486,659
Ensembl chr 8:19,440,611...19,486,659
|
|
G |
Dnmt3a |
DNA methyltransferase 3 alpha |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Ethanol results in increased degradation of DNMT3A protein] |
CTD |
PMID:23395981 |
|
NCBI chr 6:26,791,517...26,902,161
Ensembl chr 6:26,822,609...26,896,687
|
|
G |
Dnmt3b |
DNA methyltransferase 3 beta |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Ethanol results in increased degradation of DNMT3B protein] |
CTD |
PMID:23395981 |
|
NCBI chr 3:142,130,588...142,169,128
Ensembl chr 3:142,130,592...142,169,124
|
|
G |
Dnmt3l |
DNA methyltransferase 3 like |
multiple interactions increases expression |
ISO |
MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of DNMT3L mRNA] |
CTD |
PMID:25566086 |
|
NCBI chr20:10,614,933...10,629,337
Ensembl chr20:10,614,934...10,629,516
|
|
G |
Dpp7 |
dipeptidylpeptidase 7 |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [[DPP7 protein results in increased cleavage of Dipeptides] which results in increased abundance of 4-nitroaniline] |
CTD |
PMID:16725115 |
|
NCBI chr 3:8,165,091...8,169,343
Ensembl chr 3:8,165,091...8,169,355
|
|
G |
Dusp1 |
dual specificity phosphatase 1 |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [SKP2 protein results in decreased expression of DUSP1 protein] |
CTD |
PMID:34697729 |
|
NCBI chr10:16,680,478...16,683,275
|
|
G |
Dync1h1 |
dynein cytoplasmic 1 heavy chain 1 |
increases expression multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of DYNC1H1 mRNA MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of DYNC1H1 mRNA] |
CTD |
PMID:25566086 |
|
NCBI chr 6:129,615,208...129,680,888
Ensembl chr 6:129,609,397...129,680,883
|
|
G |
Dync1i1 |
dynein cytoplasmic 1 intermediate chain 1 |
increases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of DYNC1I1 mRNA |
CTD |
PMID:20061341 |
|
NCBI chr 4:33,852,597...34,166,159
Ensembl chr 4:33,852,927...34,166,149
|
|
G |
E2f1 |
E2F transcription factor 1 |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Dronabinol results in decreased expression of E2F1 protein] |
CTD |
PMID:17934890 |
|
NCBI chr 3:143,064,535...143,075,362
Ensembl chr 3:143,049,478...143,075,361
|
|
G |
E2f2 |
E2F transcription factor 2 |
decreases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of E2F2 mRNA |
CTD |
PMID:31806706 |
|
NCBI chr 5:148,399,193...148,422,595
Ensembl chr 5:148,399,642...148,421,217
|
|
G |
Edn1 |
endothelin 1 |
increases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of EDN1 mRNA |
CTD |
PMID:18457675 |
|
NCBI chr17:22,454,924...22,460,812
Ensembl chr17:22,454,420...22,460,885
|
|
G |
Egf |
epidermal growth factor |
multiple interactions increases expression |
ISO EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [EGF protein affects the localization of RELA protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [EGF protein results in increased secretion of MUC5AC protein] benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of EGF mRNA benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [EGF protein results in increased phosphorylation of RPS6KB1 protein]; Cycloheximide inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [EGF protein results in increased phosphorylation of RPS6KB1 protein]] |
CTD |
PMID:22689575 PMID:22766066 PMID:31806706 |
|
NCBI chr 2:218,219,408...218,302,359
Ensembl chr 2:218,219,415...218,302,064
|
|
G |
Egfl7 |
EGF-like-domain, multiple 7 |
multiple interactions |
ISO |
[MYBPC3 protein affects the susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde] which results in decreased expression of EGFL7 mRNA |
CTD |
PMID:25566086 |
|
NCBI chr 3:9,404,622...9,416,879
Ensembl chr 3:9,407,520...9,416,879
|
|
G |
Egfr |
epidermal growth factor receptor |
multiple interactions decreases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Gemcitabine results in increased phosphorylation of and results in increased degradation of EGFR protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [MUC1 affects the expression of EGFR protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [platycodin D results in decreased expression of EGFR protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [sulindac sulfide results in decreased expression of EGFR protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [sulindac sulfone results in decreased expression of EGFR protein] benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of EGFR protein |
CTD |
PMID:17146438 PMID:20332299 PMID:22457794 PMID:28711525 |
|
NCBI chr14:91,176,979...91,349,722
Ensembl chr14:91,177,067...91,344,382
|
|
G |
Egln1 |
egl-9 family hypoxia-inducible factor 1 |
multiple interactions decreases expression |
ISO |
MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of EGLN1 mRNA] |
CTD |
PMID:25566086 |
|
NCBI chr19:52,867,900...52,907,308
Ensembl chr19:52,869,486...52,907,777
|
|
G |
Egln3 |
egl-9 family hypoxia-inducible factor 3 |
decreases expression multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of EGLN3 mRNA MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of EGLN3 mRNA] |
CTD |
PMID:25566086 |
|
NCBI chr 6:71,650,297...71,675,766
Ensembl chr 6:71,650,297...71,675,766
|
|
G |
Eif2ak2 |
eukaryotic translation initiation factor 2-alpha kinase 2 |
multiple interactions |
ISO |
[MYBPC3 protein affects the susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde] which results in increased expression of EIF2AK2 mRNA |
CTD |
PMID:25566086 |
|
NCBI chr 6:16,189,000...16,224,972
Ensembl chr 6:16,188,979...16,224,971
|
|
G |
Eif2ak3 |
eukaryotic translation initiation factor 2 alpha kinase 3 |
multiple interactions increases phosphorylation |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [1,2-dithiol-3-thione inhibits the reaction [Tunicamycin results in increased expression of EIF2AK3 mRNA]] 4-phenylbutyric acid inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased phosphorylation of EIF2AK3 protein] |
CTD |
PMID:22959925 PMID:27638906 |
|
NCBI chr 4:102,805,495...102,866,914
Ensembl chr 4:102,805,510...102,866,911
|
|
G |
Eif2s1 |
eukaryotic translation initiation factor 2 subunit alpha |
increases phosphorylation multiple interactions increases expression |
EXP ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased phosphorylation of EIF2S1 protein 4-phenylbutyric acid inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased phosphorylation of EIF2S1 protein]; [XBP1 mutant form co-treated with benzyloxycarbonylleucyl-leucyl-leucine aldehyde] inhibits the reaction [Tobacco Smoke Pollution analog results in increased phosphorylation of EIF2S1 protein]; PTPN1 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased phosphorylation of EIF2S1 protein] benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of EIF2S1 protein modified form |
CTD |
PMID:21090173 PMID:22321511 PMID:23684743 PMID:25568320 PMID:27638906 PMID:28359145 More...
|
|
NCBI chr 6:97,672,829...97,697,499
Ensembl chr 6:97,672,766...97,706,225
|
|
G |
Eif4e |
eukaryotic translation initiation factor 4E |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Cadmium Chloride results in decreased expression of EIF4E protein] |
CTD |
PMID:15878868 |
|
NCBI chr 2:227,066,519...227,099,261
Ensembl chr 2:227,066,673...227,098,683
|
|
G |
Elavl1 |
ELAV like RNA binding protein 1 |
increases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of ELAVL1 mRNA; benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of ELAVL1 protein |
CTD |
PMID:23922739 |
|
NCBI chr12:2,640,936...2,684,787
Ensembl chr12:2,645,061...2,684,784
|
|
G |
Emcn |
endomucin |
decreases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of EMCN mRNA |
CTD |
PMID:25566086 |
|
NCBI chr 2:225,891,100...225,970,932
Ensembl chr 2:225,891,100...225,970,929
|
|
G |
Eno3 |
enolase 3 |
decreases expression multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of ENO3 mRNA MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of ENO3 mRNA] |
CTD |
PMID:25566086 |
|
NCBI chr10:55,370,531...55,375,921
Ensembl chr10:55,366,975...55,375,921
|
|
G |
Ep300 |
E1A binding protein p300 |
multiple interactions |
ISO EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Curcumin affects the localization of EP300 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Curcumin results in decreased expression of EP300 mRNA]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Curcumin results in decreased expression of EP300 protein] benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Doxorubicin results in increased degradation of EP300 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [SIRT6 protein results in decreased expression of EP300 protein] |
CTD |
PMID:15767673 PMID:17927689 PMID:27094368 |
|
NCBI chr 7:113,108,476...113,178,529
Ensembl chr 7:113,106,247...113,136,088 Ensembl chr 7:113,106,247...113,136,088
|
|
G |
Epas1 |
endothelial PAS domain protein 1 |
multiple interactions increases ubiquitination increases expression increases hydroxylation increases stability |
EXP ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Oxygen inhibits the reaction [AQP3 protein results in increased stability of EPAS1 protein]]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Oxygen inhibits the reaction [AQP5 protein results in increased stability of EPAS1 protein]] benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased ubiquitination of EPAS1 protein benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of EPAS1 protein [Formaldehyde co-treated with pevonedistat co-treated with benzyloxycarbonylleucyl-leucyl-leucine aldehyde] affects the folding of EPAS1 protein; [Formaldehyde co-treated with VH298 co-treated with benzyloxycarbonylleucyl-leucyl-leucine aldehyde] affects the folding of EPAS1 protein; [VH298 co-treated with benzyloxycarbonylleucyl-leucyl-leucine aldehyde] affects the folding of EPAS1 protein; arsenite inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased ubiquitination of EPAS1 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [MALAT1 mRNA promotes the reaction [sodium arsenite results in increased expression of EPAS1 protein]]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [sodium arsenite results in increased expression of EPAS1 protein]; MALAT1 mRNA promotes the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased hydroxylation of EPAS1 protein]; MALAT1 mRNA promotes the reaction [sodium arsenite promotes the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased hydroxylation of EPAS1 protein]]; sodium arsenite promotes the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased hydroxylation of EPAS1 protein] benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased stability of EPAS1 protein |
CTD |
PMID:22447124 PMID:23545307 PMID:26735578 PMID:35504338 |
|
NCBI chr 6:7,790,236...7,871,717
Ensembl chr 6:7,790,647...7,871,228
|
|
G |
Ephb4 |
EPH receptor B4 |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Homoharringtonine results in decreased expression of EPHB4 protein] |
CTD |
PMID:31726078 |
|
NCBI chr12:19,326,411...19,351,667
Ensembl chr12:19,326,427...19,351,314
|
|
G |
Ephx1 |
epoxide hydrolase 1 |
increases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of EPHX1 mRNA |
CTD |
PMID:20061341 |
|
NCBI chr13:92,714,315...92,744,105
Ensembl chr13:92,714,315...92,790,235
|
|
G |
Ephx2 |
epoxide hydrolase 2 |
increases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of EPHX2 mRNA |
CTD |
PMID:20061341 |
|
NCBI chr15:40,289,901...40,327,632
Ensembl chr15:40,289,902...40,327,615
|
|
G |
Epo |
erythropoietin |
multiple interactions increases expression |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [methylmercuric chloride results in decreased expression of EPO protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Methylmercury Compounds results in decreased expression of EPO protein] benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of EPO protein |
CTD |
PMID:31850806 PMID:32461003 |
|
NCBI chr12:19,204,258...19,207,948
Ensembl chr12:19,204,508...19,207,946
|
|
G |
Eppk1 |
epiplakin 1 |
decreases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of EPPK1 mRNA |
CTD |
PMID:25566086 |
|
NCBI chr 7:107,816,919...107,842,946
Ensembl chr 7:107,817,693...107,831,159
|
|
G |
Erbb2 |
erb-b2 receptor tyrosine kinase 2 |
decreases expression multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of ERBB2 mRNA; benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of ERBB2 protein benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Berberine results in decreased expression of ERBB2 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [demethoxycurcumin results in increased degradation of ERBB2 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Quercetin results in decreased expression of ERBB2 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [sulindac sulfide results in decreased expression of ERBB2 protein] |
CTD |
PMID:18655187 PMID:20332299 PMID:31806706 PMID:33325633 PMID:34291863 |
|
NCBI chr10:83,411,197...83,435,078
Ensembl chr10:83,411,313...83,435,078
|
|
G |
Erbb3 |
erb-b2 receptor tyrosine kinase 3 |
multiple interactions decreases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [sulindac sulfide results in decreased expression of ERBB3 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [sulindac sulfone results in decreased expression of ERBB3 protein] benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of ERBB3 protein |
CTD |
PMID:20332299 |
|
NCBI chr 7:994,549...1,015,876
Ensembl chr 7:996,225...1,015,525
|
|
G |
Ercc6 |
ERCC excision repair 6, chromatin remodeling factor |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [ERCC6 gene mutant form results in decreased expression of SIRT1 protein] |
CTD |
PMID:25440059 |
|
NCBI chr16:7,764,983...7,835,587
Ensembl chr16:7,765,013...7,835,587
|
|
G |
Ern1 |
endoplasmic reticulum to nucleus signaling 1 |
increases expression increases phosphorylation multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of ERN1 protein benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased phosphorylation of ERN1 protein ERN1 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of ACE2 protein]; ERN1 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased cleavage of CTSD protein] |
CTD |
PMID:19139269 PMID:27638906 |
|
NCBI chr10:91,326,889...91,421,201
Ensembl chr10:91,330,654...91,421,029
|
|
G |
Esr1 |
estrogen receptor 1 |
multiple interactions increases expression increases ubiquitination decreases expression |
ISO EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [6-prenylnaringenin results in decreased expression of ESR1 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [8-prenylnaringenin results in decreased expression of ESR1 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [baohuoside I results in increased degradation of ESR1 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Butyrophenones results in increased degradation of ESR1 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Carbamazepine results in decreased expression of ESR1 mRNA]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Carbamazepine results in decreased expression of ESR1 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Diethylhexyl Phthalate inhibits the reaction [AHR protein results in increased expression of ESR1 protein]]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Estradiol inhibits the reaction [ESR1 protein binds to GSK3B protein]]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Estradiol results in decreased expression of ESR1 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Fulvestrant results in decreased expression of ESR1 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Okadaic Acid results in increased degradation of ESR1 mRNA]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Plant Extracts results in decreased expression of ESR1 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Resveratrol results in increased degradation of ESR1 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of ESR1 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Tetrachlorodibenzodioxin results in increased degradation of ESR1 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [xanthohumol results in decreased expression of ESR1 protein] benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of ESR1 protein benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased ubiquitination of ESR1 protein benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of ESR1 mRNA benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [fulvestrant results in increased degradation of ESR1 protein] benzyloxycarbonylleucyl-leucyl-leucine aldehyde affects the reaction [PTK2B protein affects the ubiquitination of ESR1 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Estradiol results in decreased expression of ESR1 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Gonadotropin-Releasing Hormone results in decreased expression of ESR1 protein] |
CTD |
PMID:12612060 PMID:14702340 PMID:14750165 PMID:15965230 PMID:16055746 PMID:16564422 PMID:16965676 PMID:20419096 PMID:21041310 PMID:26990689 PMID:29428397 PMID:31806706 PMID:32986415 PMID:34801851 PMID:35802278 More...
|
|
NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002
|
|
G |
Esr2 |
estrogen receptor 2 |
multiple interactions increases expression |
ISO EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [Estradiol results in increased expression of ESR2 mRNA] benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of ESR2 protein |
CTD |
PMID:14702340 PMID:15207704 PMID:16564422 |
|
NCBI chr 6:94,858,438...94,909,630
Ensembl chr 6:94,809,547...94,908,919
|
|
G |
Esrra |
estrogen related receptor, alpha |
multiple interactions increases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [HDAC6 protein results in increased expression of ESRRA protein] benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of ESRRA protein |
CTD |
PMID:34524571 |
|
NCBI chr 1:204,104,100...204,114,182
Ensembl chr 1:204,104,101...204,114,268
|
|
G |
Fahd1 |
fumarylacetoacetate hydrolase domain containing 1 |
multiple interactions |
ISO |
[MYBPC3 protein affects the susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde] which results in decreased expression of FAHD1 mRNA |
CTD |
PMID:25566086 |
|
NCBI chr10:13,873,539...13,874,978
Ensembl chr10:13,873,527...13,875,012
|
|
G |
Fam13b |
family with sequence similarity 13, member B |
multiple interactions |
ISO |
[MYBPC3 protein affects the susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde] which results in increased expression of FAM13B mRNA |
CTD |
PMID:25566086 |
|
NCBI chr18:26,040,285...26,107,112
Ensembl chr18:26,040,285...26,106,587
|
|
G |
Fam78a |
family with sequence similarity 78, member A |
decreases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of FAM78A mRNA |
CTD |
PMID:25566086 |
|
NCBI chr 3:15,355,958...15,376,330
Ensembl chr 3:15,355,955...15,373,812
|
|
G |
Faslg |
Fas ligand |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [evodiamine results in increased expression of FASLG protein] |
CTD |
PMID:20005289 |
|
NCBI chr13:74,151,519...74,172,760
Ensembl chr13:74,154,954...74,162,215
|
|
G |
Fbxl12 |
F-box and leucine-rich repeat protein 12 |
decreases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of FBXL12 mRNA |
CTD |
PMID:20061341 |
|
NCBI chr 8:19,175,864...19,183,373
Ensembl chr 8:19,160,352...19,183,607
|
|
G |
Fbxo10 |
F-box protein 10 |
multiple interactions decreases expression |
ISO |
MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of FBXO10 mRNA] |
CTD |
PMID:25566086 |
|
NCBI chr 5:59,297,016...59,343,429
Ensembl chr 5:59,297,045...59,343,348
|
|
G |
Fbxo2 |
F-box protein 2 |
increases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of FBXO2 mRNA |
CTD |
PMID:25566086 |
|
NCBI chr 5:158,592,926...158,598,355
Ensembl chr 5:158,592,925...158,598,355
|
|
G |
Fbxo32 |
F-box protein 32 |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [FBXO32 protein results in decreased expression of KCNN2 protein] |
CTD |
PMID:30635400 |
|
NCBI chr 7:89,731,428...89,764,997
Ensembl chr 7:89,730,232...89,765,436
|
|
G |
Fbxo6 |
F-box protein 6 |
increases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of FBXO6 mRNA |
CTD |
PMID:20061341 |
|
NCBI chr 5:158,576,729...158,582,520
Ensembl chr 5:158,576,759...158,582,525
|
|
G |
Fbxw7 |
F-box and WD repeat domain containing 7 |
multiple interactions |
ISO |
FBXW7 protein promotes the reaction [NFKB1 gene mutant form inhibits the reaction [arsenite inhibits the reaction [Cycloheximide inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased degradation of and results in increased expression of MYC protein]]]] |
CTD |
PMID:24457827 |
|
NCBI chr 2:170,149,706...170,311,536
Ensembl chr 2:170,149,694...170,309,941
|
|
G |
Fhl2 |
four and a half LIM domains 2 |
decreases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of FHL2 mRNA |
CTD |
PMID:25566086 |
|
NCBI chr 9:45,388,979...45,462,421
Ensembl chr 9:45,388,981...45,431,192
|
|
G |
Fis1 |
fission, mitochondrial 1 |
multiple interactions increases expression |
EXP ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [[ponasterone A results in increased expression of PINK1 protein] which results in decreased expression of FIS1 protein] benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of FIS1 protein benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [[PARK protein co-treated with UBB protein] results in decreased expression of FIS1 protein] |
CTD |
PMID:20164189 |
|
NCBI chr12:19,708,560...19,723,392
Ensembl chr12:19,708,558...19,723,377
|
|
G |
Flnc |
filamin C |
increases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of FLNC mRNA |
CTD |
PMID:25566086 |
|
NCBI chr 4:58,034,088...58,061,882
Ensembl chr 4:58,034,189...58,061,844
|
|
G |
Fn1 |
fibronectin 1 |
decreases secretion |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased secretion of FN1 protein |
CTD |
PMID:11594554 |
|
NCBI chr 9:73,196,044...73,264,695
Ensembl chr 9:73,196,044...73,264,678
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
EXP ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [Hydrogen Peroxide results in increased expression of FOS protein] [Arachidonic Acid co-treated with Quercetin co-treated with benzyloxycarbonylleucyl-leucyl-leucine aldehyde] results in decreased expression of FOS protein |
CTD |
PMID:15136564 PMID:20551291 |
|
NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036
|
|
G |
Fosl1 |
FOS like 1, AP-1 transcription factor subunit |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Curcumin inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of FOSL1 protein]] |
CTD |
PMID:17148446 |
|
NCBI chr 1:202,754,549...202,763,057
Ensembl chr 1:202,754,529...202,764,930
|
|
G |
Foxm1 |
forkhead box M1 |
multiple interactions decreases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [palbociclib results in decreased expression of FOXM1 protein] benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of FOXM1 mRNA |
CTD |
PMID:22094256 PMID:31806706 |
|
NCBI chr 4:161,639,538...161,652,012
Ensembl chr 4:161,638,816...161,650,684
|
|
G |
Foxo1 |
forkhead box O1 |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [dorsomorphin results in decreased expression of FOXO1 protein] |
CTD |
PMID:25065674 |
|
NCBI chr 2:136,312,168...136,390,603
Ensembl chr 2:136,312,168...136,387,790
|
|
G |
Foxo3 |
forkhead box O3 |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Arsenic Trioxide results in increased expression of FOXO3 protein] |
CTD |
PMID:31421153 |
|
NCBI chr20:45,669,708...45,764,606
Ensembl chr20:45,672,995...45,764,561
|
|
G |
Fsd2 |
fibronectin type III and SPRY domain containing 2 |
decreases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of FSD2 mRNA |
CTD |
PMID:25566086 |
|
NCBI chr 1:135,484,002...135,522,517
Ensembl chr 1:135,489,266...135,522,472
|
|
G |
Fth1 |
ferritin heavy chain 1 |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [diallyl trisulfide results in increased degradation of and results in decreased expression of FTH1 protein] |
CTD |
PMID:16707465 |
|
NCBI chr 1:206,627,142...206,629,430
Ensembl chr 1:206,627,103...206,725,424
|
|
G |
Ftl1 |
ferritin light chain 1 |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [diallyl trisulfide results in increased degradation of and results in decreased expression of FTL protein] |
CTD |
PMID:16707465 |
|
NCBI chr 1:95,936,387...95,938,234
Ensembl chr 1:95,936,387...95,939,725 Ensembl chr10:95,936,387...95,939,725 Ensembl chr 2:95,936,387...95,939,725
|
|
G |
Fundc1 |
FUN14 domain containing 1 |
multiple interactions increases expression |
ISO |
[benzyloxycarbonylleucyl-leucyl-leucine aldehyde co-treated with Rotenone] results in increased expression of FUNDC1 protein; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Rotenone results in decreased expression of FUNDC1 protein] benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of FUNDC1 protein |
CTD |
PMID:32001317 PMID:37156403 |
|
NCBI chr X:5,083,635...5,100,293
Ensembl chr X:5,083,617...5,100,284
|
|
G |
G0s2 |
G0/G1switch 2 |
multiple interactions |
ISO |
[MYBPC3 protein affects the susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde] which results in decreased expression of G0S2 mRNA |
CTD |
PMID:25566086 |
|
NCBI chr13:104,806,351...104,807,263
Ensembl chr13:104,806,156...104,807,451
|
|
G |
Gabarapl1 |
GABA type A receptor associated protein like 1 |
increases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of GABARAPL1 mRNA |
CTD |
PMID:31806706 |
|
NCBI chr 4:162,980,309...162,989,452
Ensembl chr 4:162,980,249...162,989,450
|
|
G |
Gabbr2 |
gamma-aminobutyric acid type B receptor subunit 2 |
multiple interactions |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction and affects the localization of [PSMC5 protein binds to GABBR2 protein] |
CTD |
PMID:24482233 |
|
NCBI chr 5:60,947,517...61,288,104
Ensembl chr 5:60,947,526...61,288,104
|
|
G |
Gad1 |
glutamate decarboxylase 1 |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Oxygen deficiency results in decreased expression of GAD1 protein] |
CTD |
PMID:29107683 |
|
NCBI chr 3:55,369,704...55,410,335
Ensembl chr 3:55,369,704...55,410,333
|
|
G |
Gad2 |
glutamate decarboxylase 2 |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Oxygen deficiency results in decreased expression of GAD2 protein] |
CTD |
PMID:29107683 |
|
NCBI chr17:84,763,630...84,826,155
Ensembl chr17:84,763,628...84,826,155
|
|
G |
Gadd45a |
growth arrest and DNA-damage-inducible, alpha |
increases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of GADD45A mRNA |
CTD |
PMID:20061341 PMID:25566086 |
|
NCBI chr 4:96,154,789...96,157,091
Ensembl chr 4:96,154,789...96,157,115
|
|
G |
Gadd45g |
growth arrest and DNA-damage-inducible, gamma |
multiple interactions |
ISO |
[MYBPC3 protein affects the susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde] which results in increased expression of GADD45G mRNA |
CTD |
PMID:25566086 |
|
NCBI chr17:13,376,842...13,378,587
Ensembl chr17:13,376,839...13,378,610
|
|
G |
Gclc |
glutamate-cysteine ligase, catalytic subunit |
multiple interactions increases expression |
ISO |
[benzyloxycarbonylleucyl-leucyl-leucine aldehyde co-treated with Hemin] results in increased expression of GCLC mRNA; [benzyloxycarbonylleucyl-leucyl-leucine aldehyde co-treated with Hemin] results in increased expression of GCLC protein; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Dichlorodiphenyl Dichloroethylene results in decreased expression of GCLC mRNA]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Dichlorodiphenyl Dichloroethylene results in decreased expression of GCLC protein]; NFE2L2 protein promotes the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of GCLC mRNA] benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of GCLC mRNA; benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of GCLC protein |
CTD |
PMID:25263748 PMID:30186748 PMID:33434570 |
|
NCBI chr 8:78,629,899...78,668,547
Ensembl chr 8:78,630,127...78,668,544
|
|
G |
Gclm |
glutamate cysteine ligase, modifier subunit |
increases expression multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of GCLM mRNA benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of GCLM mRNA; benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of GCLM protein [benzyloxycarbonylleucyl-leucyl-leucine aldehyde co-treated with Hemin] results in increased expression of GCLM mRNA; [benzyloxycarbonylleucyl-leucyl-leucine aldehyde co-treated with Hemin] results in increased expression of GCLM protein |
CTD |
PMID:20061341 PMID:33434570 |
|
NCBI chr 2:210,347,482...210,367,537
Ensembl chr 2:210,347,482...210,367,535
|
|
G |
Gdf15 |
growth differentiation factor 15 |
multiple interactions increases expression |
ISO |
MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of GDF15 mRNA] |
CTD |
PMID:25566086 |
|
NCBI chr16:18,804,457...18,808,043
Ensembl chr16:18,805,239...18,808,055
|
|
G |
Gja1 |
gap junction protein, alpha 1 |
multiple interactions |
EXP ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [antofine results in decreased expression of GJA1 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [ioxynil analog results in decreased expression of GJA1 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [ioxynil results in decreased expression of GJA1 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Tetradecanoylphorbol Acetate results in increased phosphorylation of GJA1 protein] benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [fulvestrant results in decreased expression of GJA1 protein] |
CTD |
PMID:15685554 PMID:20510257 PMID:23403203 PMID:29180066 |
|
NCBI chr20:35,756,007...35,768,481
Ensembl chr20:35,755,991...35,768,582
|
|
G |
Gja5 |
gap junction protein, alpha 5 |
decreases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of GJA5 mRNA |
CTD |
PMID:25566086 |
|
NCBI chr 2:184,602,407...184,621,952
Ensembl chr 2:184,564,475...184,621,952
|
|
G |
Gls |
glutaminase |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [diphenylarsinic acid results in increased degradation of GLS protein alternative form] |
CTD |
PMID:22493432 |
|
NCBI chr 9:49,344,616...49,416,900
Ensembl chr 9:49,344,781...49,416,900
|
|
G |
Gpr146 |
G protein-coupled receptor 146 |
multiple interactions |
ISO |
[MYBPC3 protein affects the susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde] which results in decreased expression of GPR146 mRNA |
CTD |
PMID:25566086 |
|
NCBI chr12:15,251,936...15,267,217
Ensembl chr12:15,251,813...15,267,206
|
|
G |
Gpx1 |
glutathione peroxidase 1 |
multiple interactions increases expression decreases expression |
ISO |
[sodium arsenite co-treated with benzyloxycarbonylleucyl-leucyl-leucine aldehyde] results in decreased expression of GPX1 mRNA; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [sodium arsenite results in decreased expression of GPX1 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [sodium arsenite results in decreased expression of GPX1 mRNA]; sodium arsenite inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of GPX1 protein]; sodium arsenite inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of GPX1 mRNA] |
CTD |
PMID:32301004 |
|
NCBI chr 8:109,026,905...109,028,031
Ensembl chr 8:109,026,905...109,028,024
|
|
G |
Gria1 |
glutamate ionotropic receptor AMPA type subunit 1 |
increases localization increases expression |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased localization of GRIA1 protein MG-132 increases expression of Gria1 protein in nucleus accumbens cultured cells |
CTD RGD |
PMID:19674091 PMID:19674091 |
RGD:4107725 |
NCBI chr10:41,210,713...41,527,283
Ensembl chr10:41,210,713...41,527,283
|
|
G |
Gria2 |
glutamate ionotropic receptor AMPA type subunit 2 |
increases localization increases expression |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased localization of GRIA2 protein MG-132 increases expression of Gria2 protein in nucleus accumbens cultured cells |
CTD RGD |
PMID:19674091 PMID:19674091 |
RGD:4107725 |
NCBI chr 2:165,949,379...166,069,510
Ensembl chr 2:165,947,521...166,069,510
|
|
G |
Grip1 |
glutamate receptor interacting protein 1 |
increases expression multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of GRIP1 mRNA benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [GRIP1 protein binds to NR1I3 protein] |
CTD |
PMID:24224465 PMID:25566086 |
|
NCBI chr 7:54,934,856...55,592,274
Ensembl chr 7:54,934,250...55,592,273
|
|
G |
Gsdmd |
gasdermin D |
multiple interactions |
ISO |
[lipopolysaccharide, Escherichia coli O111 B4 co-treated with benzyloxycarbonylleucyl-leucyl-leucine aldehyde] results in increased expression of and results in increased cleavage of GSDMD protein; [lipopolysaccharide, Escherichia coli O111 B4 co-treated with benzyloxycarbonylleucyl-leucyl-leucine aldehyde] results in increased expression of GSDMD protein; benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with sodium arsenite] results in increased expression of and results in increased cleavage of GSDMD protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with sodium arsenite] results in increased expression of GSDMD protein] |
CTD |
PMID:34920032 |
|
NCBI chr 7:107,542,489...107,547,051
Ensembl chr 7:107,542,083...107,547,055
|
|
G |
Gsg1l |
GSG1-like |
multiple interactions decreases expression |
ISO |
MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of GSG1L mRNA] |
CTD |
PMID:25566086 |
|
NCBI chr 1:180,440,398...180,654,342
Ensembl chr 1:180,442,630...180,654,134
|
|
G |
Gsk3b |
glycogen synthase kinase 3 beta |
multiple interactions increases phosphorylation decreases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Estradiol inhibits the reaction [ESR1 protein binds to GSK3B protein]] benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased phosphorylation of GSK3B protein benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of GSK3B protein modified form |
CTD |
PMID:24085292 PMID:26990689 PMID:30703377 |
|
NCBI chr11:62,498,997...62,648,665
Ensembl chr11:62,504,316...62,648,646
|
|
G |
Gsr |
glutathione-disulfide reductase |
increases expression multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of GSR mRNA benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of GSR mRNA; benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of GSR protein [benzyloxycarbonylleucyl-leucyl-leucine aldehyde co-treated with Hemin] results in increased expression of GSR mRNA; [benzyloxycarbonylleucyl-leucyl-leucine aldehyde co-treated with Hemin] results in increased expression of GSR protein |
CTD |
PMID:20061341 PMID:33434570 |
|
NCBI chr16:58,482,209...58,525,256
Ensembl chr16:58,482,505...58,525,661
|
|
G |
Gss |
glutathione synthetase |
increases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of GSS mRNA |
CTD |
PMID:20061341 |
|
NCBI chr 3:144,047,849...144,078,197
Ensembl chr 3:144,047,850...144,078,198
|
|
G |
Gsta2 |
glutathione S-transferase alpha 2 |
increases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of GSTA2 mRNA |
CTD |
PMID:12446695 PMID:20061341 |
|
NCBI chr 8:79,184,535...79,196,827
Ensembl chr 8:79,184,322...79,196,798
|
|
G |
Gsta5 |
glutathione S-transferase alpha 5 |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Cycloheximide inhibits the reaction [Lead results in increased expression of GSTA1 mRNA]]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Cycloheximide inhibits the reaction [Mercury results in increased expression of GSTA1 mRNA]]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of GSTA1 mRNA]]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Cycloheximide promotes the reaction [Copper results in decreased expression of GSTA1 mRNA]] |
CTD |
PMID:16243960 |
|
NCBI chr 8:79,105,561...79,117,472
Ensembl chr 8:79,105,661...79,117,472
|
|
G |
Gstm1 |
glutathione S-transferase mu 1 |
increases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of GSTM1 mRNA; benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of GSTM5 mRNA |
CTD |
PMID:20061341 |
|
NCBI chr 2:195,649,845...195,655,402
Ensembl chr 2:195,649,845...195,655,411
|
|
G |
Gstm2 |
glutathione S-transferase mu 2 |
increases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of GSTM2 mRNA |
CTD |
PMID:20061341 |
|
NCBI chr 2:195,624,015...195,628,774
Ensembl chr 2:195,544,426...195,628,961
|
|
G |
Gstm5 |
glutathione S-transferase, mu 5 |
increases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of GSTM3 mRNA |
CTD |
PMID:20061341 |
|
NCBI chr 2:195,531,599...195,534,562
Ensembl chr 2:195,531,495...195,534,553
|
|
G |
Gsto1 |
glutathione S-transferase omega 1 |
multiple interactions increases expression |
ISO |
[benzyloxycarbonylleucyl-leucyl-leucine aldehyde co-treated with Hemin] results in increased expression of GSTO1 mRNA benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of GSTO1 mRNA |
CTD |
PMID:33434570 |
|
NCBI chr 1:246,721,089...246,731,228
Ensembl chr 1:246,721,221...246,731,468
|
|
G |
Gsto2 |
glutathione S-transferase omega 2 |
increases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of GSTO2 mRNA |
CTD |
PMID:33434570 |
|
NCBI chr 1:246,731,314...246,757,592
Ensembl chr 1:246,732,089...246,753,866
|
|
G |
Gstp1 |
glutathione S-transferase pi 1 |
increases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of GSTP1 protein |
CTD |
PMID:15863507 |
|
NCBI chr 1:201,337,762...201,340,230
Ensembl chr 1:201,321,672...201,340,226
|
|
G |
Gucy1a1 |
guanylate cyclase 1 soluble subunit alpha 1 |
decreases expression multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of GUCY1A1 mRNA MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of GUCY1A1 mRNA] |
CTD |
PMID:25566086 |
|
NCBI chr 2:167,418,615...167,482,293
Ensembl chr 2:167,418,640...167,481,671
|
|
G |
Gyg1 |
glycogenin 1 |
multiple interactions decreases expression |
ISO |
MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of GYG1 mRNA] |
CTD |
PMID:25566086 |
|
NCBI chr 2:102,611,888...102,653,916
Ensembl chr 2:102,598,496...102,653,797
|
|
G |
H19 |
H19 imprinted maternally expressed transcript |
decreases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of H19 mRNA |
CTD |
PMID:25566086 |
|
NCBI chr 1:197,730,698...197,733,374
Ensembl chr 1:197,730,698...197,733,134
|
|
G |
H2ac10 |
H2A clustered histone 10 |
multiple interactions |
ISO |
[MYBPC3 protein affects the susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde] which results in decreased expression of H2AC10 mRNA |
CTD |
PMID:25566086 |
|
NCBI chr17:41,570,532...41,571,020
Ensembl chr17:41,570,273...41,571,049
|
|
G |
H2ac12 |
H2A clustered histone 12 |
multiple interactions |
ISO |
[MYBPC3 protein affects the susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde] which results in decreased expression of H2AC12 mRNA |
CTD |
PMID:25566086 |
|
NCBI chr17:42,486,415...42,486,880
Ensembl chr17:42,486,415...42,486,941
|
|
G |
H2ax |
H2A.X variant histone |
multiple interactions |
ISO EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [veliparib promotes the reaction [Camptothecin results in increased expression of H2AX protein]] benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Doxorubicin results in increased expression of H2AX protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Etoposide results in increased expression of H2AX protein] |
CTD |
PMID:17875725 PMID:21227924 |
|
NCBI chr 8:44,671,907...44,673,262
Ensembl chr 8:44,671,786...44,673,239 Ensembl chr 4:44,671,786...44,673,239
|
|
G |
Haghl |
hydroxyacylglutathione hydrolase-like |
multiple interactions |
ISO |
[MYBPC3 protein affects the susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde] which results in decreased expression of HAGHL mRNA |
CTD |
PMID:25566086 |
|
NCBI chr10:14,804,957...14,809,495
Ensembl chr10:14,804,997...14,807,665
|
|
G |
Hax1 |
HCLS1 associated protein X-1 |
affects expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde affects the expression of HAX1 protein |
CTD |
PMID:19763263 |
|
NCBI chr 2:175,434,242...175,437,926
Ensembl chr 2:175,434,238...175,437,714
|
|
G |
Hdac1 |
histone deacetylase 1 |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Curcumin affects the localization of HDAC1 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Curcumin results in decreased expression of HDAC1 mRNA]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Curcumin results in decreased expression of HDAC1 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Particulate Matter results in increased degradation of HDAC1 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Vehicle Emissions results in increased degradation of HDAC1 protein] |
CTD |
PMID:17395887 PMID:17927689 |
|
NCBI chr 5:141,853,992...141,881,057
Ensembl chr 5:141,853,989...141,881,111
|
|
G |
Hdac2 |
histone deacetylase 2 |
increases ubiquitination multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased ubiquitination of HDAC2 protein [SOD2 protein co-treated with benzyloxycarbonylleucyl-leucyl-leucine aldehyde] results in decreased expression of HDAC2 protein; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Smoke results in increased degradation of and results in decreased expression of HDAC2 protein]; CAT protein inhibits the reaction [[SOD2 protein co-treated with benzyloxycarbonylleucyl-leucyl-leucine aldehyde] results in decreased expression of HDAC2 protein] |
CTD |
PMID:18421014 PMID:24973648 |
|
NCBI chr20:40,548,244...40,571,609
Ensembl chr20:40,548,250...40,571,609
|
|
G |
Hdac6 |
histone deacetylase 6 |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [HDAC6 protein results in increased expression of ESRRA protein] |
CTD |
PMID:34524571 |
|
NCBI chr X:14,550,645...14,572,445
Ensembl chr X:14,551,044...14,572,441
|
|
G |
Hes1 |
hes family bHLH transcription factor 1 |
multiple interactions decreases expression |
ISO |
MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of HES1 mRNA] |
CTD |
PMID:25566086 |
|
NCBI chr11:70,705,763...70,708,176
Ensembl chr11:70,705,764...70,708,192
|
|
G |
Hif1a |
hypoxia inducible factor 1 subunit alpha |
decreases degradation multiple interactions increases expression |
ISO EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased degradation of HIF1A protein benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [methylmercuric chloride results in decreased expression of HIF1A protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Methylmercury Compounds results in decreased expression of HIF1A protein] benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of HIF1A protein benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of HIF1A protein; benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of HIF1A protein modified form 3-(4-bromophenyl)-2-(ethylsulfonyl)-6-methylquinoxaline-1,4-dioxide inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [Oxygen deficiency results in increased expression of HIF1A protein]]; [andrographolide co-treated with benzyloxycarbonylleucyl-leucyl-leucine aldehyde] results in increased ubiquitination of HIF1A protein; [benzyloxycarbonylleucyl-leucyl-leucine aldehyde co-treated with Ketoglutaric Acids co-treated with Ascorbic Acid co-treated with ferrous chloride] promotes the reaction [VHL protein binds to HIF1A protein]; [benzyloxycarbonylleucyl-leucyl-leucine aldehyde co-treated with Oxygen deficiency] affects the expression of HIF1A protein; [Formaldehyde co-treated with pevonedistat co-treated with benzyloxycarbonylleucyl-leucyl-leucine aldehyde] affects the folding of HIF1A protein; [Formaldehyde co-treated with VH298 co-treated with benzyloxycarbonylleucyl-leucyl-leucine aldehyde] affects the folding of HIF1A protein; [Oxygen deficiency co-treated with benzyloxycarbonylleucyl-leucyl-leucine aldehyde] affects the expression of HIF1A protein; [VH298 co-treated with benzyloxycarbonylleucyl-leucyl-leucine aldehyde] affects the folding of HIF1A protein; benzyloxycarbonylleucyl-leucyl-leucine aldehyde affects the reaction [[Apigenin co-treated with Oxygen deficiency] affects the expression of HIF1A protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [andrographolide results in decreased expression of HIF1A protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [andrographolide results in increased degradation of HIF1A protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [deguelin results in increased degradation of HIF1A protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [geldanamycin results in increased degradation of HIF1A protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [L-4F peptide inhibits the reaction [INS protein results in increased expression of HIF1A protein]]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [MALAT1 mRNA affects the reaction [sodium arsenite results in increased expression of HIF1A protein]]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Resveratrol inhibits the reaction [Oxygen deficiency results in increased expression of HIF1A protein]]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [scutellarin inhibits the reaction [[cobaltous chloride co-treated with Glucose] results in increased expression of HIF1A protein]]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [scutellarin results in decreased expression of HIF1A protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [[Dinoprostone binds to and results in increased activity of PTGER1 protein] which results in increased expression of HIF1A protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [HIF1A protein binds to VHL protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [Oxygen deficiency results in increased expression of HIF1A protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [VHL protein binds to HIF1A protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased degradation of and results in increased expression of HIF1A protein; bruceine D inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [Oxygen deficiency results in increased expression of HIF1A protein]]; Curcumin analog inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [Oxygen deficiency results in increased expression of HIF1A protein]]; Curcumin analog inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of HIF1A protein modified form]; diallyl trisulfide inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased degradation of HIF1A protein]; dictamnine inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [Oxygen deficiency results in increased expression of HIF1A protein]]; Digitoxin inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [Oxygen deficiency results in increased expression of HIF1A protein]]; dihydrotanshinone I inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [Oxygen deficiency results in increased expression of HIF1A protein]]; genipin affects the reaction [[Oxygen deficiency co-treated with benzyloxycarbonylleucyl-leucyl-leucine aldehyde] affects the expression of HIF1A protein]; Glucosamine affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of HIF1A protein]; manganese chloride inhibits the reaction [[benzyloxycarbonylleucyl-leucyl-leucine aldehyde co-treated with Ketoglutaric Acids co-treated with Ascorbic Acid co-treated with ferrous chloride] promotes the reaction [VHL protein binds to HIF1A protein]]; Quercetin inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [HIF1A protein binds to VHL protein]]; Resveratrol inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [Oxygen deficiency results in increased expression of HIF1A protein]] benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [resveratrol results in decreased expression of HIF1A protein]; Cycloheximide inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of HIF1A protein] |
CTD |
PMID:11980636 PMID:17764071 PMID:17973296 PMID:18682687 PMID:19254699 PMID:19263519 PMID:20335389 PMID:20524035 PMID:20554536 PMID:21134392 PMID:22537771 PMID:23593480 PMID:24221993 PMID:24497960 PMID:24975222 PMID:25192544 PMID:26282490 PMID:27287256 PMID:28574600 PMID:28651835 PMID:29630948 PMID:30266538 PMID:31850806 PMID:32461003 PMID:34717917 PMID:34900531 PMID:35504338 PMID:35513012 More...
|
|
NCBI chr 6:92,624,059...92,669,262
Ensembl chr 6:92,624,390...92,669,261
|
|
G |
Higd1b |
HIG1 hypoxia inducible domain family, member 1B |
decreases expression multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of HIGD1B mRNA MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of HIGD1B mRNA] |
CTD |
PMID:25566086 |
|
NCBI chr10:87,798,864...87,804,459
|
|
G |
Hipk2 |
homeodomain interacting protein kinase 2 |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [cobaltous chloride results in decreased expression of HIPK2 protein] |
CTD |
PMID:19714248 |
|
NCBI chr 4:67,439,327...67,619,223
Ensembl chr 4:67,440,501...67,619,223
|
|
G |
Hist1h2af |
histone cluster 1 H2A family member F |
multiple interactions |
ISO |
[MYBPC3 protein affects the susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde] which results in decreased expression of H2AC13 mRNA |
CTD |
PMID:25566086 |
|
NCBI chr17:41,379,404...41,379,796
Ensembl chr17:41,379,404...41,379,796
|
|
G |
Hist1h2ah |
histone cluster 1 H2A family member H |
multiple interactions |
ISO |
[MYBPC3 protein affects the susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde] which results in decreased expression of H2AC22 mRNA |
CTD |
PMID:25566086 |
|
NCBI chr17:41,384,521...41,385,018
|
|
G |
Hmox1 |
heme oxygenase 1 |
increases expression increases ubiquitination multiple interactions |
ISO EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of HMOX1 mRNA; benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of HMOX1 protein benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased ubiquitination of HMOX1 protein [benzyloxycarbonylleucyl-leucyl-leucine aldehyde co-treated with Hemin] results in decreased expression of HMOX1 protein; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Hemin results in increased expression of HMOX1 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [Hemin results in decreased expression of HMOX1 protein] [benzyloxycarbonylleucyl-leucyl-leucine aldehyde co-treated with Hemin] results in increased expression of HMOX1 mRNA; [benzyloxycarbonylleucyl-leucyl-leucine aldehyde co-treated with Hemin] results in increased expression of HMOX1 protein; [USP7 protein co-treated with benzyloxycarbonylleucyl-leucyl-leucine aldehyde] results in increased ubiquitination of HMOX1 protein; [USP7 protein mutant form co-treated with benzyloxycarbonylleucyl-leucyl-leucine aldehyde] results in increased ubiquitination of HMOX1 protein; Arsenic inhibits the reaction [[USP7 protein mutant form co-treated with benzyloxycarbonylleucyl-leucyl-leucine aldehyde] results in increased ubiquitination of HMOX1 protein]; Arsenic inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased ubiquitination of HMOX1 protein]; Arsenic promotes the reaction [[USP7 protein co-treated with benzyloxycarbonylleucyl-leucyl-leucine aldehyde] results in increased ubiquitination of HMOX1 protein]; Arsenic promotes the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [HMOX1 protein binds to USP7 protein]]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [Hemin results in increased expression of HMOX1 mRNA]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [HMOX1 protein binds to USP7 protein]; HMOX1 protein inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of HMOX1 protein]; HMOX1 protein promotes the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of HMOX1 protein]; NFE2L2 protein promotes the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of HMOX1 mRNA]; USP7 protein affects the reaction [Arsenic inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased ubiquitination of HMOX1 protein]]; USP7 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased ubiquitination of HMOX1 protein] benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [Tetrachlorodibenzodioxin results in increased expression of HMOX1 mRNA] |
CTD |
PMID:12441344 PMID:18550526 PMID:18835339 PMID:25824035 PMID:30186748 PMID:33434570 PMID:35821281 More...
|
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Hnrnpa1 |
heterogeneous nuclear ribonucleoprotein A1 |
multiple interactions increases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Tetracaine results in decreased expression of HNRNPA1 mRNA]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [Thapsigargin affects the localization of HNRNPA1 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [Tunicamycin affects the localization of HNRNPA1 protein] benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of HNRNPA1 mRNA |
CTD |
PMID:23106379 PMID:34822839 |
|
NCBI chr 7:134,375,318...134,381,610
Ensembl chr 7:134,375,150...134,381,609
|
|
G |
Hnrnpk |
heterogeneous nuclear ribonucleoprotein K |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [NSC606985 results in decreased expression of HNRNPK protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [PRKCD protein results in increased ubiquitination of HNRNPK protein] |
CTD |
PMID:19747914 |
|
NCBI chr17:6,262,936...6,275,001
Ensembl chr17:6,262,998...6,274,997
|
|
G |
Hopx |
HOP homeobox |
multiple interactions |
ISO |
[MYBPC3 protein affects the susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde] which results in decreased expression of HOPX mRNA |
CTD |
PMID:25566086 |
|
NCBI chr14:31,055,912...31,082,909
Ensembl chr14:31,075,148...31,082,909
|
|
G |
Hp |
haptoglobin |
decreases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of HP mRNA |
CTD |
PMID:20061341 |
|
NCBI chr19:37,539,626...37,544,178
Ensembl chr19:37,539,627...37,544,523
|
|
G |
Hr |
HR, lysine demethylase and nuclear receptor corepressor |
multiple interactions decreases expression |
ISO |
MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of HR mRNA] |
CTD |
PMID:25566086 |
|
NCBI chr15:45,626,835...45,646,313
Ensembl chr15:45,626,835...45,646,313
|
|
G |
Hsd11b2 |
hydroxysteroid 11-beta dehydrogenase 2 |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Progesterone results in increased expression of HSD11B2 mRNA] |
CTD |
PMID:15857753 |
|
NCBI chr19:33,397,656...33,402,899
Ensembl chr19:33,397,656...33,402,899
|
|
G |
Hsf1 |
heat shock transcription factor 1 |
increases activity multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased activity of HSF1 protein HSF1 promotes the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of HSPA4 mRNA]; HSF1 promotes the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of UBC mRNA] |
CTD |
PMID:11893605 PMID:30186748 |
|
NCBI chr 7:108,196,040...108,223,011
Ensembl chr 7:108,196,056...108,223,011
|
|
G |
Hsf2 |
heat shock transcription factor 2 |
increases activity increases expression multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased activity of HSF2 protein benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of HSF2 protein Quercetin inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of HSF2 protein] |
CTD |
PMID:11893605 PMID:15914627 |
|
NCBI chr20:36,819,864...36,847,490
Ensembl chr20:36,819,864...36,850,174
|
|
G |
Hsf4 |
heat shock transcription factor 4 |
increases expression multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of HSF4 protein Quercetin inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of HSF4 protein] |
CTD |
PMID:15914627 |
|
NCBI chr19:33,147,755...33,153,479
Ensembl chr19:33,147,755...33,153,479
|
|
G |
Hsp90aa1 |
heat shock protein 90 alpha family class A member 1 |
increases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of HSP90AA1 mRNA |
CTD |
PMID:25566086 |
|
NCBI chr 6:129,702,376...129,707,907
Ensembl chr 6:129,702,383...129,707,268
|
|
G |
Hspa1a |
heat shock protein family A (Hsp70) member 1A |
multiple interactions increases expression |
EXP ISO |
PARK7 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of HSPA1A protein] benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of HSPA1A mRNA |
CTD |
PMID:18331584 PMID:25566086 |
|
NCBI chr20:3,870,765...3,873,221
Ensembl chr20:3,856,006...3,873,227
|
|
G |
Hspa1b |
heat shock protein family A (Hsp70) member 1B |
increases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of HSPA1B mRNA; benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of HSPA1B protein |
CTD |
PMID:15525353 PMID:25566086 |
|
NCBI chr20:3,855,104...3,859,148
Ensembl chr20:3,856,006...3,873,240 Ensembl chr20:3,856,006...3,873,240
|
|
G |
Hspa4 |
heat shock protein family A (Hsp70) member 4 |
multiple interactions increases expression |
ISO |
Quercetin inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of HSPA4 protein] HSF1 promotes the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of HSPA4 mRNA] |
CTD |
PMID:15914627 PMID:30186748 |
|
NCBI chr10:37,408,025...37,449,080
Ensembl chr10:37,408,025...37,449,001
|
|
G |
Hspa5 |
heat shock protein family A (Hsp70) member 5 |
increases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of HSPA5 protein |
CTD |
PMID:19139269 PMID:21692457 |
|
NCBI chr 3:18,055,507...18,059,969
Ensembl chr 3:18,055,405...18,059,891
|
|
G |
Hspa8 |
heat shock protein family A (Hsp70) member 8 |
multiple interactions |
ISO |
[MYBPC3 protein affects the susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde] which results in increased expression of HSPA8 mRNA |
CTD |
PMID:25566086 |
|
NCBI chr 8:41,183,397...41,187,260
Ensembl chr 8:41,183,264...41,187,259
|
|
G |
Hspa9 |
heat shock protein family A (Hsp70) member 9 |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Acrylamide results in decreased expression of HSPA9 protein] |
CTD |
PMID:37353096 |
|
NCBI chr18:26,536,131...26,554,294
Ensembl chr18:26,535,798...26,554,292
|
|
G |
Hspb1 |
heat shock protein family B (small) member 1 |
increases expression multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of HSPB1 mRNA; benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of HSPB1 protein benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [bufalin results in decreased expression of HSPB1 protein] Quercetin inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of HSPB1 protein] |
CTD |
PMID:15914627 PMID:23091618 |
|
NCBI chr12:20,794,014...20,795,675
Ensembl chr12:20,794,028...20,795,743
|
|
G |
Hspb2 |
heat shock protein family B (small) member 2 |
decreases expression multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of HSPB2 mRNA MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of HSPB2 mRNA] |
CTD |
PMID:25566086 |
|
NCBI chr 8:51,093,267...51,094,528
Ensembl chr 8:51,081,342...51,094,533
|
|
G |
Hsph1 |
heat shock protein family H (Hsp110) member 1 |
increases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of HSPH1 mRNA |
CTD |
PMID:25566086 |
|
NCBI chr12:5,390,916...5,410,224
Ensembl chr12:5,390,922...5,410,224
|
|
G |
Htra2 |
HtrA serine peptidase 2 |
increases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of HTRA2 protein |
CTD |
PMID:19763263 |
|
NCBI chr 4:115,556,914...115,560,202
Ensembl chr 4:115,556,916...115,560,095
|
|
G |
Icam1 |
intercellular adhesion molecule 1 |
multiple interactions decreases expression |
ISO EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [TNF protein results in increased expression of ICAM1 mRNA]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [TNF protein results in increased expression of ICAM1 protein] MG132 pretreatment decreases expression of protein in liver of intestinal ischemia/reperfusion rats |
CTD RGD |
PMID:11698246 PMID:14572618 PMID:22079846 |
RGD:401794136 |
NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438
|
|
G |
Ifng |
interferon gamma |
multiple interactions |
ISO EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [IFNG protein results in increased activity of CASP1 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [IFNG protein results in increased activity of CASP6 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [IFNG protein results in increased activity of CASP8 protein]; Quercetin inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [IFNG protein results in increased activity of CASP1 protein]]; Quercetin inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [IFNG protein results in increased activity of CASP6 protein]]; Quercetin inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [IFNG protein results in increased activity of CASP8 protein]] benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased expression of NOS2 mRNA]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [[TNF protein co-treated with IL1B protein co-treated with IFNG protein] results in increased expression of NOS2 mRNA]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Diclofenac promotes the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased expression of NOS2 mRNA]]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Diclofenac promotes the reaction [[TNF protein co-treated with IL1B protein co-treated with IFNG protein] results in increased expression of NOS2 mRNA]] |
CTD |
PMID:15914627 PMID:19393675 PMID:23395999 |
|
NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375
|
|
G |
Igf1r |
insulin-like growth factor 1 receptor |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [platycodin D results in decreased expression of IGF1R protein] |
CTD |
PMID:28711525 |
|
NCBI chr 1:121,549,831...121,838,548
Ensembl chr 1:121,550,743...121,831,777
|
|
G |
Igf2 |
insulin-like growth factor 2 |
multiple interactions decreases response to substance |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [IGF2 protein results in increased expression of STS mRNA]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [IGF2 protein results in increased expression of STS protein] benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased susceptibility to IGF2 protein |
CTD |
PMID:24055520 |
|
NCBI chr 1:197,814,409...197,831,802
Ensembl chr 1:197,814,410...197,823,018
|
|
G |
Il18 |
interleukin 18 |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Isoproterenol results in increased secretion of IL18 protein] [lipopolysaccharide, Escherichia coli O111 B4 co-treated with benzyloxycarbonylleucyl-leucyl-leucine aldehyde] results in increased expression of IL18 protein; benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with sodium arsenite] results in increased expression of IL18 protein] |
CTD |
PMID:15178407 PMID:34920032 |
|
NCBI chr 8:50,904,630...50,932,887
Ensembl chr 8:50,906,960...50,932,887
|
|
G |
Il1a |
interleukin 1 alpha |
multiple interactions decreases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [[IL1A co-treated with PDGFB] results in increased secretion of MMP9 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [IL1A protein results in increased secretion of CCL2 protein] benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of IL1A mRNA |
CTD |
PMID:11230753 PMID:15728660 PMID:20061341 |
|
NCBI chr 3:116,526,601...116,537,055
Ensembl chr 3:116,526,604...116,536,822
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions decreases response to substance |
ISO EXP |
[benzyloxycarbonylleucyl-leucyl-leucine aldehyde co-treated with IL1B protein] results in increased expression of and results in increased phosphorylation of NFKBIA protein; [lipopolysaccharide, Escherichia coli O111 B4 co-treated with benzyloxycarbonylleucyl-leucyl-leucine aldehyde] results in increased expression of IL1B protein; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [IL1B protein results in increased activity of [RELA protein binds to NFKB1 protein]]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with sodium arsenite] results in increased expression of IL1B protein]; sodium arsenite inhibits the reaction [[benzyloxycarbonylleucyl-leucyl-leucine aldehyde co-treated with IL1B protein] results in increased expression of and results in increased phosphorylation of NFKBIA protein] benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased susceptibility to IL1B protein benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased expression of NOS2 mRNA]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [[TNF protein co-treated with IL1B protein co-treated with IFNG protein] results in increased expression of NOS2 mRNA]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Diclofenac promotes the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased expression of NOS2 mRNA]]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Diclofenac promotes the reaction [[TNF protein co-treated with IL1B protein co-treated with IFNG protein] results in increased expression of NOS2 mRNA]]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [IL1B protein results in increased expression of CCL2 mRNA] |
CTD |
PMID:10541287 PMID:11835394 PMID:14581482 PMID:19393675 PMID:23395999 PMID:34920032 More...
|
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il6 |
interleukin 6 |
increases expression decreases expression multiple interactions |
ISO EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of IL6 mRNA; benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of IL6 protein MG132 pretreatment decreases expression of TNFa, IL6 protein in serum of intestinal ischemia/reperfusion rats benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [[Chloroquine co-treated with lipopolysaccharide, E coli O55-B5] results in increased secretion of IL6 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased secretion of IL6 protein] Quercetin inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of IL6 mRNA]; Quercetin inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of IL6 protein] |
CTD RGD |
PMID:11893605 PMID:18457675 PMID:28134560 PMID:31806706 PMID:22079846 |
RGD:401794136 |
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Impact |
impact RWD domain protein |
increases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of IMPACT mRNA |
CTD |
PMID:25566086 |
|
NCBI chr18:4,108,872...4,147,571
Ensembl chr18:4,108,853...4,147,569
|
|
G |
Inafm2 |
InaF motif containing 2 |
decreases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of INAFM2 mRNA |
CTD |
PMID:25566086 |
|
NCBI chr 3:105,728,208...105,733,766
|
|
G |
Ins1 |
insulin 1 |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [INS1 protein results in decreased expression of IRS1 protein] |
CTD |
PMID:24219910 |
|
NCBI chr 1:251,244,973...251,245,540
Ensembl chr 1:251,244,973...251,245,536
|
|
G |
Ins2 |
insulin 2 |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [L-4F peptide inhibits the reaction [INS protein results in increased expression of HIF1A protein]] |
CTD |
PMID:22537771 |
|
NCBI chr 1:197,843,277...197,992,522
Ensembl chr 1:197,843,281...197,864,775
|
|
G |
Insl6 |
insulin-like 6 |
multiple interactions increases expression |
ISO |
MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of INSL6 mRNA] |
CTD |
PMID:25566086 |
|
NCBI chr 1:227,069,958...227,073,493
Ensembl chr 1:227,069,958...227,073,493
|
|
G |
Irf8 |
interferon regulatory factor 8 |
decreases degradation |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased degradation of IRF8 protein |
CTD |
PMID:15837792 |
|
NCBI chr19:48,790,581...48,812,363
Ensembl chr19:48,790,588...48,811,829
|
|
G |
Irs1 |
insulin receptor substrate 1 |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [INS1 protein results in decreased expression of IRS1 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [triptolide results in decreased expression of IRS1 protein] |
CTD |
PMID:24219910 PMID:32061799 |
|
NCBI chr 9:83,552,964...83,605,797
Ensembl chr 9:83,548,944...83,606,122
|
|
G |
Irx3 |
iroquois homeobox 3 |
decreases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of IRX3 mRNA |
CTD |
PMID:25566086 |
|
NCBI chr19:15,211,882...15,215,317
Ensembl chr19:15,211,878...15,215,317
|
|
G |
Itgam |
integrin subunit alpha M |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [Tretinoin results in increased expression of ITGAM protein] |
CTD |
PMID:20945414 |
|
NCBI chr 1:182,659,047...182,709,501
Ensembl chr 1:182,659,000...182,709,503
|
|
G |
Itgb1bp2 |
integrin subunit beta 1 binding protein 2 |
decreases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of ITGB1BP2 mRNA |
CTD |
PMID:25566086 |
|
NCBI chr X:66,572,537...66,577,174
Ensembl chr X:66,572,537...66,577,174
|
|
G |
Itgb3 |
integrin subunit beta 3 |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [GW 4064 results in decreased expression of ITGB3 protein] |
CTD |
PMID:38216027 |
|
NCBI chr10:89,509,917...89,564,679
Ensembl chr10:89,509,989...89,564,679
|
|
G |
Itpr3 |
inositol 1,4,5-trisphosphate receptor, type 3 |
multiple interactions |
EXP ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Acrylamide results in decreased expression of ITPR3 protein] |
CTD |
PMID:37353096 |
|
NCBI chr20:5,136,968...5,202,339
Ensembl chr20:5,136,441...5,202,337
|
|
G |
Ivl |
involucrin |
increases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of IVL mRNA |
CTD |
PMID:25566086 |
|
NCBI chr 2:178,146,694...178,160,807
Ensembl chr 2:178,147,061...178,149,100
|
|
G |
Jun |
Jun proto-oncogene, AP-1 transcription factor subunit |
increases expression multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of JUN protein benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [KU-32 compound inhibits the reaction [NRG1 protein results in increased expression of and results in increased phosphorylation of JUN protein]]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [NRG1 protein results in increased expression of and results in increased phosphorylation of JUN protein]; Cycloheximide inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of JUN protein] |
CTD |
PMID:23240583 PMID:23593480 |
|
NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656
|
|
G |
Junb |
JunB proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Curcumin inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of JUNB protein]] |
CTD |
PMID:17148446 |
|
NCBI chr19:23,176,265...23,178,049
Ensembl chr19:23,176,294...23,178,035
|
|
G |
Kat5 |
lysine acetyltransferase 5 |
multiple interactions increases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [KAT5 protein results in increased acetylation of and results in increased degradation of SRSF2 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [sodium arsenite results in decreased expression of KAT5 protein] benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of KAT5 protein |
CTD |
PMID:21157427 PMID:28837777 |
|
NCBI chr 1:202,895,751...202,903,178
Ensembl chr 1:202,895,751...202,903,458
|
|
G |
Katnb1 |
katanin regulatory subunit B1 |
increases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of KATNB1 mRNA |
CTD |
PMID:25566086 |
|
NCBI chr19:9,921,216...9,940,853
Ensembl chr19:9,921,219...9,940,650
|
|
G |
Kbtbd11 |
kelch repeat and BTB domain containing 11 |
multiple interactions |
ISO |
[MYBPC3 protein affects the susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde] which results in decreased expression of KBTBD11 mRNA |
CTD |
PMID:25566086 |
|
NCBI chr16:74,618,291...74,638,010
Ensembl chr16:74,615,792...74,637,736
|
|
G |
Kcng2 |
potassium voltage-gated channel modifier subfamily G member 2 |
decreases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of KCNG2 mRNA |
CTD |
PMID:25566086 |
|
NCBI chr18:73,742,224...73,810,420
Ensembl chr18:73,743,074...73,808,723
|
|
G |
Kcnh2 |
potassium voltage-gated channel subfamily H member 2 |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [arsenic trioxide results in increased degradation of KCNH2 protein] |
CTD |
PMID:28521025 |
|
NCBI chr 4:10,826,834...10,859,009
Ensembl chr 4:10,826,928...10,859,008
|
|
G |
Kcnip3 |
potassium voltage-gated channel interacting protein 3 |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [[SOD1 protein results in increased susceptibility to Thimerosal] which results in decreased expression of KCNIP3 protein] |
CTD |
PMID:30503815 |
|
NCBI chr 3:114,677,027...114,742,923
Ensembl chr 3:114,677,030...114,743,556
|
|
G |
Kcnn2 |
potassium calcium-activated channel subfamily N member 2 |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [FBXO32 protein results in decreased expression of KCNN2 protein] |
CTD |
PMID:30635400 |
|
NCBI chr18:37,817,966...38,258,347
Ensembl chr18:37,817,957...38,258,347
|
|
G |
Kdm1a |
lysine demethylase 1A |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [SP2509 results in decreased stability of KDM1A protein] |
CTD |
PMID:29581250 |
|
NCBI chr 5:148,782,976...148,838,319
Ensembl chr 5:148,782,976...148,838,319
|
|
G |
Keap1 |
Kelch-like ECH-associated protein 1 |
multiple interactions |
ISO |
[2-tert-butylhydroquinone co-treated with benzyloxycarbonylleucyl-leucyl-leucine aldehyde] promotes the reaction [NFE2L2 protein binds to KEAP1 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [NFE2L2 protein binds to KEAP1 protein] |
CTD |
PMID:18512965 |
|
NCBI chr 8:19,768,375...19,777,862
Ensembl chr 8:19,768,375...19,777,862
|
|
G |
Kif1a |
kinesin family member 1A |
increases expression multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of KIF1A mRNA MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of KIF1A mRNA] |
CTD |
PMID:25566086 |
|
NCBI chr 9:93,563,033...93,647,412
Ensembl chr 9:93,563,045...93,647,480
|
|
G |
Kif1b |
kinesin family member 1B |
increases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of KIF1B mRNA |
CTD |
PMID:25566086 |
|
NCBI chr 5:159,607,697...159,742,778
Ensembl chr 5:159,561,271...159,742,778
|
|
G |
Kif20a |
kinesin family member 20A |
decreases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of KIF20A mRNA |
CTD |
PMID:20061341 |
|
NCBI chr18:26,230,294...26,238,780
Ensembl chr18:26,230,230...26,238,780
|
|
G |
Kif4a |
kinesin family member 4A |
decreases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of KIF4 mRNA |
CTD |
PMID:20061341 |
|
NCBI chr X:65,721,746...65,824,277
Ensembl chr X:65,721,779...65,824,139
|
|
G |
Klf2 |
KLF transcription factor 2 |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [TRAF2 protein results in decreased expression of KLF2 protein] |
CTD |
PMID:35635602 |
|
NCBI chr16:17,521,107...17,523,739
Ensembl chr16:17,514,552...17,523,944
|
|
G |
Klf6 |
KLF transcription factor 6 |
increases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of KLF6 mRNA |
CTD |
PMID:31806706 |
|
NCBI chr17:64,539,456...64,548,451
Ensembl chr17:64,531,463...64,588,570
|
|
G |
Klhl6 |
kelch-like family member 6 |
multiple interactions decreases expression |
ISO |
MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of KLHL6 mRNA] |
CTD |
PMID:25566086 |
|
NCBI chr11:80,970,917...81,010,593
Ensembl chr11:80,970,917...81,009,677
|
|
G |
Knstrn |
kinetochore-localized astrin/SPAG5 binding protein |
decreases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of KNSTRN mRNA |
CTD |
PMID:20061341 |
|
NCBI chr 3:105,800,762...105,820,555
Ensembl chr 3:105,800,954...105,820,715
|
|
G |
Kras |
KRAS proto-oncogene, GTPase |
increases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of KRAS mRNA |
CTD |
PMID:31806706 |
|
NCBI chr 4:178,185,418...178,218,484
|
|
G |
Krt5 |
keratin 5 |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde affects the reaction [Diacetyl affects the expression of and affects the ubiquitination of KRT5 protein] |
CTD |
PMID:32112875 |
|
NCBI chr 7:132,846,132...132,851,861
Ensembl chr 7:132,846,136...132,851,850
|
|
G |
Ky |
kyphoscoliosis peptidase |
multiple interactions |
ISO |
[MYBPC3 protein affects the susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde] which results in decreased expression of KY mRNA |
CTD |
PMID:25566086 |
|
NCBI chr 8:103,086,959...103,126,305
Ensembl chr 8:103,086,630...103,126,024
|
|
G |
Lat2 |
linker for activation of T cells family, member 2 |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [10-(octyloxy)decyl-2-(trimethylammonium)ethyl phosphate results in decreased expression of LAT2 protein] |
CTD |
PMID:23001822 |
|
NCBI chr12:22,104,173...22,118,294
Ensembl chr12:22,104,219...22,118,288
|
|
G |
Ldb3 |
LIM domain binding 3 |
multiple interactions decreases expression |
ISO |
MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of LDB3 mRNA] |
CTD |
PMID:25566086 |
|
NCBI chr16:9,855,768...9,920,108
Ensembl chr16:9,855,927...9,918,532
|
|
G |
Lgals1 |
galectin 1 |
multiple interactions |
ISO |
[MYBPC3 protein affects the susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde] which results in decreased expression of LGALS1 mRNA |
CTD |
PMID:25566086 |
|
NCBI chr 7:110,485,239...110,488,345
Ensembl chr 7:110,481,392...110,488,345
|
|
G |
Lmo7 |
LIM domain 7 |
multiple interactions decreases expression |
ISO |
MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of LMO7 mRNA] |
CTD |
PMID:25566086 |
|
NCBI chr15:78,566,999...78,769,833
Ensembl chr15:78,567,023...78,769,783
|
|
G |
Lnx1 |
ligand of numb-protein X 1 |
decreases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of LNX1 mRNA |
CTD |
PMID:20061341 |
|
NCBI chr14:33,514,429...33,617,086
Ensembl chr14:33,514,436...33,617,086
|
|
G |
Lpin1 |
lipin 1 |
multiple interactions increases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [TGFB1 protein results in decreased expression of LPIN1 protein] benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of LPIN1 protein |
CTD |
PMID:27345520 |
|
NCBI chr 6:39,309,198...39,417,034
Ensembl chr 6:39,312,748...39,417,097
|
|
G |
Lrrc10 |
leucine-rich repeat-containing 10 |
decreases expression multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of LRRC10 mRNA [MYBPC3 protein affects the susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde] which results in decreased expression of LRRC10 mRNA; MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of LRRC10 mRNA] |
CTD |
PMID:25566086 |
|
NCBI chr 7:52,686,972...52,688,369
Ensembl chr 7:52,686,972...52,688,369
|
|
G |
Lrrc75a |
leucine rich repeat containing 75A |
multiple interactions |
ISO |
[MYBPC3 protein affects the susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde] which results in decreased expression of LRRC75A mRNA |
CTD |
PMID:25566086 |
|
NCBI chr10:47,298,222...47,343,301
Ensembl chr10:47,297,288...47,343,664
|
|
G |
Lrrk2 |
leucine-rich repeat kinase 2 |
increases ubiquitination |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased ubiquitination of LRRK2 protein |
CTD |
PMID:24942733 |
|
NCBI chr 7:122,826,696...122,987,711
Ensembl chr 7:122,826,696...122,987,703
|
|
G |
Luc7l |
LUC7-like |
multiple interactions |
ISO |
[MYBPC3 protein affects the susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde] which results in increased expression of LUC7L mRNA |
CTD |
PMID:25566086 |
|
NCBI chr10:15,273,340...15,307,131
Ensembl chr10:15,273,348...15,303,112
|
|
G |
Lxn |
latexin |
decreases expression multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of LXN mRNA MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of LXN mRNA] |
CTD |
PMID:25566086 |
|
NCBI chr 2:151,727,556...151,733,426
Ensembl chr 2:151,727,102...151,733,460
|
|
G |
Maf1 |
MAF1 homolog, negative regulator of RNA polymerase III |
multiple interactions |
ISO |
[benzyloxycarbonylleucyl-leucyl-leucine aldehyde co-treated with Sirolimus] results in decreased degradation of MAF1 protein; benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased ubiquitination of and results in decreased degradation of MAF1 protein; CUL2 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased ubiquitination of MAF1 protein] |
CTD |
PMID:31645432 |
|
NCBI chr 7:108,075,173...108,078,252
Ensembl chr 7:108,075,189...108,078,249
|
|
G |
Map1b |
microtubule-associated protein 1B |
increases expression multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of MAP1B mRNA MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of MAP1B mRNA] |
CTD |
PMID:25566086 |
|
NCBI chr 2:30,817,261...30,910,458
Ensembl chr 2:30,817,261...30,910,317
|
|
G |
Map1lc3b |
microtubule-associated protein 1 light chain 3 beta |
increases expression multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of MAP1LC3B protein modified form benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [trovafloxacin results in increased expression of and results in increased lipidation of MAP1LC3B protein]; MAP1LC3B protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased phosphorylation of NFKBIA protein] |
CTD |
PMID:24085292 PMID:26409479 PMID:33609687 |
|
NCBI chr19:49,665,795...49,673,655
Ensembl chr19:49,665,791...49,677,690 Ensembl chr16:49,665,791...49,677,690
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:25780039 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:25780039 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mapk8 |
mitogen-activated protein kinase 8 |
increases phosphorylation decreases response to substance multiple interactions |
EXP ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased phosphorylation of MAPK8 protein MAPK8 gene mutant form results in decreased susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde MAPK8 affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of PMAIP1 mRNA] |
CTD |
PMID:18463101 PMID:23593480 |
|
NCBI chr16:8,638,897...8,721,960
Ensembl chr16:8,638,924...8,721,981
|
|
G |
Mapk9 |
mitogen-activated protein kinase 9 |
multiple interactions |
ISO |
MAPK9 inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of PMAIP1 mRNA] |
CTD |
PMID:23593480 |
|
NCBI chr10:34,169,661...34,211,138
Ensembl chr10:34,169,675...34,210,178
|
|
G |
Mapkapk2 |
MAPK activated protein kinase 2 |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Benzo(a)pyrene results in increased degradation of MAPKAPK2 protein] |
CTD |
PMID:35427736 |
|
NCBI chr13:42,513,762...42,560,061
Ensembl chr13:42,513,762...42,560,457
|
|
G |
Marchf6 |
membrane associated ring-CH-type finger 6 |
increases stability |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased stability of MARCHF6 protein |
CTD |
PMID:30545937 |
|
NCBI chr 2:82,455,686...82,532,917
Ensembl chr 2:82,455,689...82,532,910
|
|
G |
Masp1 |
MBL associated serine protease 1 |
decreases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of MASP1 mRNA |
CTD |
PMID:25566086 |
|
NCBI chr11:77,334,794...77,405,271
Ensembl chr11:77,334,859...77,402,974
|
|
G |
Mb |
myoglobin |
decreases expression multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of MB mRNA MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of MB mRNA] |
CTD |
PMID:25566086 |
|
NCBI chr 7:108,759,903...108,767,134
Ensembl chr 7:108,759,904...108,767,383
|
|
G |
Mbd2 |
methyl-CpG binding domain protein 2 |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Ethanol results in increased degradation of MBD2 protein] |
CTD |
PMID:23395981 |
|
NCBI chr18:64,174,002...64,240,795
Ensembl chr18:64,174,002...64,240,794
|
|
G |
Mbd3 |
methyl-CpG binding domain protein 3 |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Ethanol results in increased degradation of MBD3 protein] |
CTD |
PMID:23395981 |
|
NCBI chr 7:9,312,961...9,320,166
Ensembl chr 7:9,313,098...9,320,165
|
|
G |
Mcl1 |
MCL1 apoptosis regulator, BCL2 family member |
multiple interactions increases expression decreases degradation increases ubiquitination |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [[Resveratrol co-treated with Clofarabine] results in decreased expression of MCL1 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [[Sorafenib co-treated with PRKN protein] results in decreased expression of MCL1 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [[WEHI-539 co-treated with venetoclax] results in decreased expression of MCL1 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Arsenic Trioxide promotes the reaction [Ethacrynic Acid results in decreased expression of MCL1 protein]]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Arsenic Trioxide results in decreased expression of MCL1 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [arsenite results in decreased expression of MCL1 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Clofarabine promotes the reaction [Resveratrol results in decreased expression of MCL1 protein]]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Cycloheximide results in decreased expression of MCL1 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Daunorubicin results in decreased expression of MCL1 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Metformin results in decreased expression of MCL1 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [NVP-BKM120 results in decreased expression of MCL1 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Quercetin results in decreased expression of MCL1 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Resveratrol promotes the reaction [Clofarabine results in decreased expression of MCL1 protein]]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Sirolimus inhibits the reaction [[[sodium arsenite results in increased abundance of Arsenic] which co-treated with Benzo(a)pyrene] results in increased expression of MCL1 protein]]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [USP7 protein affects the reaction [[[sodium arsenite results in increased abundance of Arsenic] which co-treated with Benzo(a)pyrene] results in increased expression of MCL1 protein]]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Wortmannin inhibits the reaction [[[sodium arsenite results in increased abundance of Arsenic] which co-treated with Benzo(a)pyrene] results in increased expression of MCL1 protein]]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [[Resveratrol co-treated with Clofarabine] results in increased expression of MCL1 protein] benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of MCL1 protein benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased degradation of MCL1 protein benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased ubiquitination of MCL1 protein |
CTD |
PMID:16109713 PMID:17553788 PMID:20802529 PMID:21750559 PMID:21933852 PMID:23082001 PMID:23341456 PMID:23353698 PMID:24924397 PMID:25408576 PMID:28673964 PMID:32305283 PMID:32802178 PMID:34963561 PMID:35561756 PMID:36346691 PMID:38479708 More...
|
|
NCBI chr 2:183,219,137...183,235,676
Ensembl chr 2:183,219,220...183,222,303
|
|
G |
Mcm5 |
minichromosome maintenance complex component 5 |
multiple interactions |
ISO |
[MYBPC3 protein affects the susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde] which results in decreased expression of MCM5 mRNA |
CTD |
PMID:25566086 |
|
NCBI chr19:13,483,030...13,504,389
Ensembl chr19:13,483,066...13,504,389
|
|
G |
Mdm2 |
MDM2 proto-oncogene |
increases expression multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of MDM2 mRNA benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [Etoposide promotes the reaction [MDM2 protein binds to TOP2A protein]] |
CTD |
PMID:17575151 PMID:20061341 |
|
NCBI chr 7:53,290,660...53,315,205
Ensembl chr 7:53,290,664...53,314,915
|
|
G |
Mecp2 |
methyl CpG binding protein 2 |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Ethanol results in increased degradation of MECP2 protein] |
CTD |
PMID:23395981 |
|
NCBI chr X:151,781,177...151,844,687
Ensembl chr X:151,789,930...151,844,689
|
|
G |
Mgarp |
mitochondria-localized glutamic acid-rich protein |
decreases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of MGARP mRNA |
CTD |
PMID:25566086 |
|
NCBI chr 2:135,431,283...135,439,425
Ensembl chr 2:135,431,283...135,439,612
|
|
G |
Mgll |
monoglyceride lipase |
decreases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of MGLL mRNA |
CTD |
PMID:25566086 |
|
NCBI chr 4:121,192,186...121,294,187
Ensembl chr 4:121,192,195...121,294,179
|
|
G |
Mgmt |
O-6-methylguanine-DNA methyltransferase |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Tamoxifen results in increased degradation of MGMT protein] |
CTD |
PMID:17597106 |
|
NCBI chr 1:191,710,980...191,937,760
Ensembl chr 1:191,710,930...191,937,756
|
|
G |
Mgst1 |
microsomal glutathione S-transferase 1 |
increases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of MGST1 mRNA |
CTD |
PMID:20061341 |
|
NCBI chr 4:171,029,666...171,044,893
Ensembl chr 4:171,029,630...171,044,892
|
|
G |
Mir122 |
microRNA 122 |
decreases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of MIR122 mRNA |
CTD |
PMID:31806706 |
|
NCBI chr18:58,758,703...58,758,787
|
|
G |
Mir146a |
microRNA 146a |
decreases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of MIR146A |
CTD |
PMID:32392329 |
|
NCBI chr10:27,848,516...27,848,610
Ensembl chr10:27,848,516...27,848,610
|
|
G |
Mitf |
melanocyte inducing transcription factor |
multiple interactions decreases expression |
ISO |
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [[Phytol inhibits the reaction [alpha-MSH results in increased expression of MITF protein]] which results in decreased ubiquitination of MITF protein]]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [[Phytol inhibits the reaction [alpha-MSH results in increased expression of MITF protein]] which results in decreased ubiquitination of MITF protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Phytol inhibits the reaction [alpha-MSH results in increased expression of MITF protein]] benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of MITF mRNA |
CTD |
PMID:29486182 PMID:31806706 |
|
NCBI chr 4:130,409,020...130,621,145
Ensembl chr 4:130,409,217...130,621,145
|
|
G |
Mlkl |
mixed lineage kinase domain like pseudokinase |
increases expression multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of MLKL mRNA MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of MLKL mRNA] |
CTD |
PMID:25566086 |
|
NCBI chr19:39,277,526...39,304,555
Ensembl chr19:39,276,785...39,304,502
|
|
G |
Mllt11 |
MLLT11, transcription factor 7 cofactor |
increases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of MLLT11 mRNA |
CTD |
PMID:25566086 |
|
NCBI chr 2:182,795,790...182,804,960
Ensembl chr 2:182,795,790...182,797,199
|
|
G |
Mmp13 |
matrix metallopeptidase 13 |
multiple interactions |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [halofuginone results in increased expression of MMP13 mRNA] |
CTD |
PMID:16489207 |
|
NCBI chr 8:4,497,960...4,508,239
Ensembl chr 8:4,497,960...4,508,239
|
|
G |
Mmp23 |
matrix metallopeptidase 23 |
multiple interactions |
ISO |
[MYBPC3 protein affects the susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde] which results in decreased expression of MMP23 mRNA |
CTD |
PMID:25566086 |
|
NCBI chr 5:166,239,643...166,242,734
Ensembl chr 5:166,239,644...166,242,433
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [[IL1A co-treated with PDGFB] results in increased secretion of MMP9 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [TNF protein results in increased activity of MMP9 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [TNF protein results in increased expression of MMP9 mRNA]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [butein results in decreased expression of MMP9 protein] |
CTD |
PMID:15728660 PMID:20696233 PMID:24613819 |
|
NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120
|
|
G |
Mocos |
molybdenum cofactor sulfurase |
increases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of MOCOS mRNA |
CTD |
PMID:20061341 PMID:25566086 |
|
NCBI chr18:15,931,659...15,977,415
Ensembl chr18:15,931,654...15,977,187
|
|
G |
Mocs1 |
molybdenum cofactor synthesis 1 |
increases expression multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of MOCS1 mRNA MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of MOCS1 mRNA] |
CTD |
PMID:25566086 |
|
NCBI chr 9:11,547,533...11,573,935
Ensembl chr 9:11,547,531...11,567,790
|
|
G |
Mocs2 |
molybdenum cofactor synthesis 2 |
increases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of MOCS2 mRNA |
CTD |
PMID:25566086 |
|
NCBI chr 2:46,504,588...46,516,327
Ensembl chr 2:46,504,588...46,516,324
|
|
G |
Mt3 |
metallothionein 3 |
multiple interactions increases expression |
ISO |
MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of MT3 mRNA] |
CTD |
PMID:25566086 |
|
NCBI chr19:10,848,754...10,850,158
Ensembl chr19:10,848,755...10,850,158
|
|
G |
Mterf3 |
mitochondrial transcription termination factor 3 |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Cycloheximide results in decreased expression of MTERF3 protein] |
CTD |
PMID:35904214 |
|
NCBI chr 7:63,826,418...63,844,747
Ensembl chr 7:63,826,427...63,844,658
|
|
G |
Mthfd1 |
methylenetetrahydrofolate dehydrogenase, cyclohydrolase and formyltetrahydrofolate synthetase 1 |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [arsenic trioxide results in increased degradation of MTHFD1 protein] |
CTD |
PMID:28265077 |
|
NCBI chr 6:94,977,862...95,045,375
Ensembl chr 6:94,977,862...95,045,372
|
|
G |
Mtor |
mechanistic target of rapamycin kinase |
increases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of MTOR protein |
CTD |
PMID:25897075 |
|
NCBI chr 5:158,884,856...158,994,311
Ensembl chr 5:158,884,804...158,994,311
|
|
G |
Mttp |
microsomal triglyceride transfer protein |
multiple interactions increases expression |
ISO |
[benzyloxycarbonylleucyl-leucyl-leucine aldehyde co-treated with Chloroquine] results in increased expression of MTTP protein benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of MTTP protein |
CTD |
PMID:34516972 |
|
NCBI chr 2:226,613,090...226,654,239
Ensembl chr 2:226,613,090...226,654,239
|
|
G |
Mtus1 |
microtubule associated scaffold protein 1 |
decreases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of MTUS1 mRNA |
CTD |
PMID:25566086 |
|
NCBI chr16:51,202,497...51,347,794
Ensembl chr16:51,253,562...51,347,793
|
|
G |
Muc1 |
mucin 1, cell surface associated |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [MUC1 affects the expression of EGFR protein] |
CTD |
PMID:22457794 |
|
NCBI chr 2:174,635,989...174,640,738
Ensembl chr 2:174,635,995...174,640,733
|
|
G |
Muc5ac |
mucin 5AC, oligomeric mucus/gel-forming |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [EGF protein results in increased secretion of MUC5AC protein] |
CTD |
PMID:22766066 |
|
NCBI chr 1:196,864,336...196,896,475
Ensembl chr 1:196,864,336...196,896,475
|
|
G |
Mybpc3 |
myosin binding protein C3 |
decreases expression affects response to substance multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of MYBPC3 mRNA MYBPC3 protein affects the susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde [MYBPC3 protein affects the susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde] which results in decreased expression of BOK mRNA; [MYBPC3 protein affects the susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde] which results in decreased expression of CAV1 mRNA; [MYBPC3 protein affects the susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde] which results in decreased expression of CCNB1 mRNA; [MYBPC3 protein affects the susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde] which results in decreased expression of CDH3 mRNA; [MYBPC3 protein affects the susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde] which results in decreased expression of CDK1 mRNA; [MYBPC3 protein affects the susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde] which results in decreased expression of CKB mRNA; [MYBPC3 protein affects the susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde] which results in decreased expression of EGFL7 mRNA; [MYBPC3 protein affects the susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde] which results in decreased expression of FAHD1 mRNA; [MYBPC3 protein affects the susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde] which results in decreased expression of G0S2 mRNA; [MYBPC3 protein affects the susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde] which results in decreased expression of GPR146 mRNA; [MYBPC3 protein affects the susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde] which results in decreased expression of H2AC10 mRNA; [MYBPC3 protein affects the susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde] which results in decreased expression of H2AC12 mRNA; [MYBPC3 protein affects the susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde] which results in decreased expression of H2AC13 mRNA; [MYBPC3 protein affects the susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde] which results in decreased expression of H2AC15 mRNA; [MYBPC3 protein affects the susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde] which results in decreased expression of H2AC22 mRNA; [MYBPC3 protein affects the susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde] which results in decreased expression of H2AC7 mRNA; [MYBPC3 protein affects the susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde] which results in decreased expression of HAGHL mRNA; [MYBPC3 protein affects the susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde] which results in decreased expression of HOPX mRNA; [MYBPC3 protein affects the susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde] which results in decreased expression of KBTBD11 mRNA; [MYBPC3 protein affects the susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde] which results in decreased expression of KY mRNA; [MYBPC3 protein affects the susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde] which results in decreased expression of LGALS1 mRNA; [MYBPC3 protein affects the susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde] which results in decreased expression of LRRC10 mRNA; [MYBPC3 protein affects the susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde] which results in decreased expression of LRRC75A mRNA; [MYBPC3 protein affects the susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde] which results in decreased expression of MCM5 mRNA; [MYBPC3 protein affects the susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde] which results in decreased expression of MMP23 mRNA; [MYBPC3 protein affects the susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde] which results in decreased expression of MYL12B mRNA; [MYBPC3 protein affects the susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde] which results in decreased expression of MYLK mRNA; [MYBPC3 protein affects the susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde] which results in decreased expression of NRM mRNA; [MYBPC3 protein affects the susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde] which results in decreased expression of PBK mRNA; [MYBPC3 protein affects the susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde] which results in decreased expression of PDLIM4 mRNA; [MYBPC3 protein affects the susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde] which results in decreased expression of PLEKHG2 mRNA; [MYBPC3 protein affects the susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde] which results in decreased expression of PLK1 mRNA; [MYBPC3 protein affects the susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde] which results in decreased expression of PPARGC1B mRNA; [MYBPC3 protein affects the susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde] which results in decreased expression of PPP1R3G mRNA; [MYBPC3 protein affects the susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde] which results in decreased expression of ROBO4 mRNA; [MYBPC3 protein affects the susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde] which results in decreased expression of RRM2 mRNA; [MYBPC3 protein affects the susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde] which results in decreased expression of SYNPO mRNA; [MYBPC3 protein affects the susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde] which results in decreased expression of TK1 mRNA; [MYBPC3 protein affects the susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde] which results in decreased expression of TMEM176A mRNA; [MYBPC3 protein affects the susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde] which results in decreased expression of TMEM176B mRNA; [MYBPC3 protein affects the susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde] which results in decreased expression of TRIB2 mRNA; [MYBPC3 protein affects the susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde] which results in decreased expression of ZFYVE21 mRNA; [MYBPC3 protein affects the susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde] which results in increased expression of ATG12 mRNA; [MYBPC3 protein affects the susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde] which results in increased expression of EIF2AK2 mRNA; [MYBPC3 protein affects the susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde] which results in increased expression of FAM13B mRNA; [MYBPC3 protein affects the susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde] which results in increased expression of GADD45G mRNA; [MYBPC3 protein affects the susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde] which results in increased expression of HSPA8 mRNA; [MYBPC3 protein affects the susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde] which results in increased expression of LUC7L mRNA; [MYBPC3 protein affects the susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde] which results in increased expression of NRIP3 mRNA; [MYBPC3 protein affects the susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde] which results in increased expression of SF1 mRNA; [MYBPC3 protein affects the susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde] which results in increased expression of SWT1 mRNA; [MYBPC3 protein affects the susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde] which results in increased expression of UFD1 mRNA; MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of ACAA2 mRNA]; MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of ACTC1 mRNA]; MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of ADSS1 mRNA]; MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of APH1A mRNA]; MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of ARG1 mRNA]; MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of ART3 mRNA]; MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of C1QB mRNA]; MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of CAR14 mRNA]; MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of CAVIN1 mRNA]; MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of CENPA mRNA]; MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of CHRM2 mRNA]; MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of CKMT2 mRNA]; MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of CLIP4 mRNA]; MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of CMYA5 mRNA]; MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of CORIN mRNA]; MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of EGLN1 mRNA]; MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of EGLN3 mRNA]; MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of ENO3 mRNA]; MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of FBXO10 mRNA]; MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of GSG1L mRNA]; MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of GUCY1A1 mRNA]; MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of GYG1 mRNA]; MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of H2-AB1 mRNA]; MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of HES1 mRNA]; MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of HIGD1B mRNA]; MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of HR mRNA]; MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of HSPB2 mRNA]; MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of KLHL6 mRNA]; MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of LDB3 mRNA]; MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of LMO7 mRNA]; MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of LRRC10 mRNA]; MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of LXN mRNA]; MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of MB mRNA]; MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of MYBPC3 mRNA]; MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of MYBPHL mRNA]; MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of MYL1 mRNA]; MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of MYL7 mRNA]; MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of MYO5B mRNA]; MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of MYZAP mRNA]; MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of NACAD mRNA]; MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of NIPSNAP2 mRNA]; MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of NMRK2 mRNA]; MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of PCDH7 mRNA]; MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of PDK1 mRNA]; MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of PDLIM5 mRNA]; MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of PERM1 mRNA]; MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of PFKP mRNA]; MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of PIP5K1B mRNA]; MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of PLAC8 mRNA]; MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of PPP1R14C mRNA]; MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of PRC1 mRNA]; MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of RARRES2 mRNA]; MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of SH3KBP1 mRNA]; MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of SNRK mRNA]; MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of SPON2 mRNA]; MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of SPSB4 mRNA]; MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of SSPN mRNA]; MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of TFRC mRNA]; MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of THY1 mRNA]; MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of TMEM204 mRNA]; MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of TMOD1 mRNA]; MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of TNNI2 mRNA]; MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of TRIL mRNA]; MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of TSC22D4 mRNA]; MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of UNC13C mRNA]; MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of ZBTB8B mRNA]; MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of CD14 mRNA]; MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of CLDN4 mRNA]; MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of DNMT3L mRNA]; MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of DYNC1H1 mRNA]; MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of GDF15 mRNA]; MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of INSL6 mRNA]; MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of KIF1A mRNA]; MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of MAP1B mRNA]; MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of MLKL mRNA]; MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of MOCS1 mRNA]; MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of MT3 mRNA]; MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of NGF mRNA]; MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of PDPN mRNA]; MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of SLC6A9 mRNA]; MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of SPRR2G mRNA]; MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of SYBU mRNA]; MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of TENM4 mRNA] |
CTD |
PMID:25566086 |
|
NCBI chr 3:77,095,165...77,113,406
Ensembl chr 3:77,095,252...77,113,405
|
|
G |
Mybphl |
myosin binding protein H-like |
decreases expression multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of MYBPHL mRNA MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of MYBPHL mRNA] |
CTD |
PMID:25566086 |
|
NCBI chr 2:196,005,297...196,018,826
Ensembl chr 2:196,005,325...196,018,824
|
|
G |
Myc |
MYC proto-oncogene, bHLH transcription factor |
multiple interactions increases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [5-(4-ethylbenzylidene)-2-thioxothiazolidin-4-one inhibits the reaction [STK11 mutant form results in increased expression of MYC protein]]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [deguelin results in decreased expression of MYC protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Drugs, Chinese Herbal results in decreased expression of MYC protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [lobetyolin results in decreased expression of MYC protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [nickel sulfate results in increased degradation of MYC protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [Tretinoin results in decreased expression of MYC protein] benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of MYC protein [arsenite co-treated with benzyloxycarbonylleucyl-leucyl-leucine aldehyde] results in increased expression of MYC protein; [arsenite co-treated with benzyloxycarbonylleucyl-leucyl-leucine aldehyde] results in increased expression of MYC protein modified form; arsenite inhibits the reaction [Cycloheximide inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased degradation of and results in increased expression of MYC protein]]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased degradation of and results in increased expression of MYC protein; Cycloheximide inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased degradation of and results in increased expression of MYC protein]; Cycloheximide inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of MYC protein]; FBXW7 protein promotes the reaction [NFKB1 gene mutant form inhibits the reaction [arsenite inhibits the reaction [Cycloheximide inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased degradation of and results in increased expression of MYC protein]]]]; NFKB1 gene mutant form inhibits the reaction [arsenite inhibits the reaction [Cycloheximide inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased degradation of and results in increased expression of MYC protein]]] |
CTD |
PMID:20046830 PMID:20945414 PMID:21472727 PMID:23593480 PMID:24457827 PMID:24793789 PMID:25897075 PMID:28548306 PMID:34075790 More...
|
|
NCBI chr 7:93,593,705...93,598,633
Ensembl chr 7:93,593,705...93,598,630
|
|
G |
Myh6 |
myosin heavy chain 6 |
decreases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of MYH6 mRNA |
CTD |
PMID:25566086 |
|
NCBI chr15:28,418,120...28,442,316
Ensembl chr15:28,417,616...28,441,720
|
|
G |
Myl1 |
myosin, light chain 1 |
multiple interactions decreases expression |
ISO |
MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of MYL1 mRNA] |
CTD |
PMID:25566086 |
|
NCBI chr 9:68,437,514...68,458,256
Ensembl chr 9:68,437,517...68,458,261
|
|
G |
Myl12b |
myosin light chain 12B |
multiple interactions |
ISO |
[MYBPC3 protein affects the susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde] which results in decreased expression of MYL12B mRNA |
CTD |
PMID:25566086 |
|
NCBI chr 9:110,873,855...110,888,187
|
|
G |
Myl7 |
myosin light chain 7 |
decreases expression multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of MYL7 mRNA MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of MYL7 mRNA] |
CTD |
PMID:25566086 |
|
NCBI chr14:80,780,684...80,783,259
Ensembl chr14:80,779,776...80,783,244
|
|
G |
Mylk |
myosin light chain kinase |
multiple interactions |
ISO |
[MYBPC3 protein affects the susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde] which results in decreased expression of MYLK mRNA |
CTD |
PMID:25566086 |
|
NCBI chr11:65,783,008...66,030,239
Ensembl chr11:65,783,008...66,030,261
|
|
G |
Mylk3 |
myosin light chain kinase 3 |
decreases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of MYLK3 mRNA |
CTD |
PMID:25566086 |
|
NCBI chr19:21,685,085...21,743,587
Ensembl chr19:21,691,929...21,742,954
|
|
G |
Myo5b |
myosin Vb |
decreases expression multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of MYO5B mRNA MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of MYO5B mRNA] |
CTD |
PMID:25566086 |
|
NCBI chr18:68,038,759...68,341,568
Ensembl chr18:68,038,759...68,338,745
|
|
G |
Myzap |
myocardial zonula adherens protein |
decreases expression multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of MYZAP mRNA MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of MYZAP mRNA] |
CTD |
PMID:25566086 |
|
NCBI chr 8:72,155,817...72,243,036
Ensembl chr 8:72,131,530...72,243,036
|
|
G |
Nacad |
NAC alpha domain containing |
decreases expression multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of NACAD mRNA MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of NACAD mRNA] |
CTD |
PMID:25566086 |
|
NCBI chr14:81,465,299...81,473,866
Ensembl chr14:81,465,299...81,473,781
|
|
G |
Nanog |
Nanog homeobox |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [resveratrol results in decreased expression of NANOG protein] |
CTD |
PMID:23651583 |
|
NCBI chr 4:155,943,737...155,951,116
Ensembl chr 4:155,943,737...155,951,116
|
|
G |
Napb |
NSF attachment protein beta |
increases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of NAPB mRNA |
CTD |
PMID:25566086 |
|
NCBI chr 3:136,132,248...136,179,280
Ensembl chr 3:136,133,428...136,179,345
|
|
G |
Ncoa1 |
nuclear receptor coactivator 1 |
increases expression |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of NCOA1 protein |
CTD |
PMID:16564422 |
|
NCBI chr 6:27,232,609...27,507,992
Ensembl chr 6:27,232,611...27,475,664
|
|
G |
Ncoa3 |
nuclear receptor coactivator 3 |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Tretinoin results in increased degradation of NCOA3 protein] |
CTD |
PMID:16456540 |
|
NCBI chr 3:154,738,566...154,821,395
Ensembl chr 3:154,738,581...154,818,594
|
|
G |
Ncor1 |
nuclear receptor co-repressor 1 |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased stability of and results in increased expression of NCOR1 protein |
CTD |
PMID:15857753 |
|
NCBI chr10:46,999,536...47,142,294
Ensembl chr10:46,999,536...47,141,032
|
|
G |
Ncor2 |
nuclear receptor co-repressor 2 |
multiple interactions increases expression |
ISO EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased stability of and results in increased expression of NCOR2 protein benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of NCOR2 protein |
CTD |
PMID:15857753 PMID:16564422 |
|
NCBI chr12:31,466,418...31,628,319
Ensembl chr12:31,466,412...31,628,319
|
|
G |
Ndfip1 |
Nedd4 family interacting protein 1 |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [NDFIP1 protein results in decreased expression of SLC6A3 protein] |
CTD |
PMID:26300475 |
|
NCBI chr18:30,265,808...30,316,068
Ensembl chr18:30,250,613...30,322,311
|
|
G |
Nedd4l |
NEDD4 like E3 ubiquitin protein ligase |
increases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of NEDD4L mRNA |
CTD |
PMID:20061341 |
|
NCBI chr18:58,393,759...58,726,709
Ensembl chr18:58,393,509...58,723,137
|
|
G |
Neurl2 |
neuralized E3 ubiquitin protein ligase 2 |
decreases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of NEURL2 mRNA |
CTD |
PMID:25566086 |
|
NCBI chr 3:153,566,659...153,569,380
Ensembl chr 3:153,566,660...153,569,380
|
|
G |
Nfat5 |
nuclear factor of activated T-cells 5 |
multiple interactions |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Doxorubicin results in increased degradation of NFAT5 protein] |
CTD |
PMID:17105721 |
|
NCBI chr19:35,199,737...35,286,675
Ensembl chr19:35,199,016...35,286,675
|
|
G |
Nfe2l1 |
NFE2 like bZIP transcription factor 1 |
decreases degradation multiple interactions increases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased degradation of NFE2L1 protein alternative form benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [Glucose results in increased expression of NFE2L1 protein]; Glucose promotes the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of NFE2L1 protein]; Metformin inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of NFE2L1 protein] |
CTD |
PMID:28549828 PMID:33838154 |
|
NCBI chr10:81,796,055...81,812,926
Ensembl chr10:81,800,366...81,832,318
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
multiple interactions decreases expression increases ubiquitination decreases degradation increases expression increases activity |
ISO EXP |
2-tert-butyl-4-quinone inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased ubiquitination of NFE2L2 protein]; 2-tert-butylhydroquinone inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased ubiquitination of NFE2L2 protein]; [benzyloxycarbonylleucyl-leucyl-leucine aldehyde co-treated with Hemin] results in increased expression of and affects the localization of NFE2L2 protein; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Dichlorodiphenyl Dichloroethylene results in decreased expression of NFE2L2 mRNA]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Dichlorodiphenyl Dichloroethylene results in decreased expression of NFE2L2 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Homocysteine results in decreased phosphorylation of and results in decreased expression of NFE2L2 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [Glucose results in increased expression of NFE2L2 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [NFE2L2 protein binds to NQO1 promoter]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [sulforaphane results in increased expression of NFE2L2 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of and affects the localization of NFE2L2 protein; benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of and results in increased stability of and results in increased ubiquitination of NFE2L2 protein; benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased localization of and results in increased activity of NFE2L2 protein; Curcumin inhibits the reaction [Cycloheximide inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of NFE2L2 protein]]; cyanoginosin LR inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased ubiquitination of NFE2L2 protein]; Cycloheximide inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of NFE2L2 protein]; hydroquinone inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased ubiquitination of NFE2L2 protein]; Metformin inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of NFE2L2 protein]; NFE2L2 protein promotes the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of GCLC mRNA]; NFE2L2 protein promotes the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of HMOX1 mRNA]; quinone inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased ubiquitination of NFE2L2 protein] benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of NFE2L2 protein modified form benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased degradation of NFE2L2 protein benzyloxycarbonylleucyl-leucyl-leucine aldehyde affects the reaction [triptolide affects the expression of NFE2L2 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [N-acetylsphingosine results in decreased localization of NFE2L2 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [NFE2L2 protein inhibits the reaction [Streptozocin results in increased expression of USP15 protein]]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [triptolide results in increased ubiquitination of NFE2L2 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [sulforaphane results in increased activity of NFE2L2 protein] benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased activity of NFE2L2 protein [2-tert-butylhydroquinone co-treated with benzyloxycarbonylleucyl-leucyl-leucine aldehyde] promotes the reaction [NFE2L2 protein binds to KEAP1 protein]; [benzyloxycarbonylleucyl-leucyl-leucine aldehyde co-treated with 1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in increased expression of and results in increased ubiquitination of NFE2L2 protein; [benzyloxycarbonylleucyl-leucyl-leucine aldehyde co-treated with 2-tert-butylhydroquinone] results in increased expression of NFE2L2 protein; [benzyloxycarbonylleucyl-leucyl-leucine aldehyde co-treated with Cycloheximide] results in increased expression of NFE2L2 protein; baicalin inhibits the reaction [[benzyloxycarbonylleucyl-leucyl-leucine aldehyde co-treated with 1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in increased ubiquitination of NFE2L2 protein]; baicalin promotes the reaction [[benzyloxycarbonylleucyl-leucyl-leucine aldehyde co-treated with 1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in increased expression of NFE2L2 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Cycloheximide inhibits the reaction [Particulate Matter analog results in increased expression of NFE2L2 protein]]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Cycloheximide inhibits the reaction [Vehicle Emissions analog results in increased expression of NFE2L2 protein]]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [2-tert-butylhydroquinone results in increased ubiquitination of NFE2L2 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [Cadmium Chloride affects the ubiquitination of NFE2L2 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [NFE2L2 protein binds to KEAP1 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of and affects the localization of NFE2L2 protein; Exenatide inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased ubiquitination of NFE2L2 protein] [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of NFE2L2 protein] which results in increased expression of CBR3 mRNA; benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of NFE2L2 mRNA; benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of NFE2L2 protein |
CTD |
PMID:12441344 PMID:12446695 PMID:14510636 PMID:15319326 PMID:15322212 PMID:18512965 PMID:18550526 PMID:19786557 PMID:20722399 PMID:20806931 PMID:22019695 PMID:22558124 PMID:22606287 PMID:22964297 PMID:25263748 PMID:26598004 PMID:27939242 PMID:28645578 PMID:29618784 PMID:30186748 PMID:30703377 PMID:30926361 PMID:31319135 PMID:31806706 PMID:33434570 PMID:33838154 PMID:34758851 PMID:35478295 PMID:38016618 More...
|
|
NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Nfkb1 |
nuclear factor kappa B subunit 1 |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [IL1B protein results in increased activity of [RELA protein binds to NFKB1 protein]]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Tetradecanoylphorbol Acetate results in increased activity of [NFKB1 protein binds to RELA protein]]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased activity of [NFKB1 protein binds to RELA protein] benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Lipopolysaccharides results in increased localization of NFKB1 protein]; FBXW7 protein promotes the reaction [NFKB1 gene mutant form inhibits the reaction [arsenite inhibits the reaction [Cycloheximide inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased degradation of and results in increased expression of MYC protein]]]]; NFKB1 gene mutant form inhibits the reaction [arsenite inhibits the reaction [Cycloheximide inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased degradation of and results in increased expression of MYC protein]]] |
CTD |
PMID:11543732 PMID:14527959 PMID:14581482 PMID:16026644 PMID:24457827 |
|
NCBI chr 2:224,016,214...224,132,135
Ensembl chr 2:224,016,214...224,110,404
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
multiple interactions increases expression increases phosphorylation |
ISO EXP |
[benzyloxycarbonylleucyl-leucyl-leucine aldehyde co-treated with IL1B protein] results in increased expression of and results in increased phosphorylation of NFKBIA protein; [benzyloxycarbonylleucyl-leucyl-leucine aldehyde co-treated with TNF protein] results in increased phosphorylation of NFKBIA protein; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased degradation of NFKBIA protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [evodiamine results in increased phosphorylation of and results in increased degradation of NFKBIA protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [osthol results in decreased phosphorylation of and results in decreased degradation of NFKBIA protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [TNF protein results in increased degradation of NFKBIA protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [Deoxycholic Acid results in increased phosphorylation of NFKBIA protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased phosphorylation of and results in increased degradation of NFKBIA protein; MAP1LC3B protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased phosphorylation of NFKBIA protein]; sodium arsenite inhibits the reaction [[benzyloxycarbonylleucyl-leucyl-leucine aldehyde co-treated with IL1B protein] results in increased expression of and results in increased phosphorylation of NFKBIA protein]; TNF protein affects the reaction [[benzyloxycarbonylleucyl-leucyl-leucine aldehyde co-treated with Thiopental] affects the phosphorylation of NFKBIA protein] MG132 pretreatment increases expression of protein in liver of intestinal ischemia/reperfusion rats benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of NFKBIA protein benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Ammonium Chloride results in increased degradation of NFKBIA protein] benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Lipopolysaccharides results in decreased expression of NFKBIA protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Lipopolysaccharides results in increased degradation of NFKBIA protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Zymosan results in increased degradation of NFKBIA protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Zymosan results in increased phosphorylation of NFKBIA protein] |
CTD RGD |
PMID:11543732 PMID:11698246 PMID:11835394 PMID:11923223 PMID:12185005 PMID:12628480 PMID:12721113 PMID:12883408 PMID:15477007 PMID:16421291 PMID:17644113 PMID:20005289 PMID:22503731 PMID:23423712 PMID:24085292 PMID:25780039 PMID:22079846 More...
|
RGD:401794136 |
NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941
|
|
G |
Nfkbib |
NFKB inhibitor beta |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Lipopolysaccharides results in increased degradation of NFKBIB protein] |
CTD |
PMID:11543732 |
|
NCBI chr 1:84,046,292...84,053,862
Ensembl chr 1:84,046,295...84,053,862
|
|
G |
Nfkbie |
NFKB inhibitor epsilon |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Lipopolysaccharides results in decreased expression of NFKBIE protein] |
CTD |
PMID:12185005 |
|
NCBI chr 9:15,443,600...15,450,437
Ensembl chr 9:15,436,941...15,450,437
|
|
G |
Ngf |
nerve growth factor |
multiple interactions increases expression |
ISO |
MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of NGF mRNA] |
CTD |
PMID:25566086 |
|
NCBI chr 2:189,901,058...189,954,452
Ensembl chr 2:189,901,058...189,954,452
|
|
G |
Ngly1 |
N-glycanase 1 |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [NGLY1 protein binds to UBXN1 protein] |
CTD |
PMID:15362974 |
|
NCBI chr15:9,153,738...9,210,228
Ensembl chr15:9,153,738...9,204,630
|
|
G |
Nipsnap2 |
nipsnap homolog 2 |
decreases expression multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of NIPSNAP2 mRNA MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of NIPSNAP2 mRNA] |
CTD |
PMID:25566086 |
|
NCBI chr12:26,906,068...26,944,201
Ensembl chr12:26,911,723...26,944,166
|
|
G |
Nme3 |
NME/NM23 nucleoside diphosphate kinase 3 |
decreases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of NME3 mRNA |
CTD |
PMID:25566086 |
|
NCBI chr10:13,917,309...13,918,415
Ensembl chr10:13,917,403...13,918,359
|
|
G |
Nmrk2 |
nicotinamide riboside kinase 2 |
decreases expression multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of NMRK2 mRNA MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of NMRK2 mRNA] |
CTD |
PMID:25566086 |
|
NCBI chr 7:8,514,855...8,517,916
Ensembl chr 7:8,514,927...8,517,922
|
|
G |
Nol3 |
nucleolar protein 3 |
multiple interactions |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde affects the reaction [Doxorubicin results in increased degradation of NOL3 protein] |
CTD |
PMID:19139834 |
|
NCBI chr19:33,154,061...33,158,250
Ensembl chr19:33,154,062...33,158,250
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions decreases expression |
ISO EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [pirinixic acid inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [zinc protoporphyrin inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [zinc protoporphyrin inhibits the reaction [lipoteichoic acid results in increased expression of NOS2 protein]]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [zinc protoporphyrin inhibits the reaction [Peptidoglycan results in increased expression of NOS2 protein]]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Zymosan results in increased expression of NOS2 protein] benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased expression of NOS2 mRNA]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [[TNF protein co-treated with IL1B protein co-treated with IFNG protein] results in increased expression of NOS2 mRNA]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Ammonium Chloride results in increased expression of NOS2 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Diclofenac promotes the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased expression of NOS2 mRNA]]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Diclofenac promotes the reaction [[TNF protein co-treated with IL1B protein co-treated with IFNG protein] results in increased expression of NOS2 mRNA]] benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of NOS2 protein |
CTD |
PMID:11923223 PMID:12628480 PMID:12721113 PMID:17891158 PMID:19376148 PMID:19393675 PMID:20675566 PMID:23395999 More...
|
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Nos3 |
nitric oxide synthase 3 |
decreases degradation increases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased degradation of NOS3 protein benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of NOS3 protein |
CTD |
PMID:20229525 PMID:20675566 |
|
NCBI chr 4:10,793,834...10,814,170
Ensembl chr 4:10,793,834...10,814,166
|
|
G |
Notch1 |
notch receptor 1 |
increases expression multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of NOTCH1 mRNA benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Arsenic Trioxide results in decreased expression of NOTCH1 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [triptonide results in increased degradation of NOTCH1 protein] |
CTD |
PMID:24497960 PMID:24801890 PMID:31597699 PMID:31866380 |
|
NCBI chr 3:9,277,955...9,323,531
Ensembl chr 3:9,278,086...9,323,531
|
|
G |
Nqo1 |
NAD(P)H quinone dehydrogenase 1 |
multiple interactions increases expression |
ISO EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Cycloheximide inhibits the reaction [Lead results in increased expression of NQO1 mRNA]]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Cycloheximide inhibits the reaction [Mercury results in increased expression of NQO1 mRNA]]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of NQO1 mRNA]]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Cycloheximide promotes the reaction [Copper results in decreased expression of NQO1 mRNA]] benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of NQO1 mRNA; benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of NQO1 protein [benzyloxycarbonylleucyl-leucyl-leucine aldehyde co-treated with Hemin] results in increased expression of NQO1 mRNA; [benzyloxycarbonylleucyl-leucyl-leucine aldehyde co-treated with Hemin] results in increased expression of NQO1 protein; benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [NFE2L2 protein binds to NQO1 promoter] |
CTD |
PMID:16243960 PMID:20061341 PMID:22606287 PMID:30186748 PMID:33434570 |
|
NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557
|
|
G |
Nr1i3 |
nuclear receptor subfamily 1, group I, member 3 |
multiple interactions increases ubiquitination decreases activity increases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [DNAJC7 protein results in increased expression of NR1I3 protein]; NR1I3 protein affects the reaction [1,4-bis(2-(3,5-dichloropyridyloxy))benzene promotes the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased ubiquitination of DNAJC7 protein]] benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased ubiquitination of NR1I3 protein benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased activity of NR1I3 protein benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime affects the localization of NR1I3 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime results in increased activity of NR1I3 protein modified form]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Diethylhexyl Phthalate results in increased activity of NR1I3 protein modified form]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [GRIP1 protein binds to NR1I3 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Phenobarbital affects the localization of NR1I3 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [SRC protein binds to NR1I3 protein] benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of NR1I3 protein |
CTD |
PMID:24224465 PMID:24789201 |
|
NCBI chr13:83,632,940...83,638,193
Ensembl chr13:83,632,899...83,637,906
|
|
G |
Nr3c1 |
nuclear receptor subfamily 3, group C, member 1 |
multiple interactions increases expression |
ISO EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Dexamethasone results in increased degradation of NR3C1 protein] benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of NR3C1 mRNA benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [tubacin results in decreased expression of and results in increased degradation of NR3C1 mRNA] |
CTD |
PMID:20619282 PMID:31778773 PMID:31806706 |
|
NCBI chr18:31,271,681...31,393,320
Ensembl chr18:31,271,681...31,393,375
|
|
G |
Nrg1 |
neuregulin 1 |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [KU-32 compound inhibits the reaction [NRG1 protein results in increased expression of and results in increased phosphorylation of JUN protein]]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [NRG1 protein results in increased expression of and results in increased phosphorylation of JUN protein] |
CTD |
PMID:23240583 |
|
NCBI chr16:59,250,658...60,304,519
Ensembl chr16:59,250,854...60,296,884
|
|
G |
Nrip3 |
nuclear receptor interacting protein 3 |
multiple interactions |
ISO |
[MYBPC3 protein affects the susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde] which results in increased expression of NRIP3 mRNA |
CTD |
PMID:25566086 |
|
NCBI chr 1:163,789,738...163,815,036
Ensembl chr 1:163,789,738...163,815,600
|
|
G |
Nrm |
nurim |
multiple interactions |
ISO |
[MYBPC3 protein affects the susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde] which results in decreased expression of NRM mRNA |
CTD |
PMID:25566086 |
|
NCBI chr20:2,888,321...2,892,804
Ensembl chr20:2,877,567...2,891,802
|
|
G |
Nsd2 |
nuclear receptor binding SET domain protein 2 |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [3-deazaneplanocin results in increased degradation of NSD2 protein] |
CTD |
PMID:32001260 |
|
NCBI chr14:76,833,179...76,911,304
Ensembl chr14:76,835,637...76,913,641
|
|
G |
Nuf2 |
NUF2 component of NDC80 kinetochore complex |
decreases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of NUF2 mRNA |
CTD |
PMID:20061341 |
|
NCBI chr13:81,693,675...81,722,765
Ensembl chr13:81,693,598...81,722,766
|
|
G |
Nupr1 |
nuclear protein 1, transcriptional regulator |
increases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of NUPR1 mRNA |
CTD |
PMID:31806706 |
|
NCBI chr 1:181,213,292...181,215,327
Ensembl chr 1:181,213,368...181,215,281
|
|
G |
Ogg1 |
8-oxoguanine DNA glycosylase |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [TH5487 inhibits the reaction [TGFB1 protein results in increased expression of OGG1 protein]]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [TGFB1 protein results in increased expression of OGG1 protein] |
CTD |
PMID:35654123 |
|
NCBI chr 4:146,474,701...146,481,959
Ensembl chr 4:146,474,750...146,484,766
|
|
G |
Opa1 |
OPA1, mitochondrial dynamin like GTPase |
increases expression |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of OPA1 protein alternative form |
CTD |
PMID:20678484 |
|
NCBI chr11:71,108,100...71,185,170
Ensembl chr11:71,109,873...71,185,109
|
|
G |
Oprd1 |
opioid receptor, delta 1 |
multiple interactions |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [ARL6IP5 mutant form inhibits the reaction [Morphine results in increased expression of OPRD1 protein]] |
CTD |
PMID:21600884 |
|
NCBI chr 5:144,306,188...144,340,960
Ensembl chr 5:144,306,188...144,340,960
|
|
G |
Osgin1 |
oxidative stress induced growth inhibitor 1 |
increases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of OSGIN1 mRNA |
CTD |
PMID:20061341 PMID:25566086 |
|
NCBI chr19:47,471,750...47,500,517
Ensembl chr19:47,492,171...47,500,516
|
|
G |
P2rx6 |
purinergic receptor P2X 6 |
increases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of P2RX6 mRNA |
CTD |
PMID:20061341 |
|
NCBI chr11:83,439,922...83,450,449
Ensembl chr11:83,439,924...83,450,481
|
|
G |
Park7 |
Parkinsonism associated deglycase |
multiple interactions decreases response to substance |
EXP ISO |
PARK7 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of HSPA1A protein] benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Paraquat results in increased sulfation of and results in increased oxidation of PARK7 protein] PARK7 protein results in decreased susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde |
CTD |
PMID:18331584 PMID:26409479 |
|
NCBI chr 5:161,353,718...161,376,993
Ensembl chr 5:161,353,719...161,376,970
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
increases cleavage |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased cleavage of PARP1 protein |
CTD |
PMID:15498850 PMID:16051428 PMID:18790767 PMID:20100472 PMID:34418242 |
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Pax2 |
paired box 2 |
increases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of PAX2 mRNA |
CTD |
PMID:25566086 |
|
NCBI chr 1:243,616,509...243,697,454
Ensembl chr 1:243,616,606...243,695,321
|
|
G |
Pbk |
PDZ binding kinase |
multiple interactions |
ISO |
[MYBPC3 protein affects the susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde] which results in decreased expression of PBK mRNA |
CTD |
PMID:25566086 |
|
NCBI chr15:40,022,873...40,034,014
Ensembl chr15:40,023,002...40,034,014
|
|
G |
Pcdh7 |
protocadherin 7 |
decreases expression multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of PCDH7 mRNA MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of PCDH7 mRNA] |
CTD |
PMID:25566086 |
|
NCBI chr14:52,471,801...52,901,696
Ensembl chr14:52,475,610...52,902,051 Ensembl chr14:52,475,610...52,902,051
|
|
G |
Pdcd6ip |
programmed cell death 6 interacting protein |
increases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of PDCD6IP protein |
CTD |
PMID:21692457 |
|
NCBI chr 8:113,590,998...113,646,795
Ensembl chr 8:113,590,998...113,646,773
|
|
G |
Pdgfb |
platelet derived growth factor subunit B |
multiple interactions decreases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [[IL1A co-treated with PDGFB] results in increased secretion of MMP9 protein] benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of PDGFB mRNA |
CTD |
PMID:15728660 PMID:25566086 |
|
NCBI chr 7:111,539,444...111,557,984
Ensembl chr 7:111,540,345...111,557,984
|
|
G |
Pdk1 |
pyruvate dehydrogenase kinase 1 |
decreases expression multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of PDK1 mRNA MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of PDK1 mRNA] |
CTD |
PMID:25566086 |
|
NCBI chr 3:56,705,824...56,733,040
Ensembl chr 3:56,705,871...56,733,038
|
|
G |
Pdlim4 |
PDZ and LIM domain 4 |
multiple interactions |
ISO |
[MYBPC3 protein affects the susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde] which results in decreased expression of PDLIM4 mRNA |
CTD |
PMID:25566086 |
|
NCBI chr10:38,198,686...38,212,935
Ensembl chr10:38,198,689...38,212,938
|
|
G |
Pdlim5 |
PDZ and LIM domain 5 |
decreases expression multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of PDLIM5 mRNA MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of PDLIM5 mRNA] |
CTD |
PMID:25566086 |
|
NCBI chr 2:230,952,251...231,120,329
Ensembl chr 2:230,952,248...231,120,275
|
|
G |
Pdpn |
podoplanin |
multiple interactions increases expression |
ISO |
MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of PDPN mRNA] |
CTD |
PMID:25566086 |
|
NCBI chr 5:155,601,691...155,635,656
Ensembl chr 5:155,601,691...155,635,656
|
|
G |
Pdxp |
pyridoxal phosphatase |
decreases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of PDXP mRNA |
CTD |
PMID:25566086 |
|
NCBI chr 7:110,472,515...110,477,963
Ensembl chr 7:110,472,515...110,477,963
|
|
G |
Pdyn |
prodynorphin |
decreases secretion |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased secretion of PDYN protein alternative form |
CTD |
PMID:17670969 |
|
NCBI chr 3:116,900,990...116,913,334
Ensembl chr 3:116,900,992...116,913,334
|
|
G |
Perm1 |
PPARGC1 and ESRR induced regulator, muscle 1 |
decreases expression multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of PERM1 mRNA MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of PERM1 mRNA] |
CTD |
PMID:25566086 |
|
NCBI chr 5:166,800,030...166,805,323
Ensembl chr 5:166,800,030...166,805,323
|
|
G |
Pfkfb3 |
6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 |
increases expression |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of PFKFB3 protein |
CTD |
PMID:19448625 |
|
NCBI chr17:66,983,629...67,064,702
Ensembl chr17:66,983,686...67,063,125
|
|
G |
Pfkp |
phosphofructokinase, platelet |
decreases expression multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of PFKP mRNA MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of PFKP mRNA] |
CTD |
PMID:25566086 |
|
NCBI chr17:63,729,743...63,794,026
Ensembl chr17:63,729,780...63,794,018
|
|
G |
Pgr |
progesterone receptor |
increases expression |
ISO EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of PGR protein benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of PGR protein alternative form |
CTD |
PMID:15218360 PMID:16564422 |
|
NCBI chr 8:6,072,673...6,131,552
Ensembl chr 8:6,072,673...6,131,344
|
|
G |
Pin1 |
peptidylprolyl cis/trans isomerase, NIMA-interacting 1 |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Arsenic Trioxide results in decreased expression of PIN1 protein] |
CTD |
PMID:30093655 |
|
NCBI chr 8:19,189,408...19,200,785
Ensembl chr 8:19,189,373...19,200,785
|
|
G |
Pink1 |
PTEN induced kinase 1 |
multiple interactions |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [[ponasterone A results in increased expression of PINK1 protein] which results in decreased expression of FIS1 protein] |
CTD |
PMID:20164189 |
|
NCBI chr 5:150,530,523...150,542,635
Ensembl chr 5:150,530,523...150,542,635
|
|
G |
Pip5k1b |
phosphatidylinositol-4-phosphate 5-kinase type 1 beta |
multiple interactions decreases expression |
ISO |
MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of PIP5K1B mRNA] |
CTD |
PMID:25566086 |
|
NCBI chr 1:221,907,220...222,183,672
Ensembl chr 1:221,914,159...222,183,672
|
|
G |
Pkd1 |
polycystin 1, transient receptor potential channel interacting |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [STA 9090 inhibits the reaction [PKD1 gene mutant form results in increased expression of BRD4 protein]] |
CTD |
PMID:25877301 |
|
NCBI chr10:13,573,779...13,621,138
Ensembl chr10:13,573,021...13,621,128
|
|
G |
Pkig |
cAMP-dependent protein kinase inhibitor gamma |
decreases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of PKIG mRNA |
CTD |
PMID:25566086 |
|
NCBI chr 3:152,330,477...152,398,085
Ensembl chr 3:152,366,041...152,398,082
|
|
G |
Plac8 |
placenta associated 8 |
multiple interactions decreases expression |
ISO |
MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of PLAC8 mRNA] |
CTD |
PMID:25566086 |
|
NCBI chr14:9,052,601...9,074,264
Ensembl chr14:9,063,048...9,074,264
|
|
G |
Plekha6 |
pleckstrin homology domain containing A6 |
decreases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of PLEKHA6 mRNA |
CTD |
PMID:25566086 |
|
NCBI chr13:44,614,740...44,754,951
Ensembl chr13:44,615,011...44,754,673
|
|
G |
Plekhg2 |
pleckstrin homology and RhoGEF domain containing G2 |
multiple interactions |
ISO |
[MYBPC3 protein affects the susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde] which results in decreased expression of PLEKHG2 mRNA |
CTD |
PMID:25566086 |
|
NCBI chr 1:83,651,902...83,665,063
Ensembl chr 1:83,647,748...83,665,063
|
|
G |
Plk1 |
polo-like kinase 1 |
multiple interactions |
ISO |
[MYBPC3 protein affects the susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde] which results in decreased expression of PLK1 mRNA |
CTD |
PMID:25566086 |
|
NCBI chr 1:176,716,420...176,726,400
Ensembl chr 1:176,716,420...176,726,400
|
|
G |
Pln |
phospholamban |
decreases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of PLN mRNA |
CTD |
PMID:25566086 |
|
NCBI chr20:32,629,537...32,639,559
|
|
G |
Plod3 |
procollagen-lysine, 2-oxoglutarate 5-dioxygenase 3 |
decreases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of PLOD3 protein |
CTD |
PMID:21692457 |
|
NCBI chr12:19,676,384...19,686,945
Ensembl chr12:19,676,386...19,686,960
|
|
G |
Plvap |
plasmalemma vesicle associated protein |
decreases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of PLVAP mRNA |
CTD |
PMID:25566086 |
|
NCBI chr16:18,184,985...18,197,301
Ensembl chr16:18,184,975...18,197,301
|
|
G |
Pmaip1 |
phorbol-12-myristate-13-acetate-induced protein 1 |
decreases degradation increases expression multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased degradation of PMAIP1 protein benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of PMAIP1 mRNA MAPK8 affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of PMAIP1 mRNA]; MAPK9 inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of PMAIP1 mRNA] |
CTD |
PMID:20802529 PMID:23593480 PMID:31806706 |
|
NCBI chr18:59,986,020...59,992,434
Ensembl chr18:59,986,017...59,992,429
|
|
G |
Pml |
PML nuclear body scaffold |
decreases degradation |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased degradation of PML protein modified form |
CTD |
PMID:26049103 |
|
NCBI chr 8:58,627,347...58,661,927
Ensembl chr 8:58,628,837...58,658,971
|
|
G |
Pnpla3 |
patatin-like phospholipase domain containing 3 |
decreases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of PNPLA3 mRNA |
CTD |
PMID:25566086 |
|
NCBI chr 7:115,293,538...115,314,077
Ensembl chr 7:115,293,538...115,314,077
|
|
G |
Pou5f1 |
POU class 5 homeobox 1 |
increases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of POU5F1 protein |
CTD |
PMID:24497960 |
|
NCBI chr20:3,223,128...3,227,891
Ensembl chr20:3,223,129...3,227,891
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
increases activity multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased activity of PPARG protein benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [resveratrol results in decreased expression of PPARG protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [rosiglitazone results in decreased expression of PPARG protein] benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased activity of PPARG protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [alitretinoin results in increased activity of PPARG protein] |
CTD |
PMID:15707588 PMID:18555852 |
|
NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
|
|
G |
Ppargc1a |
PPARG coactivator 1 alpha |
decreases degradation |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased degradation of PPARGC1A protein |
CTD |
PMID:20860658 |
|
NCBI chr14:58,860,752...59,516,525
Ensembl chr14:58,861,144...59,512,656
|
|
G |
Ppargc1b |
PPARG coactivator 1 beta |
multiple interactions |
ISO |
[MYBPC3 protein affects the susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde] which results in decreased expression of PPARGC1B mRNA |
CTD |
PMID:25566086 |
|
NCBI chr18:54,758,891...54,861,103
Ensembl chr18:54,758,902...54,861,194
|
|
G |
Ppia |
peptidylprolyl isomerase A |
decreases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of PPIA mRNA |
CTD |
PMID:15857753 |
|
NCBI chr14:81,279,292...81,282,960
Ensembl chr14:81,275,091...81,299,601
|
|
G |
Ppl |
periplakin |
increases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of PPL mRNA |
CTD |
PMID:20061341 |
|
NCBI chr10:10,450,919...10,496,575
Ensembl chr10:10,450,919...10,496,575
|
|
G |
Ppp1r14c |
protein phosphatase 1, regulatory (inhibitor) subunit 14c |
decreases expression multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of PPP1R14C mRNA MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of PPP1R14C mRNA] |
CTD |
PMID:25566086 |
|
NCBI chr 1:39,773,403...39,886,970
Ensembl chr 1:39,773,403...39,886,956
|
|
G |
Ppp1r15a |
protein phosphatase 1, regulatory subunit 15A |
increases expression multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of PPP1R15A mRNA benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Cycloheximide results in decreased expression of PPP1R15A protein] |
CTD |
PMID:19135031 PMID:25566086 PMID:29109149 |
|
NCBI chr 1:96,000,053...96,003,128
Ensembl chr 1:96,000,058...96,003,171
|
|
G |
Ppp1r3g |
protein phosphatase 1, regulatory subunit 3G |
multiple interactions |
ISO |
[MYBPC3 protein affects the susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde] which results in decreased expression of PPP1R3G mRNA |
CTD |
PMID:25566086 |
|
NCBI chr17:28,874,956...28,878,288
Ensembl chr17:28,876,482...28,877,525
|
|
G |
Prc1 |
protein regulator of cytokinesis 1 |
decreases expression multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of PRC1 mRNA MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of PRC1 mRNA] |
CTD |
PMID:25566086 |
|
NCBI chr 1:134,250,086...134,271,765
Ensembl chr 1:134,250,081...134,271,765
|
|
G |
Prdx1 |
peroxiredoxin 1 |
increases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of PRDX1 mRNA |
CTD |
PMID:20061341 |
|
NCBI chr 5:130,147,258...130,162,856
Ensembl chr 5:130,147,204...130,162,856
|
|
G |
Prkcb |
protein kinase C, beta |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Deoxycholic Acid results in increased expression of PRKCB protein] |
CTD |
PMID:17644113 |
|
NCBI chr 1:176,832,173...177,163,539
Ensembl chr 1:176,832,226...177,163,536
|
|
G |
Prkcd |
protein kinase C, delta |
multiple interactions increases phosphorylation |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [NSC606985 results in increased activity of and results in increased cleavage of PRKCD protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [PRKCD protein results in increased ubiquitination of HNRNPK protein]; Glutathione inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased phosphorylation of PRKCD protein] |
CTD |
PMID:15707588 PMID:19662097 PMID:19747914 |
|
NCBI chr16:5,769,217...5,799,380
Ensembl chr16:5,769,215...5,799,352
|
|
G |
Prkcsh |
PRKCSH beta subunit of glucosidase II |
increases response to substance |
ISO |
PRKCSH gene mutant form results in increased susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde |
CTD |
PMID:21685914 |
|
NCBI chr 8:20,534,787...20,546,493
Ensembl chr 8:20,534,880...20,546,492
|
|
G |
Prkn |
parkin RBR E3 ubiquitin protein ligase |
multiple interactions decreases expression affects expression |
ISO EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [[Sorafenib co-treated with PRKN protein] results in decreased expression of MCL1 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [PRKN protein results in decreased expression of SLC11A2 protein alternative form]; Tretinoin affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde affects the expression of PRKN protein alternative form] benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of PRKN protein benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of PRKN mRNA |
CTD |
PMID:18586549 PMID:20089134 PMID:28673964 PMID:28688199 |
|
NCBI chr 1:48,688,651...49,882,520
Ensembl chr 1:48,690,556...49,882,555
|
|
G |
Psen1 |
presenilin 1 |
multiple interactions |
ISO |
[PSEN1 protein affects the susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde] affects the reaction [Cycloheximide results in decreased expression of RBPJ protein] |
CTD |
PMID:22302987 |
|
NCBI chr 6:103,323,052...103,375,088
Ensembl chr 6:103,323,120...103,371,650
|
|
G |
Psma1 |
proteasome 20S subunit alpha 1 |
increases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of PSMA1 mRNA |
CTD |
PMID:31806706 |
|
NCBI chr 1:168,442,421...168,453,440
Ensembl chr 1:168,440,936...168,453,472
|
|
G |
Psma2 |
proteasome 20S subunit alpha 2 |
increases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of PSMA2 mRNA |
CTD |
PMID:31806706 |
|
NCBI chr17:50,554,536...50,564,923
Ensembl chr17:50,551,924...50,564,938
|
|
G |
Psma3 |
proteasome 20S subunit alpha 3 |
increases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of PSMA3 mRNA |
CTD |
PMID:15525353 PMID:31806706 |
|
NCBI chr 6:89,483,741...89,503,775
Ensembl chr 6:89,483,727...89,504,965
|
|
G |
Psma4 |
proteasome 20S subunit alpha 4 |
increases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of PSMA4 mRNA |
CTD |
PMID:31806706 |
|
NCBI chr 8:55,340,431...55,347,893
Ensembl chr 8:55,340,386...55,347,890
|
|
G |
Psma5 |
proteasome 20S subunit alpha 5 |
increases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of PSMA5 mRNA |
CTD |
PMID:15525353 PMID:31806706 |
|
NCBI chr 2:195,896,369...195,919,733
Ensembl chr 2:195,896,365...195,919,731
|
|
G |
Psma6 |
proteasome 20S subunit alpha 6 |
increases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of PSMA6 mRNA |
CTD |
PMID:31806706 |
|
NCBI chr 6:72,765,534...72,796,554
Ensembl chr 6:72,765,473...72,796,554
|
|
G |
Psma7 |
proteasome 20S subunit alpha 7 |
increases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of PSMA7 mRNA |
CTD |
PMID:31806706 |
|
NCBI chr 3:167,137,279...167,143,626
Ensembl chr 3:167,137,263...167,143,672
|
|
G |
Psmb10 |
proteasome 20S subunit beta 10 |
decreases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of PSMB10 mRNA |
CTD |
PMID:31806706 |
|
NCBI chr19:33,830,958...33,833,442
Ensembl chr19:33,827,229...33,833,626
|
|
G |
Psmb2 |
proteasome 20S subunit beta 2 |
increases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of PSMB2 mRNA |
CTD |
PMID:31806706 |
|
NCBI chr 5:138,970,564...139,002,715
Ensembl chr 5:138,970,533...139,021,137
|
|
G |
Psmb3 |
proteasome 20S subunit beta 3 |
increases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of PSMB3 mRNA |
CTD |
PMID:31806706 |
|
NCBI chr10:82,697,425...82,704,521
Ensembl chr10:82,697,425...82,704,521
|
|
G |
Psmb4 |
proteasome 20S subunit beta 4 |
increases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of PSMB4 mRNA |
CTD |
PMID:31806706 |
|
NCBI chr 2:182,442,757...182,445,532
Ensembl chr 2:182,442,756...182,445,746
|
|
G |
Psmb5 |
proteasome 20S subunit beta 5 |
increases expression decreases expression multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of PSMB5 mRNA benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of PSMB5 mRNA; benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of PSMB5 protein [sodium arsenite co-treated with benzyloxycarbonylleucyl-leucyl-leucine aldehyde] results in decreased expression of PSMB5 mRNA; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [sodium arsenite results in increased expression of PSMB5 mRNA]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [sodium arsenite results in decreased expression of PSMB5 protein]; sodium arsenite promotes the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of PSMB5 mRNA] |
CTD |
PMID:15525353 PMID:31806706 PMID:32301004 |
|
NCBI chr15:28,072,772...28,077,367
Ensembl chr15:28,072,781...28,077,440
|
|
G |
Psmb6 |
proteasome 20S subunit beta 6 |
increases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of PSMB6 mRNA |
CTD |
PMID:31806706 |
|
NCBI chr10:55,239,256...55,241,586
Ensembl chr10:55,239,241...55,241,586
|
|
G |
Psmb7 |
proteasome 20S subunit beta 7 |
increases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of PSMB7 mRNA |
CTD |
PMID:31806706 |
|
NCBI chr 3:22,357,777...22,417,748
Ensembl chr 3:22,354,698...22,417,937
|
|
G |
Psmb9 |
proteasome 20S subunit beta 9 |
decreases expression increases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of PSMB9 mRNA benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of PSMB9 mRNA |
CTD |
PMID:20061341 PMID:31806706 |
|
NCBI chr20:4,667,044...4,672,512
Ensembl chr20:4,666,046...4,672,512
|
|
G |
Psmc1 |
proteasome 26S subunit, ATPase 1 |
increases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of PSMC1 mRNA |
CTD |
PMID:31806706 |
|
NCBI chr 6:119,392,833...119,405,233
Ensembl chr 6:119,392,855...119,410,123
|
|
G |
Psmc2 |
proteasome 26S subunit, ATPase 2 |
increases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of PSMC2 mRNA |
CTD |
PMID:31806706 |
|
NCBI chr 4:13,255,850...13,270,160
Ensembl chr 4:13,255,856...13,270,185
|
|
G |
Psmc3 |
proteasome 26S subunit, ATPase 3 |
increases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of PSMC3 mRNA |
CTD |
PMID:31806706 |
|
NCBI chr 3:77,031,825...77,037,207
Ensembl chr 3:77,031,825...77,043,358
|
|
G |
Psmc4 |
proteasome 26S subunit, ATPase 4 |
increases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of PSMC4 mRNA |
CTD |
PMID:31806706 |
|
NCBI chr 1:83,349,127...83,357,497
Ensembl chr 1:83,348,592...83,357,494
|
|
G |
Psmc5 |
proteasome 26S subunit, ATPase 5 |
multiple interactions increases expression |
EXP ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction and affects the localization of [PSMC5 protein binds to GABBR2 protein] benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of PSMC5 mRNA |
CTD |
PMID:24482233 PMID:31806706 |
|
NCBI chr10:91,187,763...91,193,697
Ensembl chr10:91,187,743...91,213,135
|
|
G |
Psmc6 |
proteasome 26S subunit, ATPase 6 |
increases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of PSMC6 mRNA |
CTD |
PMID:31806706 |
|
NCBI chr15:18,542,585...18,564,057
Ensembl chr15:18,542,563...18,564,055
|
|
G |
Psmd1 |
proteasome 26S subunit, non-ATPase 1 |
increases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of PSMD1 mRNA |
CTD |
PMID:31806706 |
|
NCBI chr 9:86,709,714...86,785,213
Ensembl chr 9:86,709,947...86,785,211
|
|
G |
Psmd11 |
proteasome 26S subunit, non-ATPase 11 |
increases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of PSMD11 mRNA |
CTD |
PMID:31806706 |
|
NCBI chr10:65,433,853...65,479,774
Ensembl chr10:65,433,853...65,479,766
|
|
G |
Psmd12 |
proteasome 26S subunit, non-ATPase 12 |
increases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of PSMD12 mRNA |
CTD |
PMID:31806706 |
|
NCBI chr10:92,438,223...92,457,323
Ensembl chr10:92,438,298...92,457,287
|
|
G |
Psmd13 |
proteasome 26S subunit, non-ATPase 13 |
increases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of PSMD13 mRNA |
CTD |
PMID:31806706 |
|
NCBI chr 1:195,964,617...195,976,895
Ensembl chr 1:195,964,138...195,976,905
|
|
G |
Psmd14 |
proteasome 26S subunit, non-ATPase 14 |
increases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of PSMD14 mRNA |
CTD |
PMID:31806706 |
|
NCBI chr 3:46,254,338...46,347,076
Ensembl chr 3:46,254,330...46,347,076
|
|
G |
Psmd2 |
proteasome 26S subunit ubiquitin receptor, non-ATPase 2 |
increases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of PSMD2 mRNA |
CTD |
PMID:31806706 |
|
NCBI chr11:80,248,364...80,258,991
Ensembl chr11:80,248,364...80,259,043
|
|
G |
Psmd3 |
proteasome 26S subunit, non-ATPase 3 |
increases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of PSMD3 mRNA |
CTD |
PMID:31806706 |
|
NCBI chr10:83,643,473...83,655,620
Ensembl chr10:83,643,647...83,655,618
|
|
G |
Psmd4 |
proteasome 26S subunit ubiquitin receptor, non-ATPase 4 |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [VCP protein binds to UBXN1 protein binds to PSMD4 protein] |
CTD |
PMID:15362974 |
|
NCBI chr 2:182,598,934...182,608,250
Ensembl chr 2:182,598,934...182,608,194
|
|
G |
Psmd6 |
proteasome 26S subunit, non-ATPase 6 |
increases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of PSMD6 mRNA |
CTD |
PMID:31806706 |
|
NCBI chr15:11,102,174...11,112,180
Ensembl chr15:11,102,180...11,205,620
|
|
G |
Psmd8 |
proteasome 26S subunit, non-ATPase 8 |
increases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of PSMD8 mRNA |
CTD |
PMID:31806706 |
|
NCBI chr 1:84,474,377...84,481,209
Ensembl chr 1:84,474,378...84,481,209
|
|
G |
Psme1 |
proteasome activator subunit 1 |
decreases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of PSME1 mRNA |
CTD |
PMID:31806706 |
|
NCBI chr15:29,069,012...29,071,888
Ensembl chr15:29,068,729...29,071,890
|
|
G |
Psme2 |
proteasome activator subunit 2 |
decreases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of PSME2 mRNA |
CTD |
PMID:31806706 |
|
NCBI chr15:29,078,495...29,082,794
Ensembl chr15:29,078,500...29,082,946
|
|
G |
Psme4 |
proteasome activator subunit 4 |
increases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of PSME4 mRNA |
CTD |
PMID:31806706 |
|
NCBI chr14:104,505,716...104,609,410
Ensembl chr14:104,505,716...104,609,408
|
|
G |
Pten |
phosphatase and tensin homolog |
multiple interactions increases ubiquitination increases expression |
EXP ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Zinc Sulfate results in decreased stability of PTEN protein] benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased ubiquitination of PTEN protein; benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased ubiquitination of PTEN protein modified form benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of PTEN protein benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Cadmium Chloride results in increased degradation of and results in decreased expression of PTEN protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Cadmium results in increased degradation of and results in decreased expression of PTEN protein] |
CTD |
PMID:17684018 PMID:20100827 PMID:24449419 PMID:33256086 |
|
NCBI chr 1:230,630,443...230,697,070
Ensembl chr 1:230,630,338...230,696,838
|
|
G |
Ptger1 |
prostaglandin E receptor 1 |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [[Dinoprostone binds to and results in increased activity of PTGER1 protein] which results in increased expression of HIF1A protein] |
CTD |
PMID:20335389 |
|
NCBI chr19:24,470,258...24,473,687
Ensembl chr19:24,467,532...24,473,559
|
|
G |
Ptges3 |
prostaglandin E synthase 3 |
decreases degradation multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased degradation of PTGES3 protein 4-tosylcyclonovobiocic acid promotes the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased degradation of PTGES3 protein] |
CTD |
PMID:19118525 |
|
NCBI chr 7:490,698...507,759
Ensembl chr 7:490,656...508,084
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions increases expression |
ISO EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Zymosan results in increased expression of PTGS2 protein] benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Cycloheximide inhibits the reaction [cadmium sulfate results in increased expression of PTGS2 protein]]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [manganese chloride results in increased expression of PTGS2 protein] benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [TNF protein results in increased secretion of PTGS2 protein] benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of PTGS2 mRNA; benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of PTGS2 protein |
CTD |
PMID:11230753 PMID:12628480 PMID:12721113 PMID:17084486 PMID:18457675 PMID:22767315 PMID:24085292 More...
|
|
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Ptk2b |
protein tyrosine kinase 2 beta |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde affects the reaction [PTK2B protein affects the ubiquitination of ESR1 protein] |
CTD |
PMID:29428397 |
|
NCBI chr15:40,360,722...40,481,235
Ensembl chr15:40,360,723...40,481,282
|
|
G |
Ptp4a3 |
protein tyrosine phosphatase 4A3 |
decreases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of PTP4A3 mRNA |
CTD |
PMID:25566086 |
|
NCBI chr 7:105,650,640...105,660,921
Ensembl chr 7:105,628,029...105,660,919
|
|
G |
Ptpn1 |
protein tyrosine phosphatase, non-receptor type 1 |
multiple interactions |
ISO |
PTPN1 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased phosphorylation of EIF2S1 protein] |
CTD |
PMID:28359145 |
|
NCBI chr 3:156,638,811...156,687,503
Ensembl chr 3:156,638,769...156,687,504
|
|
G |
Rab33a |
RAB33A, member RAS oncogene family |
decreases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of RAB33A mRNA |
CTD |
PMID:25566086 |
|
NCBI chr X:127,694,219...127,706,378
Ensembl chr X:127,694,964...127,706,378
|
|
G |
Rabl6 |
RAB, member RAS oncogene family-like 6 |
decreases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of RABL6 mRNA |
CTD |
PMID:31806706 |
|
NCBI chr 3:8,402,666...8,428,588
Ensembl chr 3:8,402,672...8,428,611
|
|
G |
Rad51 |
RAD51 recombinase |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [[Mitomycin co-treated with Curcumin] results in decreased expression of RAD51 mRNA]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Curcumin inhibits the reaction [Mitomycin results in increased expression of RAD51 protein]] |
CTD |
PMID:21810436 |
|
NCBI chr 3:106,099,753...106,125,038
Ensembl chr 3:106,100,381...106,125,035
|
|
G |
Raf1 |
Raf-1 proto-oncogene, serine/threonine kinase |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [[arsenic trioxide co-treated with PD 173074] results in decreased expression of RAF1 protein modified form]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [[arsenic trioxide co-treated with PD 173074] results in decreased expression of RAF1 protein] |
CTD |
PMID:27794399 |
|
NCBI chr 4:148,679,534...148,740,265
Ensembl chr 4:148,679,530...148,740,317
|
|
G |
Ramp1 |
receptor activity modifying protein 1 |
decreases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of RAMP1 mRNA |
CTD |
PMID:25566086 |
|
NCBI chr 9:91,765,481...91,816,152
Ensembl chr 9:91,781,285...91,816,151
|
|
G |
Rara |
retinoic acid receptor, alpha |
increases ubiquitination multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased ubiquitination of RARA protein benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Tretinoin results in decreased expression of RARA protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Tretinoin results in increased degradation of RARA protein] |
CTD |
PMID:20945414 PMID:24819975 |
|
NCBI chr10:83,883,490...83,928,932
Ensembl chr10:83,893,384...83,928,142
|
|
G |
Rarres2 |
retinoic acid receptor responder 2 |
decreases expression multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of RARRES2 mRNA MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of RARRES2 mRNA] |
CTD |
PMID:25566086 |
|
NCBI chr 4:77,522,549...77,525,733
Ensembl chr 4:77,522,535...77,525,556
|
|
G |
Rassf5 |
Ras association domain family member 5 |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [RASSF5 protein results in decreased expression of CTNNB1 protein] |
CTD |
PMID:25217643 |
|
NCBI chr13:42,637,513...42,703,024
Ensembl chr13:42,637,549...42,703,024
|
|
G |
Rbl1 |
RB transcriptional corepressor like 1 |
increases expression multiple interactions increases ubiquitination |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of RBL1 protein benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [palbociclib results in decreased expression of RBL1 protein]; palbociclib promotes the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased ubiquitination of RBL1 protein] |
CTD |
PMID:20100483 |
|
NCBI chr 3:145,806,160...145,869,434
Ensembl chr 3:145,807,095...145,869,330
|
|
G |
Rbp3 |
retinol binding protein 3 |
decreases degradation |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased degradation of RBP3 protein mutant form |
CTD |
PMID:23486466 |
|
NCBI chr16:9,267,538...9,276,006
Ensembl chr16:9,267,538...9,276,006
|
|
G |
Rbpj |
recombination signal binding protein for immunoglobulin kappa J region |
increases expression multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of RBPJ protein [PSEN1 protein affects the susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde] affects the reaction [Cycloheximide results in decreased expression of RBPJ protein]; Cycloheximide inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of RBPJ protein] |
CTD |
PMID:22302987 |
|
NCBI chr14:57,338,493...57,523,330
Ensembl chr14:57,338,507...57,523,353
|
|
G |
Rcn2 |
reticulocalbin 2 |
increases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of RCN2 protein |
CTD |
PMID:21692457 |
|
NCBI chr 8:56,449,206...56,466,253
Ensembl chr 8:56,449,206...56,466,251
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
increases activity decreases expression increases ubiquitination multiple interactions affects localization decreases activity |
ISO EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased activity of RELA protein MG132 pretreatment decreases expression of protein in liver of intestinal ischemia/reperfusion rats benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased ubiquitination of RELA protein Acetylcysteine inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased activity of RELA protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [(+)-JQ1 compound affects the localization of RELA protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [[Cisplatin promotes the reaction [RELA protein binds to TP63 protein alternative form]] which results in increased degradation of TP63 protein alternative form]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [BRD4 mutant form affects the localization of RELA protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [CIGB-552 peptide results in decreased expression of RELA protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Deoxycholic Acid results in increased localization of RELA protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [EGF protein affects the localization of RELA protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [IL1B protein results in increased activity of [RELA protein binds to NFKB1 protein]]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Tetradecanoylphorbol Acetate results in increased activity of [NFKB1 protein binds to RELA protein]]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [trimethyltin chloride affects the localization of RELA protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased activity of [NFKB1 protein binds to RELA protein]; SB 203580 inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased activity of RELA protein] benzyloxycarbonylleucyl-leucyl-leucine aldehyde affects the localization of RELA protein benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [halofuginone affects the localization of RELA protein] benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Lipopolysaccharides results in increased localization of RELA protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Zymosan affects the localization of RELA protein] benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased activity of RELA protein |
CTD RGD |
PMID:11543732 PMID:12628480 PMID:12721113 PMID:14527959 PMID:14581482 PMID:15498850 PMID:16026644 PMID:16489207 PMID:17644113 PMID:18457675 PMID:21088498 PMID:22766066 PMID:23401744 PMID:23423712 PMID:23686307 PMID:22079846 More...
|
RGD:401794136 |
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Rgma |
repulsive guidance molecule BMP co-receptor a |
decreases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of RGMA mRNA |
CTD |
PMID:25566086 |
|
NCBI chr 1:127,128,934...127,172,918
Ensembl chr 1:127,128,934...127,172,918
|
|
G |
Rhob |
ras homolog family member B |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [SMURF1 protein results in increased degradation of RHOB protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [sodium arsenite results in decreased expression of RHOB protein] |
CTD |
PMID:30587574 PMID:31140275 |
|
NCBI chr 6:31,363,752...31,365,926
Ensembl chr 6:31,363,548...31,366,108
|
|
G |
Rhoc |
ras homolog family member C |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [RNF168 protein results in decreased expression of RHOC protein] |
CTD |
PMID:34873829 |
|
NCBI chr 2:192,287,065...192,293,292
Ensembl chr 2:192,287,130...192,295,306
|
|
G |
Rictor |
RPTOR independent companion of MTOR, complex 2 |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of and results in increased ubiquitination of RICTOR protein |
CTD |
PMID:25897075 |
|
NCBI chr 2:55,811,877...55,903,893
Ensembl chr 2:55,811,322...55,901,426
|
|
G |
Rnf144b |
ring finger protein 144B |
decreases degradation multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased degradation of RNF144B protein benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [2-hydroxy-3-(5-((morpholin-4-yl)methyl)pyridin-2-yl)-1H-indole-5-carbonitrile inhibits the reaction [Estrogens deficiency results in decreased degradation of RNF144B protein]]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [2-hydroxy-3-(5-((morpholin-4-yl)methyl)pyridin-2-yl)-1H-indole-5-carbonitrile results in increased degradation of RNF144B protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Lithium Chloride inhibits the reaction [Estrogens deficiency results in decreased degradation of RNF144B protein]]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Lithium Chloride results in increased degradation of RNF144B protein] |
CTD |
PMID:29724995 |
|
NCBI chr17:17,431,271...17,580,687
Ensembl chr17:17,432,786...17,562,760
|
|
G |
Rnf168 |
ring finger protein 168 |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [RNF168 protein results in decreased expression of RHOC protein] |
CTD |
PMID:34873829 |
|
NCBI chr11:68,486,313...68,508,296
Ensembl chr11:68,486,321...68,508,277
|
|
G |
Rnf187 |
ring finger protein 187 |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Ro 31-8220 results in decreased stability of RNF187 protein] |
CTD |
PMID:25851810 |
|
NCBI chr10:43,709,493...43,715,392
Ensembl chr10:43,702,357...43,716,157
|
|
G |
Rnf208 |
ring finger protein 208 |
decreases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of RNF208 mRNA |
CTD |
PMID:25566086 |
|
NCBI chr 3:8,057,808...8,059,721
Ensembl chr 3:8,043,685...8,059,844
|
|
G |
Rnf31 |
ring finger protein 31 |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [RNF31 protein inhibits the reaction [Lipopolysaccharides results in increased expression of TNFAIP3 protein]] |
CTD |
PMID:34416243 |
|
NCBI chr15:29,083,047...29,095,328
Ensembl chr15:29,083,631...29,101,915
|
|
G |
Robo4 |
roundabout guidance receptor 4 |
multiple interactions |
ISO |
[MYBPC3 protein affects the susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde] which results in decreased expression of ROBO4 mRNA |
CTD |
PMID:25566086 |
|
NCBI chr 8:37,119,953...37,133,887
Ensembl chr 8:37,119,988...37,132,519
|
|
G |
Rps6kb1 |
ribosomal protein S6 kinase B1 |
multiple interactions decreases phosphorylation |
EXP ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [EGF protein results in increased phosphorylation of RPS6KB1 protein]; Cycloheximide inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [EGF protein results in increased phosphorylation of RPS6KB1 protein]] Sirolimus promotes the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased phosphorylation of RPS6KB1 protein] |
CTD |
PMID:22689575 PMID:31645432 |
|
NCBI chr10:71,323,777...71,367,908
Ensembl chr10:71,323,777...71,367,908
|
|
G |
Rptor |
regulatory associated protein of MTOR, complex 1 |
increases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of RPTOR protein |
CTD |
PMID:25897075 |
|
NCBI chr10:104,878,487...105,176,986
Ensembl chr10:104,878,487...105,176,983
|
|
G |
Rrm2 |
ribonucleotide reductase regulatory subunit M2 |
multiple interactions |
ISO |
[MYBPC3 protein affects the susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde] which results in decreased expression of RRM2 mRNA |
CTD |
PMID:25566086 |
|
NCBI chr 6:41,339,858...41,346,774
Ensembl chr 6:41,340,557...41,346,773
|
|
G |
RT1-Bb |
RT1 class II, locus Bb |
multiple interactions decreases expression |
ISO |
MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of H2-AB1 mRNA] |
CTD |
PMID:25566086 |
|
NCBI chr20:4,596,558...4,602,201
Ensembl chr20:4,596,559...4,607,597
|
|
G |
Rxra |
retinoid X receptor alpha |
multiple interactions increases expression |
ISO |
[alitretinoin co-treated with benzyloxycarbonylleucyl-leucyl-leucine aldehyde] affects the localization of RXRA protein; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [alitretinoin results in increased degradation of RXRA protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Tetradecanoylphorbol Acetate results in decreased degradation of RXRA protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased stability of and results in increased expression of RXRA protein benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of RXRA protein |
CTD |
PMID:12970875 PMID:15707588 PMID:17170071 PMID:22310326 |
|
NCBI chr 3:10,989,832...11,076,366
Ensembl chr 3:10,989,832...11,073,712
|
|
G |
Sae1 |
SUMO1 activating enzyme subunit 1 |
decreases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of SAE1 mRNA |
CTD |
PMID:20061341 |
|
NCBI chr 1:77,030,961...77,086,937
Ensembl chr 1:77,030,965...77,086,986
|
|
G |
Scarb1 |
scavenger receptor class B, member 1 |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Tobacco Smoke Pollution results in decreased expression of SCARB1 protein] |
CTD |
PMID:22442701 |
|
NCBI chr12:31,296,143...31,362,649
Ensembl chr12:31,296,156...31,362,647
|
|
G |
Selenbp1 |
selenium binding protein 1 |
decreases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of SELENBP1 mRNA |
CTD |
PMID:25566086 |
|
NCBI chr 2:182,494,004...182,504,594
Ensembl chr 2:182,493,978...182,504,594
|
|
G |
Sesn2 |
sestrin 2 |
multiple interactions increases ubiquitination increases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Cycloheximide results in decreased expression of SESN2 protein]; Lipopolysaccharides inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased ubiquitination of SESN2 protein] benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of SESN2 protein |
CTD |
PMID:25637945 |
|
NCBI chr 5:144,702,287...144,721,241
Ensembl chr 5:144,701,530...144,721,260
|
|
G |
Set |
Set nuclear proto-oncogene |
decreases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of SET protein |
CTD |
PMID:21692457 |
|
NCBI chr 3:13,334,564...13,345,598
Ensembl chr 3:13,335,041...13,363,567
|
|
G |
Sf1 |
splicing factor 1 |
multiple interactions |
ISO |
[MYBPC3 protein affects the susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde] which results in increased expression of SF1 mRNA |
CTD |
PMID:25566086 |
|
NCBI chr 1:203,670,016...203,683,432
Ensembl chr 1:203,670,018...203,684,330
|
|
G |
Sh3kbp1 |
SH3 domain-containing kinase-binding protein 1 |
multiple interactions decreases expression |
ISO |
MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of SH3KBP1 mRNA] |
CTD |
PMID:25566086 |
|
NCBI chr X:34,877,862...35,223,013
Ensembl chr X:34,877,866...35,222,747
|
|
G |
Siah2 |
siah E3 ubiquitin protein ligase 2 |
decreases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of SIAH2 mRNA |
CTD |
PMID:20061341 |
|
NCBI chr 2:142,913,924...142,931,752
Ensembl chr 2:142,914,003...142,931,950
|
|
G |
Sirt1 |
sirtuin 1 |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [ERCC6 gene mutant form results in decreased expression of SIRT1 protein] |
CTD |
PMID:25440059 |
|
NCBI chr20:25,307,225...25,329,273
Ensembl chr20:25,306,917...25,329,260
|
|
G |
Sirt6 |
sirtuin 6 |
multiple interactions |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [SIRT6 protein results in decreased expression of EP300 protein] |
CTD |
PMID:27094368 |
|
NCBI chr 7:8,082,312...8,087,776
Ensembl chr 7:8,082,364...8,098,914
|
|
G |
Skp1 |
S-phase kinase-associated protein 1 |
increases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of SKP1 mRNA |
CTD |
PMID:20061341 |
|
NCBI chr10:36,401,987...36,417,066
Ensembl chr10:36,402,153...36,417,388
|
|
G |
Skp2 |
S-phase kinase associated protein 2 |
increases expression multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of SKP2 mRNA benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [SKP2 protein results in decreased expression of DUSP1 protein] |
CTD |
PMID:20061341 PMID:34697729 |
|
NCBI chr 2:58,161,226...58,189,293
Ensembl chr 2:58,161,229...58,189,338
|
|
G |
Slbp |
stem-loop histone mRNA binding protein |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [sodium arsenite results in decreased expression of SLBP protein] |
CTD |
PMID:25266719 |
|
NCBI chr14:77,071,441...77,081,911
Ensembl chr14:77,071,632...77,081,906
|
|
G |
Slc10a2 |
solute carrier family 10 member 2 |
increases expression multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of SLC10A2 protein benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [resveratrol results in decreased expression of SLC10A2 protein] |
CTD |
PMID:23872411 PMID:24498857 |
|
NCBI chr16:84,386,528...84,409,475
Ensembl chr16:84,374,862...84,409,475
|
|
G |
Slc11a2 |
solute carrier family 11 member 2 |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [PRKN protein results in decreased expression of SLC11A2 protein alternative form] |
CTD |
PMID:20089134 |
|
NCBI chr 7:131,503,076...131,540,246
Ensembl chr 7:131,503,081...131,540,145
|
|
G |
Slc1a5 |
solute carrier family 1 member 5 |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [lobetyolin results in decreased expression of SLC1A5 protein] |
CTD |
PMID:34075790 |
|
NCBI chr 1:77,456,849...77,470,952
Ensembl chr 1:77,456,694...77,470,952
|
|
G |
Slc29a1 |
solute carrier family 29 member 1 |
increases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of SLC29A1 mRNA |
CTD |
PMID:31806706 |
|
NCBI chr 9:15,399,661...15,414,203
Ensembl chr 9:15,399,612...15,414,203
|
|
G |
Slc2a1 |
solute carrier family 2 member 1 |
increases expression multiple interactions |
ISO EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of SLC2A1 protein benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [methylmercuric chloride results in decreased expression of SLC2A1 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Methylmercury Compounds results in decreased expression of SLC2A1 protein] |
|